PT J
AU Smeester, BA
   Al-Gizawiy, M
   Beitz, AJ
AF Smeester, Branden A.
   Al-Gizawiy, Mona
   Beitz, Alvin J.
TI Effects of Different Electroacupuncture Scheduling Regimens on Murine Bone Tumor-Induced Hyperalgesia: Sex Differences and Role of Inflammation
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID cancer pain; acupuncture treatment; animal-models; expression; mechanisms; complementary; oncology; edema; rats; st36
AB Previous studies have shown that electroacupuncture (EA) is able to reduce hyperalgesia in rodent models of persistent pain, but very little is known about the analgesic effects and potential sex differences of different EA treatment regimens. In the present study, we examined the effects of five different EA treatments on tumor-induced hyperalgesia in male and female mice. EA applied to the ST-36 acupoint either twice weekly (EA-2X/3) beginning on postimplantation day (PID) 3 or prophylactically three times prior to implantation produced the most robust and longest lasting antinociceptive effects. EA treatment given once per week beginning at PID 7 only produced an antinociceptive effect in female animals. The analgesic effect of EA-2X/3 began earlier in males, but lasted longer in females indicating sex differences in EA. We further demonstrate that EA-2X/3 elicits a marked decrease in tumor-associated inflammation as evidenced by a significant reduction in tumor-associated neutrophils at PID 7. Moreover, EA-2X/3 produced a significant reduction in tumor-associated PGE(2) as measured in microperfusate samples. Collectively, these data provide evidence that EA-2X/3 treatment reduces tumor-induced hyperalgesia, which is associated with a decrease in tumor-associated inflammation and PGE(2) concentration at the tumor site suggesting possible mechanisms by which EA reduces tumor nociception.
C1 [Smeester, Branden A.; Beitz, Alvin J.] Univ Minnesota, Coll Vet Med, Dept Vet & Biomed Sci, St Paul, MN 55108 USA.
   [Al-Gizawiy, Mona] Med Coll Wisconsin, Dept Radiol, Milwaukee, WI 53226 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities; Medical College of Wisconsin
RP Beitz, AJ (corresponding author), Univ Minnesota, Coll Vet Med, Dept Vet & Biomed Sci, St Paul, MN 55108 USA.
EM beitz001@umn.edu
FU National Cancer Institute at NIH [5R01/CA084233]
CR Baumgarten SC, 2012, MOL ENDOCRINOL, V26, P360, DOI 10.1210/me.2011-1302
   Bell-Krotoski J A, 1995, J HAND THER, V8, P155
   Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001
   Cassileth BR, 2007, CHEST, V132, P340S, DOI 10.1378/chest.07-1389
   Chae Y, 2011, COMPLEMENT THER MED, V19, PS8, DOI 10.1016/j.ctim.2010.09.002
   Cheng KJ, 2009, ACUPUNCT MED, V27, P61, DOI 10.1136/aim.2009.000455
   Chiu JH, 2003, CAN J VET RES, V67, P94
   Choi DC, 2010, NEUROBIOL DIS, V39, P272, DOI 10.1016/j.nbd.2010.04.003
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   da Silva MD, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq036
   Demaria S, 2010, J IMMUNOTHER, V33, P335, DOI 10.1097/CJI.0b013e3181d32e74
   Dhanani NM, 2011, CURR PAIN HEADACHE R, V15, P39, DOI 10.1007/s11916-010-0158-y
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Eiró N, 2012, WORLD J GASTRO SURG, V4, P62, DOI 10.4240/wjgs.v4.i3.62
   Ernst E, 2006, J INTERN MED, V259, P125, DOI 10.1111/j.1365-2796.2005.01584.x
   Filep JG, 2009, J CELL BIOCHEM, V108, P1039, DOI 10.1002/jcb.22351
   GUNN CC, 1978, AM J ACUPUNCTURE, V6, P55
   Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892
   HAKER E, 1990, CLIN J PAIN, V6, P221, DOI 10.1097/00002508-199009000-00009
   He TF, 2011, EVID-BASED COMPL ALT, V2011, P0, DOI 10.1155/2011/290489
   Hopkins Hollis Anne Seton, 2010, ONCOL NURS FORUM, V37, PE344, DOI 10.1188/10.ONF.E344-E348
   Huang C, 2008, NEUROCHEM RES, V33, P2107, DOI 10.1007/s11064-008-9721-x
   Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037
   Jiang JH, 2011, NEURODEGENER DIS, V8, P504, DOI 10.1159/000327911
   Jimenez Andrade JM, 2010, TRANSLATIONAL PAIN R, V0, P0
   Johnson Mark I, 2006, ACUPUNCT MED, V24, P71
   Kassuya CAL, 2007, BRIT J PHARMACOL, V150, P727, DOI 10.1038/sj.bjp.0707149
   Khanna C, 2000, CLIN EXP METASTAS, V18, P261, DOI 10.1023/A:1006767007547
   Kim HW, 2008, BRAIN RES BULL, V75, P698, DOI 10.1016/j.brainresbull.2007.11.015
   Kim HW, 2007, BRAIN RES, V1148, P69, DOI 10.1016/j.brainres.2007.02.030
   Kim KW, 2011, BRAIN RES BULL, V84, P61, DOI 10.1016/j.brainresbull.2010.10.002
   King T, 2007, PAIN, V132, P154, DOI 10.1016/j.pain.2007.06.026
   Kundu JK, 2012, FREE RADICAL BIO MED, V52, P2013, DOI 10.1016/j.freeradbiomed.2012.02.035
   Kwon YB, 2001, PAIN, V90, P271, DOI 10.1016/S0304-3959(00)00412-7
   Laird BJA, 2011, PAIN, V152, P460, DOI 10.1016/j.pain.2010.10.035
   Langevin HM, 2001, FASEB J, V15, P2275, DOI 10.1096/fj.01-0015hyp
   Lao LX, 2001, J PAIN, V2, P111, DOI 10.1054/jpai.2001.19575
   Lee HJ, 2009, ACUPUNCTURE ELECTRO, V34, P27, DOI 10.3727/036012909803861095
   Lee JH, 2006, AM J CHINESE MED, V34, P981, DOI 10.1142/S0192415X06004454
   Lee MS, 2011, CHIN J INTEGR MED, V17, P187, DOI 10.1007/s11655-011-0665-7
   Lin JG, 2012, AM J CHINESE MED, V40, P219, DOI 10.1142/S0192415X12500176
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Lund Irene, 2010, CHIN MED, V5, P32, DOI 10.1186/1749-8546-5-32
   Lundeberg Thomas, 2007, ACUPUNCT MED, V25, P100
   Macciò A, 2012, CYTOKINE, V58, P133, DOI 10.1016/j.cyto.2012.01.015
   Mao-Ying QL, 2006, EUR J PAIN, V10, P689, DOI 10.1016/j.ejpain.2005.11.001
   Middlemiss T, 2011, CLIN ONCOL-UK, V23, P387, DOI 10.1016/j.clon.2011.03.003
   Minton O, 2007, J PAIN SYMPTOM MANAG, V33, P115, DOI 10.1016/j.jpainsymman.2006.09.011
   Moon PD, 2007, NEUROIMMUNOMODULAT, V14, P24, DOI 10.1159/000107285
   Oke SL, 2009, ANN NY ACAD SCI, V1172, P172, DOI 10.1196/annals.1393.013
   Pacharinsak C, 2008, COMPARATIVE MED, V58, P220
   Paley CA, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq020
   Posadzki P, 2011, J ANDROL, V33, P15, DOI 10.2164/jandrol.111.013235
   Qiu WQ, 2010, BRAIN RES, V1362, P56, DOI 10.1016/j.brainres.2010.09.040
   SCHMIDT J, 1988, DIFFERENTIATION, V39, P151, DOI 10.1111/j.1432-0436.1988.tb00090.x
   Scognamillo-Szabó MVR, 2004, ANN NY ACAD SCI, V1026, P251, DOI 10.1196/annals.1307.039
   Smith HS, 2011, PAIN PHYSICIAN, V14, P0
   Stone JAM, 2010, CURR TREAT OPTION ON, V11, P118, DOI 10.1007/s11864-010-0128-y
   Tian SL, 2008, LIFE SCI, V83, P356, DOI 10.1016/j.lfs.2008.06.027
   Väyrynen JP, 2012, VIRCHOWS ARCH, V460, P455, DOI 10.1007/s00428-012-1232-0
   Vinuesa AG, 2012, CANCER RES, V72, P1705, DOI 10.1158/0008-5472.CAN-11-3693
   Wacnik PW, 2001, J NEUROSCI, V21, P9355, DOI 10.1523/JNEUROSCI.21-23-09355.2001
   Wacnik PW, 2000, PROG PAIN RES MANAG, V16, P615
   Walsh D, 2005, SUPPORT CARE CANCER, V13, P138, DOI 10.1007/s00520-004-0743-x
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Yang EJ, 2010, J NEUROIMMUNOL, V223, P84, DOI 10.1016/j.jneuroim.2010.04.005
   Zhang RX, 2007, ANESTH ANALG, V105, P1482, DOI 10.1213/01.ane.0000284705.34629.c5
   Zhang ZD, 2012, ANESTH ANALG, V114, P879, DOI 10.1213/ANE.0b013e318246536d
   Zitvogel L, 2012, NAT IMMUNOL, V13, P343, DOI 10.1038/ni.2224
NR 69
TC 15
Z9 17
U1 0
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD JUN 15
PY 2012
VL 2012
IS 
BP 
EP 
DI 10.1155/2012/671386
PG 16
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 061QH
UT WOS:000312862500001
PM 23320035
DA 2026-01-16
ER

PT J
AU Casazza, BA
AF Casazza, Brian A.
TI Diagnosis and Treatment of Acute Low Back Pain
SO AMERICAN FAMILY PHYSICIAN
LA English
DT Article
ID spinal manipulative therapy; mckenzie method; lumbar spine; care; acupuncture; prevalence; recurrence; costs; trial; heat
AB Acute low back pain is one of the most common reasons for adults to see a family physician. Although most patients recover quickly with minimal treatment, proper evaluation is imperative to identify rare cases of serious underlying pathology. Certain red flags should prompt aggressive treatment or referral to a spine specialist, whereas others are less concerning. Serious red flags include significant trauma related to age (i.e., injury related to a fall from a height or motor vehicle crash in a young patient, or from a minor fall or heavy lifting in a patient with osteoporosis or possible osteoporosis), major or progressive motor or sensory deficit, new-onset bowel or bladder incontinence or urinary retention, loss of anal sphincter tone, saddle anesthesia, history of cancer metastatic to bone, and suspected spinal infection. Without clinical signs of serious pathology, diagnostic imaging and laboratory testing often are not required. Although there are numerous treatments for nonspecific acute low back pain, most have little evidence of benefit. Patient education and medications such as nonsteroidal anti-inflammatory drugs, acetaminophen, and muscle relaxants are beneficial. Bed rest should be avoided if possible. Exercises directed by a physical therapist, such as the McKenzie method and spine stabilization exercises, may decrease recurrent pain and need for health care services. Spinal manipulation and chiropractic techniques are no more effective than established medical treatments, and adding them to established treatments does not improve outcomes. No substantial benefit has been shown with oral steroids, acupuncture, massage, traction, lumbar supports, or regular exercise programs. (Am Fam Physician. 2012;85(4):343-350. Copyright (C) 2012 American Academy of Family Physicians.)
C1 [Casazza, Brian A.] Univ N Carolina, Sch Med, Spine Ctr Chapel Hill, Chapel Hill, NC 27599 USA.
   [Casazza, Brian A.] Univ N Carolina, Sch Med, Dept Phys Med & Rehabil, Chapel Hill, NC 27599 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine
RP Casazza, BA (corresponding author), Univ N Carolina, Sch Med, Spine Ctr Chapel Hill, 101 Manning Dr,CB 7200, Chapel Hill, NC 27599 USA.
EM brian_casazza@med.unc.edu
CR Acosta Frank L Jr, 2006, CURR INFECT DIS REP, V8, P390, DOI 10.1007/s11908-006-0050-4
   Unknown -, 2008, COCHRANE DATABASE SY, V0, P0
   Assendelft WJ, 2004, COCHRANE DB SYST REV, V1, P0, DOI 10.1002/14651858.CD000447.PUB2
   Becker A, 2010, SPINE, V35, P1714, DOI 10.1097/BRS.0b013e3181cd656f
   BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013
   Carey TS, 1999, MED CARE, V37, P157, DOI 10.1097/00005650-199902000-00006
   CAREY TS, 1995, NEW ENGL J MED, V333, P913, DOI 10.1056/NEJM199510053331406
   Casazza BA, 1998, OCCUP MED, V13, P47
   Cheung KMC, 2009, SPINE, V34, P934, DOI 10.1097/BRS.0b013e3181a01b3f
   Choi BKL, 2010, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006555.pub2
   Chou R, 2009, LANCET, V373, P463, DOI 10.1016/S0140-6736(09)60172-0
   Cifuentes M, 2010, PAIN, V151, P22, DOI 10.1016/j.pain.2010.04.012
   Clarke JA, 2007, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003010.pub4
   Dahm KT, 2010, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007612.pub2
   Engers A, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004057.pub3
   French SD, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004750.pub2
   Fritz JM, 2008, SPINE, V33, P1800, DOI 10.1097/BRS.0b013e31817bd853
   FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506
   Furlan AD, 2005, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD001351.pub2
   Furlan AD, 2009, SPINE, V34, P1669, DOI 10.1097/BRS.0b013e3181ad7bd6
   Hagen KB, 2004, COCHRANE DATABASE SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD001254.pub2
   Hancock MJ, 2007, LANCET, V370, P1638, DOI 10.1016/S0140-6736(07)61686-9
   Hancock MJ, 2009, CLIN J PAIN, V25, P659, DOI 10.1097/AJP.0b013e3181a7ee3a
   Hayden JA, 2005, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD000335.pub2
   Henschke N, 2009, ARTHRITIS RHEUM-US, V60, P3072, DOI 10.1002/art.24853
   Hides J A, 2001, SPINE (PHILA PA 1976), V26, PE243, DOI 10.1097/00007632-200106010-00004
   Hoiriis KT, 2004, J MANIP PHYSIOL THER, V27, P388, DOI 10.1016/j.jmpt.2004.05.003
   Holve RL, 2008, J AM BOARD FAM MED, V21, P469, DOI 10.3122/jabfm.2008.05.070220
   Institute for Clinical Systems Improvement, 2010, AD LOW BACK PAIN GUI, V0, P0
   JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201
   Jüni P, 2009, ANN RHEUM DIS, V68, P1420, DOI 10.1136/ard.2008.093757
   Kennedy S, 2008, COMPLEMENT THER MED, V16, P139, DOI 10.1016/j.ctim.2007.03.001
   Lau PMY, 2008, AUST J PHYSIOTHER, V54, P243
   Lin CWC, 2011, EUR SPINE J, V20, P1024, DOI 10.1007/s00586-010-1676-3
   Machado LAC, 2006, SPINE, V31, PE254, DOI 10.1097/01.brs.0000214884.18502.93
   Machado LAC, 2010, BMC MED, V8, P0, DOI 10.1186/1741-7015-8-10
   Roberts ST, 2009, PM&R, V1, P657, DOI 10.1016/j.pmrj.2009.04.008
   Stanton TR, 2008, SPINE, V33, P2923, DOI 10.1097/BRS.0b013e31818a3167
   Tao XG, 2005, J OCCUP ENVIRON MED, V47, P1298, DOI 10.1097/01.jom.0000184877.01691.a3
   Van Duijvenbode ICD, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD001823.pub3
   van Tulder M W, 2003, COCHRANE DATABASE SYST REV, V0, PCD004252
   Walker BF, 2011, SPINE, V36, P230, DOI 10.1097/BRS.0b013e318202ac73
   Webster BS, 2010, J OCCUP ENVIRON MED, V52, P900, DOI 10.1097/JOM.0b013e3181ef7e53
NR 46
TC 117
Z9 159
U1 0
U2 52
PU AMER ACAD FAMILY PHYSICIANS
PI KANSAS CITY
PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA
SN 0002-838X
EI 1532-0650
J9 AM FAM PHYSICIAN
JI Am. Fam. Physician
PD FEB 15
PY 2012
VL 85
IS 4
BP 343
EP 350
DI 
PG 8
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA 980AZ
UT WOS:000306867300008
PM 22335313
DA 2026-01-16
ER

PT J
AU Lin, JG
   Chen, YH
AF Lin, Jaung-Geng
   Chen, Yi-Hung
TI The role of acupuncture in cancer supportive care.
SO The American journal of Chinese medicine
LA English
DT Review
AB Acupuncture has many beneficial effects during cancer therapy and has proven  efficacy in the management of side effects induced by chemotherapy and  radiotherapy. In this review, we discussed the benefits of acupuncture on cancer  patients. In cancer pain management, acupuncture is effective for head and neck  pain, waist pain, abdominal and chest pain. Many studies confirm the excellent  efficacy of acupuncture against symptoms of vomiting and nausea, including those  induced by chemotherapy and radiotherapy. Head and neck cancer patients receiving  radiotherapy may develop xerostomia, which may be relieved by acupuncture.  Acupuncture may also cause sedative and hypnotic effects in cancer patients for  treating nervousness and insomnia.
C1 School of Chinese Medicine, China Medical University, 91 Hsueh-Shih Road, Taichung, Taiwan. jglin@mail.cmu.edu.tw
NR 0
TC 0
SN 1793-685
EI 
J9 Am J Chin Med
PD MAR 16
PY 2012
VL 40
IS 2
BP 219
EP 29
DI 10.1142/S0192415X12500176
PG -190
WC Acupuncture Therapy; Animals; Antineoplastic Agents; adverse effects; Humans; Neoplasms; complications; Radiotherapy; adverse effects
UT PubMed:22419418
PM 22419418
DA 2012-03-16
ER

PT J
AU Enblom, A
   Johnsson, A
   Hammar, M
   Onelöv, E
   Steineck, G
   Börjeson, S
AF Enblom, A.
   Johnsson, A.
   Hammar, M.
   Onelov, E.
   Steineck, G.
   Borjeson, S.
TI Acupuncture compared with placebo acupuncture in radiotherapy-induced nausea-a randomized controlled study
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE acupuncture therapy; cancer; complementary medicine; emesis; radiotherapy
ID single-blind; stimulation; needle; chemotherapy; expectancy; emesis
AB It is not known if verum (real) acupuncture is effective for nausea and vomiting (emesis) during radiotherapy. We randomly treated 215 blinded cancer patients with verum: penetrating 'deqi' creating acupuncture (n = 109) or non-penetrating sham needles (n = 106) two to three times per week. The patients documented emesis daily during the radiotherapy period. Primary end point was the number of patients with at least one episode of nausea. In the verum and the sham acupuncture group, 70% and 62% experienced nausea at least once during the radiotherapy period (relative risk 1.1, 95% CI 0.9-1.4) for a mean number of 10.1 and 8.7 days. Twenty five percent and 28% vomited, and 42% and 37% used antiemetic drugs at least once, respectively. Ninety-five percent in the verum acupuncture group and 96% in the sham acupuncture group believed that the treatment had been effective against nausea. In both groups, 67% experienced positive effects on relaxation, mood, sleep or pain reduction and 89% wished to receive the treatment again. Acupuncture creating deqi is not more effective than sham in radiotherapy-induced nausea, but in this study, nearly all patients in both groups experienced that the treatment was effective for nausea.
C1 [Enblom, A.] Karolinska Inst, Osher Ctr Integrat Med, Dept Clin Neurosci, SE-17177 Stockholm, Sweden.
   [Enblom, A.; Borjeson, S.] Linkoping Univ, Dept Med & Hlth Sci, Div Nursing Sci, Linkoping, Sweden.
   [Enblom, A.] Lund Univ, Swedish Inst Hlth Sci, Lund, Sweden.
   [Johnsson, A.] Univ Lund Hosp, Dept Oncol, S-22185 Lund, Sweden.
   [Hammar, M.] Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden.
   [Onelov, E.; Steineck, G.] Karolinska Inst, Dept Oncol Pathol, Div Clin Canc Epidemiol, SE-17177 Stockholm, Sweden.
   [Borjeson, S.] Linkoping Univ Hosp, Dept Oncol, Ctr Surg & Oncol, S-58185 Linkoping, Sweden.
   [Steineck, G.] Sahlgrens Acad, Dept Oncol, Div Clin Canc Epidemiol, Gothenburg, Sweden.
C3 Karolinska Institutet; Linkoping University; Lund University; Lund University; Skane University Hospital; Linkoping University; Karolinska Institutet; Linkoping University; University of Gothenburg
RP Enblom, A (corresponding author), Karolinska Inst, Osher Ctr Integrat Med, Dept Clin Neurosci, SE-17177 Stockholm, Sweden.
EM anna.enblom@ki.se
FU Swedish Cancer Society [04 0483]; Swedish Institute for Health Sciences (the Vardal institute); County Council of Ostergotland [LIO-4998, 2005-279-83, LIO-4762, LIO-7433, LIO-10456, LIO-20071]; University of Linkoping [C 40111]; Vardal Foundation-for Health Care Sciences and Allergy Research; Ostgota Cancer Fund
CR Abdelsayed GG, 2007, EXP HEMATOL, V35, P34, DOI 10.1016/j.exphem.2007.01.010
   Anna E, 2008, COMPLEMENT THER MED, V16, P288, DOI 10.1016/j.ctim.2008.02.012
   Bausell RB, 2005, EVAL HEALTH PROF, V28, P9, DOI 10.1177/0163278704273081
   Borjeson S, 1997, CANCER NURS, V20, P260
   Cao XD, 2002, ACUPUNCTURE ELECTRO, V27, P1
   Carlsson Christer, 2002, ACUPUNCT MED, V20, P82
   Enblom A, 2011, ACUPUNCT MED, V29, P94, DOI 10.1136/aim.2010.003384
   Enblom A, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0014766
   Enblom A, 2009, SUPPORT CARE CANCER, V17, P23, DOI 10.1007/s00520-008-0445-x
   Ezzo JM, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002285.pub2
   Feyer PC, 2011, SUPPORT CARE CANCER, V19, PS5, DOI 10.1007/s00520-010-0950-6
   Hendley GW, 2005, ANN EMERG MED, V45, P77, DOI 10.1016/j.annemergmed.2004.07.446
   Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037
   Johnstone PAS, 2002, PALLIATIVE MED, V16, P235, DOI 10.1191/0269216302pm540oa
   Lai XS, 2009, NEUROSCI LETT, V452, P194, DOI 10.1016/j.neulet.2009.01.052
   Lee A, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003281.pub3
   Liu S, 2007, NEUROSCI LETT, V421, P203, DOI 10.1016/j.neulet.2007.04.078
   MacPherson Hugh, 2010, J EVID BASED MED, V3, P140, DOI 10.1111/j.1756-5391.2010.01086.x
   Maranzano E, 1999, INT J RADIAT ONCOL, V44, P619, DOI 10.1016/S0360-3016(99)00055-3
   Matthews A, 2010, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007575.pub2
   Miller FG, 2004, JAMA-J AM MED ASSOC, V291, P599, DOI 10.1001/jama.291.5.599
   Mystakidou K, 2006, MED ONCOL, V23, P251, DOI 10.1385/MO:23:2:251
   Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016
   Park H, 2002, AM J CHINESE MED, V30, P45, DOI 10.1142/S0192415X02000053
   Park J, 2005, ARCH INTERN MED, V165, P2026, DOI 10.1001/archinte.165.17.2026
   Park J, 1999, ACUPUNCT MED, V17, P110
   Park Jongbae, 2002, ACUPUNCT MED, V20, P168
   Richardson MA, 2000, J CLIN ONCOL, V18, P2505, DOI 10.1200/JCO.2000.18.13.2505
   Roscoe JA, 2009, J PAIN SYMPTOM MANAG, V38, P381, DOI 10.1016/j.jpainsymman.2008.09.006
   Sandberg M, 2004, EUR J PAIN, V8, P163, DOI 10.1016/S1090-3801(03)00090-9
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Steineck G, 2006, ACTA ONCOL, V45, P421, DOI 10.1080/02841860600649293
   Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8
   Streitberger K, 2003, CLIN CANCER RES, V9, P2538
   Streitberger K, 2006, AUTON NEUROSCI-BASIC, V129, P107, DOI 10.1016/j.autneu.2006.07.015
   White A, 2001, BRIT MED J, V323, P485, DOI 10.1136/bmj.323.7311.485
   White P, 2003, PAIN, V106, P401, DOI 10.1016/j.pain.2003.08.013
   Yoo SS, 2004, NEUROIMAGE, V22, P932, DOI 10.1016/j.neuroimage.2004.02.017
NR 38
TC 72
Z9 83
U1 2
U2 27
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD MAY 15
PY 2012
VL 23
IS 5
BP 1353
EP 1361
DI 10.1093/annonc/mdr402
PG 9
WC Oncology
SC Oncology
GA 933CH
UT WOS:000303336400040
DA 2026-01-16
ER

PT J
AU Burnstock, G
AF Burnstock, G
TI Purinergic signalling in the lower urinary tract.
SO Acta physiologica (Oxford, England)
LA English
DT Review
AB The aim of this review is to describe the conceptual steps contributing to our  current knowledge of purinergic signalling and to consider its involvement in the  physiology and pathophysiology of the lower urinary tract. The voiding reflex  involves ATP released as a cotransmitter with acetylcholine from parasympathetic  nerves supplying the bladder and ATP released from urothelial cells during  bladder distension to initiate the voiding reflex via P2X3 receptors on  suburothelial low threshold sensory nerve fibres. This mechanosensory  transduction pathway also participates, via high threshold sensory nerve fibres,  in the initiation of pain in bladder and ureter. Treatment of prostate and  bladder cancer with ATP is effective against the primary tumours in animal models  and human cell lines, via P2X5 and P2X7 receptors, and also improves the systemic  symptoms associated with advanced malignancy. Acupuncture is widely used for the  treatment of urinary disorders, and a purinergic hypothesis is discussed for the  underlying mechanism.
C1 Autonomic Neuroscience Centre, University College Medical School, London, UK. g.burnstock@ucl.ac.uk
NR 0
TC 0
SN 1748-171
EI 
J9 Acta Physiol (Oxf)
PD NOV 28
PY 2012
VL 207
IS 1
BP 40
EP 52
DI 10.1111/apha.12012
PG 12
WC Animals; Humans; Male; Prostate; innervation; Prostatic Neoplasms; physiopathology; Receptors, Purinergic; physiology; Signal Transduction; physiology; Ureter; innervation; Urinary Bladder; innervation; Urinary Bladder Neoplasms; physiopathology
UT PubMed:23176070
PM 23176070
DA 2012-11-28
ER

PT J
AU Smith, ME
   Bauer-Wu, S
AF Smith, Mary Elizabeth
   Bauer-Wu, Susan
TI Traditional Chinese Medicine for cancer-related symptoms.
SO Seminars in oncology nursing
LA English
DT Review
AB OBJECTIVE: To familiarize oncology nurses about the theory and research related  to Traditional Chinese Medicine (TCM) for management of cancer-related symptoms.  DATA SOURCES: Peer-reviewed journal articles, TCM texts, professional experience.  CONCLUSION: The increasing integration of TCM into mainstream medicine mandates  that oncology professionals be familiar with the benefits as well as risks.  Clinical research on acupuncture in cancer care is growing and demonstrates it is  safe for cancer patients, although results on efficacy across symptoms have been  mixed. IMPLICATIONS FOR NURSING PRACTICE: Informed oncology nurses can assist  patients by making appropriate referrals to licensed acupuncturists and qualified  TCM practitioners to help alleviate unpleasant symptoms associated with cancer  and conventional cancer treatment.
C1 Director of Chinese Medicine Services, UNM Center for Life, University of New Mexico, Department of Internal Medicine, Albuquerque, NM 87109, USA.mesmith@salud.unm.edu
NR 0
TC 0
SN 1878-344
EI 
J9 Semin Oncol Nurs
PD JAN 28
PY 2012
VL 28
IS 1
BP 64
EP 74
DI 10.1016/j.soncn.2011.11.007
PG 10
WC Acupuncture; methods; Adaptation, Psychological; Hot Flashes; Humans; Lymphedema; therapy; Medicine, Chinese Traditional; methods; Nausea; therapy; Neoplasms; complications; Oncology Nursing; methods; Pain; Pain Management; methods; Quality of Life; Referral and Consultation; Stress, Psychological; Tai Ji; Vomiting; therapy; Xerostomia; therapy
UT PubMed:22281311
PM 22281311
DA 2012-01-28
ER

PT J
AU Mao, JJ
   Leed, R
   Bowman, MA
   Desai, K
   Bramble, M
   Armstrong, K
   Barg, F
AF Mao, Jun J.
   Leed, Rana
   Bowman, Marjorie A.
   Desai, Krupali
   Bramble, Manuel
   Armstrong, Katrina
   Barg, Frances
TI Acupuncture for Hot Flashes: Decision Making by Breast Cancer Survivors
SO JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE
LA English
DT Article
DE Acupuncture; Alternative Medicine; Behavior; Breast Cancer; Complementary Medicine; Hot Flashes; Survivors
ID randomized controlled-trial; alternative medicine cam; primary-care physicians; menopausal symptoms; vasomotor symptoms; megestrol-acetate; weight-gain; complementary; women; management
AB Purpose: Hot flashes (HFs) are a particularly common and distressing symptom among breast cancer survivors (BCSs). Given its low rate of side effects, acupuncture shows promise as a therapeutic approach for HFs, but little is known about BCS's decision making about the use of acupuncture. This study seeks to identify attitudes and beliefs about using acupuncture for HFs by BCSs. Methods: Using the Theory of Planned Behavior (TPB) as a conceptual framework, we conducted semistructured interviews among women with stage I-III breast cancer who had finished primary treatment and were currently experiencing HFs. Interviews were taped, transcribed, and coded. We used a modified grounded theory approach to analyze the data. Results: Twenty-five BCSs (13 whites/12 African American) participated in the study. Respondents stated that their intended use of acupuncture for HFs would be dependent on (1) expected therapeutic effects (eg, pain relief, energy); (2) practical concerns (eg, fear of needles, practitioner experience, time commitment); and (3) source of decision support/validation (eg, family members, physicians, self). Although constructs in the TPB accounted for many decision factors, respondents identified 2 major themes outside of the TPB: (1) viewing acupuncture as a natural alternative to medications, and (2) assessing the degree of HFs as bothersome enough in the context of other medical comorbidities to trigger the need for therapy. Conclusion: BCSs expressed varied expected therapeutic benefits, practical concerns, and decision support, emphasizing the "natural appeal" and symptom appraisal as key determinants when using acupuncture for HFs. Incorporating these factors in counseling BCSs may promote patient-centered communication, leading to improved hot flash management and quality of life. (J Am Board Fam Med 2012;25:323-332.)
C1 [Mao, Jun J.; Leed, Rana; Bowman, Marjorie A.; Desai, Krupali; Bramble, Manuel; Barg, Frances] Univ Penn, Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.
   [Mao, Jun J.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
   [Mao, Jun J.; Armstrong, Katrina] Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
   [Bowman, Marjorie A.] Univ Penn, Sch Med, Ctr Publ Hlth Initiat, Philadelphia, PA 19104 USA.
   [Armstrong, Katrina; Barg, Frances] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania
RP Mao, JJ (corresponding author), Univ Penn, Sch Med, Dept Family Med & Community Hlth, 3400 Spruce St,2 Gates, Philadelphia, PA 19104 USA.
EM maoj@uphs.upenn.edu
FU American Cancer Society [CCCDA-08-107-03]; National Institutes of Health [1K23 AT004112-04]
CR AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Balneaves LG, 2007, SUPPORT CARE CANCER, V15, P973, DOI 10.1007/s00520-007-0282-3
   Bertelli G, 2002, ANN ONCOL, V13, P883, DOI 10.1093/annonc/mdf151
   Boon H, 1999, QUAL HEALTH RES, V9, P639, DOI 10.1177/104973299129122135
   Boon Heather S, 2007, BMC WOMENS HEALTH, V7, P4, DOI 10.1186/1472-6874-7-4
   Canales MK, 2003, FAM COMMUNITY HEALTH, V26, P11, DOI 10.1097/00003727-200301000-00003
   Carpenter Janet S, 2002, ONCOL NURS FORUM, V29, PE16, DOI 10.1188/02.ONF.E16-E25
   Carpenter JS, 1998, CANCER-AM CANCER SOC, V82, P1682, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1682::AID-CNCR14>3.0.CO;2-0
   Chalasani P, 2010, AM J MED, V123, P489, DOI 10.1016/j.amjmed.2009.09.042
   DiGiacomo SM, 1999, MED ANTHROPOL Q, V13, P436, DOI 10.1525/maq.1999.13.4.436
   Ganz PA, 2000, JNCI-J NATL CANCER I, V92, P1054, DOI 10.1093/jnci/92.13.1054
   Garro LC, 2000, ETHOS, V28, P275, DOI 10.1525/eth.2000.28.3.275
   Goddard G, 2005, J PAIN, V6, P237, DOI 10.1016/j.jpain.2004.12.009
   Godin G, 2007, BEHAV MED, V33, P67, DOI 10.3200/BMED.33.2.67-79
   Goodwin PJ, 1999, J CLIN ONCOL, V17, P120, DOI 10.1200/JCO.1999.17.1.120
   Greenlee H, 2009, BREAST CANCER RES TR, V117, P653, DOI 10.1007/s10549-009-0315-3
   Hervik J, 2009, BREAST CANCER RES TR, V116, P311, DOI 10.1007/s10549-008-0210-3
   Hirai K, 2008, ANN ONCOL, V19, P49, DOI 10.1093/annonc/mdm494
   Holmberg L, 2004, LANCET, V363, P453, DOI 10.1016/S0140-6736(04)15493-7
   Huang MI, 2006, FERTIL STERIL, V86, P700, DOI 10.1016/j.fertnstert.2006.02.100
   Kelly CM, 2010, BMJ-BRIT MED J, V340, P0, DOI 10.1136/bmj.c693
   Kligman L, 2010, CURR ONCOL, V17, P81
   Kronenberg F, 2002, ANN INTERN MED, V137, P805, DOI 10.7326/0003-4819-137-10-200211190-00009
   LAU RR, 1997, HDB HLTH BEHAV RES, V1, P0
   Lee MS, 2009, CLIMACTERIC, V12, P16, DOI 10.1080/13697130802566980
   Lee MS, 2009, BREAST CANCER RES TR, V115, P497, DOI 10.1007/s10549-008-0230-z
   Loprinzi Charles L, 2006, ACP J CLUB, V144, P41
   Loprinzi CL, 2000, LANCET, V356, P2059, DOI 10.1016/S0140-6736(00)03403-6
   LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602
   Mao JJ, 2009, J CLIN ONCOL, V27, P933, DOI 10.1200/JCO.2008.18.0679
   Mao JJ, 2011, J CANCER SURVIV, V5, P8, DOI 10.1007/s11764-010-0153-7
   Matsuyama H, 1998, J UROLOGY, V159, P2087, DOI 10.1016/S0022-5347(01)63262-2
   Nedstrand E, 2005, CLIMACTERIC, V8, P243, DOI 10.1080/13697130500118050
   Nelson HD, 2006, JAMA-J AM MED ASSOC, V295, P2057, DOI 10.1001/jama.295.17.2057
   Pandya KJ, 2005, LANCET, V366, P818, DOI 10.1016/S0140-6736(05)67215-7
   Pandya KJ, 2000, ANN INTERN MED, V132, P788, DOI 10.7326/0003-4819-132-10-200005160-00004
   Quella SK, 1998, CANCER, V82, P1784, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1789::AID-CNCR27>3.0.CO;2-#
   Savard J, 2004, J PAIN SYMPTOM MANAG, V27, P513, DOI 10.1016/j.jpainsymman.2003.10.013
   Stearns V, 2005, J CLIN ONCOL, V23, P6919, DOI 10.1200/JCO.2005.10.081
   Stearns V, 2002, LANCET, V360, P1851, DOI 10.1016/S0140-6736(02)11774-0
   Stearns Vered, 2002, CURR TREAT OPTIONS ONCOL, V3, P179, DOI 10.1007/s11864-002-0064-6
   Su HI, 2010, BREAST CANCER RES TR, V124, P205, DOI 10.1007/s10549-010-0802-6
   Tchen N, 2003, J CLIN ONCOL, V21, P4175, DOI 10.1200/JCO.2003.01.119
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Wong-Kim E, 2007, J HEALTH CARE POOR U, V18, P118, DOI 10.1353/hpu.2007.0123
NR 45
TC 21
Z9 26
U1 0
U2 12
PU AMER BOARD FAMILY MEDICINE
PI LEXINGTON
PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA
SN 1557-2625
EI 
J9 J AM BOARD FAM MED
JI J. Am. Board Fam. Med.
PD MAY-JUN 15
PY 2012
VL 25
IS 3
BP 323
EP 332
DI 10.3122/jabfm.2012.03.110165
PG 10
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA 939KY
UT WOS:000303810600012
PM 22570396
DA 2026-01-16
ER

PT J
AU Kuai, L
   Chen, H
   Zhang, TT
   Yang, HY
AF Kuai, Le
   Chen, Hao
   Zhang, Ting-Ting
   Yang, Hua-Yuan
TI [Study on dose-effect relationship of electroacupuncture with different current
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
AB OBJECTIVE: To observe the dose-effect relationship of electroacupuncture of  different current intensities combined with Morphine of different dosage on  alleviating the rats' tibial cancer pain, and explore the possible mechanism,  which could provide the experiment basis for alleviating the tibial cancer pain  by electroacupuncture combined with Morphine. METHODS: One hundred female Wistar  rats were randomly divided into a normal group, a model group and eight treatment  groups, 10 cases in each group. The rats in the treatment groups were treated by  combined therapies of electroacupuncture of different intensities with 2 Hz /100  Hz dense-disperse wave on "Jiaji"(EX-B 2)and different dosage Morphine in 2  factor 3 level conditions, once a day for 6 days. The pain thresholds were  observed before the treatment and 0 min, 1 h, 2 h and 5 h after the first  treatment as well as after 3 and 6 times of treatments. The glial fibrillary  acidic protein (GFAP) expression was determined by immunohistochemical method.  RESULTS: The rats' pain thresholds were significantly increased with  electroacupuncture of 2 mA and 1 mA (all P < 0.01) on the 0 min, 1 h and 2 h of  the first treatment, between which there were no significant differences (all P >  0.05). The pain threshold was still increased by electroacupuncture of 2 mA on  the 5 h of the treatment (P < 0.01), while that of 1 mA failed to take effect (P  > 0.05). After 3 and 6 times of treatments, both electroacupuncture of 2 mA and 1  mA had the effect of increasing the pain threshold (all P < 0.01), and the effect  of 2 mA was superior to that of 1 mA (P < 0.05), had the synergistic effect with  5 mg/(kg x d) Morphine (P < 0.05). After 6 times of treatments, both  electroacupuncture of 2 mA and 1 mA could inhibit the expression of GFAP (both P  < 0.01), and there was no significant difference between them (P > 0.05). Both of  5 mg/(kg x d) and 2.5 mg/(kg x d) of Morphine, however, didn't bring about  inhibition effect (P > 0.05). CONCLUSION: There is a does-effect relationship on  electroacupuncture of different current intensity for alleviating the tibial  cancer pain in rats. The electroacupuncture with 2 mA, which is better than that  with 1 mA, has the synergistic effect with 5 mg/(kg x d) of Morphine. The  electroacupuncture can inhibit the expression of GFAP to cooperate with Morphine  for the purpose of alleviating the rats' tibial cancer pain.
C1 College of Acupuncture-Moxibustion and Massage, Shanghai University of TCM, Shanghai 201203, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD JUN 28
PY 2012
VL 32
IS 4
BP 331
EP 7
DI 
PG -324
WC Animals; Bone Neoplasms; complications; Electroacupuncture; instrumentation; Female; Gene Expression Regulation, Neoplastic; Glial Fibrillary Acidic Protein; genetics; Humans; Pain; etiology; Pain Management; instrumentation; Rats; Rats, Wistar; Spine; metabolism; Tibia; metabolism
UT PubMed:22734384
PM 22734384
DA 2012-06-28
ER

PT J
AU Yoon, J
   Jeon, JH
   Lee, YW
   Cho, CK
   Kwon, KR
   Shin, JE
   Sagar, S
   Wong, R
   Yoo, HS
AF Yoon, Jeungwon
   Jeon, Ju-Hyun
   Lee, Yeon-Weol
   Cho, Chong-Kwan
   Kwon, Ki-Rok
   Shin, Ji-Eun
   Sagar, Stephen
   Wong, Raimond
   Yoo, Hwa-Seung
TI Sweet bee venom pharmacopuncture for chemotherapy-induced peripheral neuropathy.
SO Journal of acupuncture and meridian studies
LA English
DT Journal Article
AB INTRODUCTION: Chemotherapy-induced peripheral neuropathy (CIPN) is sensory and  motor nerve damage to the peripheral nervous system caused by chemotherapeutic  agents. It often causes pain and other varying degrees of neuropathic symptoms  accompanied by functional limitations and reduced quality of life. Currently,  there is no standard treatment protocol for the treatment of CIPN. OBJECTIVE: In  need of more research to develop new therapeutic options focusing on their  safety, efficacy, and long-term sustained clinical effects, a pilot study of  sweet bee venom pharmacopuncture (SBVP) for CIPN was conducted to build up  preliminary efficacy data in the process of preparing for a future larger scale  randomized controlled SBVP trial for CIPN. METHODS: We conducted a prospective  case series by analyzing the clinical observations made of CIPN patients treated  with SBVP. A total of 11 eligible consecutive CIPN patients who visited East-West  Cancer Center from June 1, 2010, to February 28, 2011, were treated with total of  six SBVP treatments given within the 3-week period. The outcomes were measured  using World Health Organization Common Toxicity Criteria for Peripheral  neuropathy (WHO grading system), Patient Neurotoxicity Questionnaire (PNQ),  Visual Analogue System (VAS), and Health-Related Quality of Life (HRQOL)  collected at the baseline, post-second, fourth, and the final treatment. Patients  were followed 3 weeks into no intervention to determine the sustained effects of  pharmacopuncture. RESULTS: Both of the WHO CIPN grade and PNQ scores have shown a  decrease in the level of neuropathy. VAS pain level has also shown a great  decrease and improvement in patients' quality of life have also been detected  though modest. Changes in WHO grade, VAS and Total HRQOL scores between the  baseline and after the last treatment session were significant. Changes in WHO  grade, Total PNQ, PNQ-sensory, VAS, Total HRQOL, and HRQOL-functional scores  between the baseline and the 3-week follow-up were significant. CONCLUSION: The  positive result of the study supports the potential value of conducting a fully  powered trial to explore further efficacy of SBVP for CIPN. However a single  positive result within this pilot study must be interpreted with caution.
C1 East-West Cancer Center, Dunsan Oriental Hospital of Daejeon University, Daejeon, Korea.
NR 0
TC 0
SN 2093-815
EI 
J9 J Acupunct Meridian Stud
PD AUG 18
PY 2012
VL 5
IS 4
BP 156
EP 65
DI 10.1016/j.jams.2012.05.003
PG -91
WC Acupuncture Points; Adult; Bee Venoms; administration & dosage; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; drug therapy; Peripheral Nervous System Diseases; drug therapy; Pilot Projects; Prospective Studies
UT PubMed:22898064
PM 22898064
DA 2012-08-18
ER

PT J
AU Walter, M
   Sammer, U
   Kessler, TM
AF Walter, M.
   Sammer, U.
   Kessler, T. M.
TI Chronic pelvic pain syndrome. Neurostimulation, neuromodulation and acupuncture
SO UROLOGE
LA German
DT Article
DE Non-malignant pain; Pelvis; Neurostimulation; Neuromodulation; Acupuncture
ID tibial nerve-stimulation; refractory interstitial cystitis; urinary-tract dysfunction; sacral neuromodulation; voiding dysfunction; randomized-trial; subthalamic stimulation; parkinsons-disease; floor dysfunction; crossover trial
AB Chronic pelvic pain syndrome (CPPS) is defined by the European Association of Urology guidelines as a non-malignant pain perceived in structures related to the pelvis of either women or men for at least 6 months without proven infection or other obvious pathology. It affects the quality of life of millions of people worldwide and has an impact similar to that reported for other chronic diseases, such as diabetes mellitus, Crohn's disease and congestive heart failure. The treatment of CPPS remains a challenge despite several established first line therapies because many patients are therapy refractory. Unconventional treatments, such as neurostimulation, neuromodulation and acupuncture may be highly successful for treating CPPS and have a favorable adverse event profile. Thus, these promising therapeutic alternatives should be considered more often in daily clinical practice.
C1 [Walter, M.; Sammer, U.; Kessler, T. M.] Univ Zurich, Uniklin Balgrist, Zentrum Paraplegie, CH-8008 Zurich, Switzerland.
C3 University of Zurich
RP Kessler, TM (corresponding author), Univ Zurich, Uniklin Balgrist, Zentrum Paraplegie, Forchstr 340, CH-8008 Zurich, Switzerland.
EM tkessler@gmx.ch
CR Aboseif S, 2002, UROLOGY, V60, P52, DOI 10.1016/S0090-4295(02)01630-8
   ACOG Committee on Practice Bulletins--Gynecology, 2004, OBSTET GYNECOL, V103, P589
   American Urological Association, 2011, GUID DIAGN TREATM IC, V0, P0
   Anothaisintawee T, 2011, JAMA-J AM MED ASSOC, V305, P78, DOI 10.1001/jama.2010.1913
   Rodríguez MAB, 2009, J UROLOGY, V182, P2123, DOI 10.1016/j.juro.2009.07.036
   Capodice Jillian L, 2007, CHIN MED, V2, P1, DOI 10.1186/1749-8546-2-1
   Capodice JL, 2005, EVID-BASED COMPL ALT, V2, P495, DOI 10.1093/ecam/neh128
   Cardarelli Sofia, 2012, UROLOGIA, V79, P90, DOI 10.5301/RU.2012.9278
   Chen R, 2003, UROLOGY, V61, P1156, DOI 10.1016/S0090-4295(03)00141-9
   Chen Richard C T, 2004, CURR UROL REP, V5, P305, DOI 10.1007/s11934-004-0057-z
   Collins MM, 2001, J GEN INTERN MED, V16, P656
   Comiter CV, 2003, J UROLOGY, V169, P1369, DOI 10.1097/01.ju.0000053863.96967.5a
   Deadman P, 1998, J CHIN MED, V0, P0
   Elhlali MM, 2005, UROLOGY, V65, P1114, DOI 10.1016/j.urology.2004.12.016
   Ellis A, 1991, FUNDAMENTALS CHINESE, VRevis, P0
   Everaert K, 2004, EUR UROL, V45, P649, DOI 10.1016/j.eururo.2003.11.015
   Everaert K, 2001, INT UROGYNECOL J PEL, V12, P9, DOI 10.1007/s001920170087
   Fall M, 2010, EUR UROL, V57, P35, DOI 10.1016/j.eururo.2009.08.020
   Fenton BW, 2009, BRAIN STIMUL, V2, P103, DOI 10.1016/j.brs.2008.09.009
   Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892
   Herzog J, 2008, BRAIN, V131, P132, DOI 10.1093/brain/awm254
   Herzog J, 2006, BRAIN, V129, P3366, DOI 10.1093/brain/awl302
   Honjo H, 2004, INT J UROL, V11, P607, DOI 10.1111/j.1442-2042.2004.00868.x
   HOSOBUCHI Y, 1986, J NEUROSURG, V64, P543, DOI 10.3171/jns.1986.64.4.0543
   International Association for the Study of Pain, 2003, PAIN CLIN UPD PREV C, V0, P0
   International Association for the Study of Pain, 2008, PAIN CLIN UPD CHRON, V0, P0
   Kessler TM, 2008, CURR MED RES OPIN, V24, P343, DOI 10.1185/030079908X253555
   Kessler TM, 2008, EUR UROL, V53, P607, DOI 10.1016/j.eururo.2007.07.015
   Kessler TM, 2007, EUR UROL, V51, P1357, DOI 10.1016/j.eururo.2006.11.011
   Kim SW, 2007, UROL INT, V78, P58, DOI 10.1159/000096936
   Krieger JN, 1999, JAMA-J AM MED ASSOC, V282, P236, DOI 10.1001/jama.282.3.236
   Lavano A, 2004, J NEUROSURG SCI, V48, P157
   Lee Sang-Hun, 2011, CURR UROL REP, V12, P288, DOI 10.1007/s11934-011-0186-0
   Lee SH, 2009, UROLOGY, V73, P1036, DOI 10.1016/j.urology.2008.10.047
   Lee SWH, 2008, AM J MED, V121, P0, DOI 10.1016/j.amjmed.2007.07.033
   Maher CF, 2001, J UROLOGY, V165, P884, DOI 10.1016/S0022-5347(05)66551-2
   Marszalek M, 2009, EUR UROL, V55, P499, DOI 10.1016/j.eururo.2008.03.073
   Martellucci J, 2012, INT J COLORECTAL DIS, V27, P921, DOI 10.1007/s00384-011-1394-2
   Nickel JC, 2004, J UROLOGY, V172, P551, DOI 10.1097/01.ju.0000131592.98562.16
   Otto W, 2012, AKTUEL UROL, V43, P162, DOI 10.1055/s-0031-1284024
   Pannek J, 2003, UROLOGE A, V42, P1470, DOI 10.1007/s00120-003-0369-5
   Parsons CL, 2007, UROLOGY, V69, P9, DOI 10.1016/j.urology.2006.03.084
   Peters KM, 2007, BJU INT, V100, P835, DOI 10.1111/j.1464-410X.2007.07082.x
   Peters KM, 2010, NEUROUROL URODYNAM, V29, P1267, DOI 10.1002/nau.20823
   Peters KM, 2005, NEUROUROL URODYNAM, V24, P643, DOI 10.1002/nau.20174
   Peters KM, 2004, BJU INT, V93, P777, DOI 10.1111/j.1464-410X.2003.04745.x
   Pham K, 2008, NEUROUROL URODYNAM, V27, P779, DOI 10.1002/nau.20577
   Posadzki P, 2011, J ANDROL, V33, P15, DOI 10.2164/jandrol.111.013235
   Potts JM, 2012, PAIN, V153, P755, DOI 10.1016/j.pain.2011.10.005
   Powell CR, 2010, J UROLOGY, V183, P173, DOI 10.1016/j.juro.2009.08.142
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Scheepens WA, 2002, J UROLOGY, V168, P2046, DOI 10.1016/S0022-5347(05)64292-9
   Shoskes Daniel A, 2005, CURR UROL REP, V6, P296, DOI 10.1007/s11934-005-0027-0
   Sibert L, 2010, PROG UROL, V20, P872, DOI 10.1016/j.purol.2010.08.004
   Siegel S, 2001, J UROLOGY, V166, P1742, DOI 10.1016/S0022-5347(05)65665-0
   Sikiru L, 2008, INT BRAZ J UROL, V34, P708, DOI 10.1590/S1677-55382008000600005
   Stojanovic M P, 2001, CURR PAIN HEADACHE REP, V5, P130, DOI 10.1007/s11916-001-0081-3
   Stux G, 2007, AKUPUNKTUR, V0, P0
   Suh Lara K, 2011, CURR UROL REP, V12, P284, DOI 10.1007/s11934-011-0188-y
   The British Pain Society, 2006, FAQ WHAT IS DEF CHRO, V0, P0
   Tugcu V, 2010, PAIN MED, V11, P518, DOI 10.1111/j.1526-4637.2009.00794.x
   van Balken MR, 2006, INT J IMPOT RES, V18, P470, DOI 10.1038/sj.ijir.3901457
   van Balken MR, 2003, EUR UROL, V43, P158, DOI 10.1016/S0302-2838(02)00552-3
   Wenninger K, 1996, J UROLOGY, V155, P965, DOI 10.1016/S0022-5347(01)66359-6
   Westesson Karin E, 2010, CURR UROL REP, V11, P261, DOI 10.1007/s11934-010-0111-y
   Wöllner J, 2012, BJU INT, V110, P146, DOI 10.1111/j.1464-410X.2012.10906.x
   Zabihi N, 2008, INT UROGYNECOL J, V19, P553, DOI 10.1007/s00192-007-0466-x
NR 68
TC 4
Z9 6
U1 0
U2 17
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-2592
EI 1433-0563
J9 UROLOGE
JI Urologe
PD DEC 15
PY 2012
VL 51
IS 12
BP 1683
EP +
DI 10.1007/s00120-012-3037-9
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 053FX
UT WOS:000312257500005
PM 23224254
DA 2026-01-16
ER

PT J
AU Saw, CL
   Chew, L
   Goh, C
AF Saw, Constance L L
   Chew, Lita
   Goh, Cynthia
TI Recent non-interventional advances in cancer pain among Singapore patients.
SO Annals of the Academy of Medicine, Singapore
LA English
DT Review
AB INTRODUCTION: Pain is a common symptom in cancer patients, but very little  information about the prevalence, severity, and treatment of pain in cancer  patients in Singapore is available. Therefore, our prospective survey in the  National Cancer Centre (NCC) outpatients is incorporated in this report. In  addition, a review concerning the recent advances on non-interventional pain  management in cancer treatment, which is relevant in the context, is discussed.  MATERIALS AND METHODS: For the prospective survey, a questionnaire was  distributed for self-administration by patients while waiting for consultation at  the NCC outpatient departments. Literature searches on advances in pain  management were conducted, reviewed and discussed. RESULTS: In the last decade,  there have been advances in pain pharmacology ranging from wider therapeutic  options and management approaches to novel delivery techniques. Acupuncture and  massage therapy became increasingly popular among cancer patients. Some clinical  trials of acupuncture show benefits in palliation of cancer pain. From the  prospective survey, 41.2% of the responders reported pain in the past week, and  only 70.8% talked to their doctors about their pain. One third of the patients  received analgesics. Of these, 86.5% said that they were taking the prescribed  medications, however, 37.4% admitted to having difficulties taking them. Non-drug  methods were used by 25.4% of the patients. Medicated oil, cream or gel was used  by 49.3%; only 2.6% reported use of Chinese herbs. CONCLUSION: Pain is a  significant symptom in outpatients attending a cancer centre, affecting 41.2% of  the patients. Although majority of patients who suffered from pain reported this  to doctors, much more medical effort is needed to help patients to relieve their  pain and proper complementary therapy could be considered.
C1 Department of Pharmacy, National Cancer Centre, Singapore. constancesaw@gmail.com
NR 0
TC 0
SN 2972-406
EI 
J9 Ann Acad Med Singap
PD OCT 12
PY 2012
VL 41
IS 9
BP 407
EP 16
DI 
PG -391
WC Acupuncture Therapy; Adult; Aged; Aged, 80 and over; Analgesics; therapeutic use; Complementary Therapies; Female; Health Care Surveys; Humans; Male; Massage; Middle Aged; Neoplasms; complications; Outpatients; Pain; drug therapy; Pain Measurement; Phytotherapy; Prevalence; Prospective Studies; Severity of Illness Index; Singapore; epidemiology; Time Factors
UT PubMed:23052435
PM 23052435
DA 2012-10-12
ER

PT J
AU Zhang, Z
   Wang, C
   Gu, G
   Li, H
   Zhao, H
   Wang, K
   Han, F
   Wang, G
AF Zhang, Zhaodi
   Wang, Changsong
   Gu, Guangying
   Li, Huiping
   Zhao, Haifang
   Wang, Kun
   Han, Fei
   Wang, Guonian
TI The effects of electroacupuncture at the ST36 (Zusanli) acupoint on cancer pain
SO Anesthesia and analgesia
LA English
DT Journal Article
AB BACKGROUND: Several studies have addressed the expression of transient receptor  potential vanilloid subfamily 1(TRPV1) playing an important role in the  generation of cancer pain. Electroacupuncture (EA) is an effective method of  acupuncture shown to attenuate different kinds of pain such as inflammatory,  neuropathic, and cancer. In this study, we investigated the effect of EA on  cancer pain caused by intraplantar injection of Walker 256 carcinoma cells and  cancer-driven TRPV1 expression in the dorsal root ganglions (DRGs). METHODS: Rats  were randomly divided into 4 groups: the nontumor cell inoculation group (normal  control, n = 8); Walker 256 carcinoma cell inoculation group (tumor control, n =  8); sham point electrical stimulation treatment with Walker 256 carcinoma cell  inoculation group (SES, n = 8); EA treatment with Walker 256 carcinoma cell  inoculation group (EA, n = 8). The time courses of thermal, mechanical  sensitivity, and spontaneous nocifensive behavior were determined. In addition,  TRPV1 expression in DRGs was observed by quantitative real-time polymerase chain  reaction and Western blotting. RESULTS: Injection of cancer cells decreased the  paw withdrawal threshold, increased spontaneous nocifensive behavior, and induced  significant thermal hyperalgesia that was attenuated by EA at the ST36 acupoint  (2 Hz, 0.3 ms, ≤1 mA). TRPV1 mRNA and protein in DRGs were upregulated in the  cancer pain model, and EA at ST36 acupoint counteracted the cancer-driven  upregulation of TRPV1 expression in the corresponding DRGs. CONCLUSIONS: EA at  ST36 could attenuate cancer-induced pain, at least in part, through suppressing  TRPV1 mRNA and protein upregulation in the DRGs.
C1 Department of Anesthesiology, Third Affiliated Hospital of Harbin Medical University, No. 6 Baojian Rd., Nangang District, Harbin 150081, China.
NR 0
TC 0
SN 1526-759
EI 
J9 Anesth Analg
PD JAN 19
PY 2012
VL 114
IS 4
BP 879
EP 85
DI 10.1213/ANE.0b013e318246536d
PG -794
WC Acupuncture Analgesia; Acupuncture Points; Animals; Carcinoma 256, Walker; physiopathology; Electroacupuncture; Male; Pain, Intractable; therapy; RNA, Messenger; analysis; Rats; Rats, Wistar; TRPV Cation Channels; analysis
UT PubMed:22253272
PM 22253272
DA 2012-01-19
ER

PT J
AU Park, SH
   Knobf, MT
   Sutton, KM
AF Park, So-Hyun
   Knobf, M. Tish
   Sutton, Karen M.
TI Etiology, Assessment, and Management of Aromatase Inhibitor-Related Musculoskeletal Symptoms
SO CLINICAL JOURNAL OF ONCOLOGY NURSING
LA English
DT Article
ID estrogen replacement therapy; early breast-cancer; postmenopausal women; tenosynovial changes; joint symptoms; acupuncture; arthralgia; knee; pain; trial
AB Aromatase inhibitors (AIs) are recommended as adjuvant endocrine therapy for postmenopausal women with hormone-responsive breast cancer. With the widespread use of AI adjuvant endocrine therapy, a significant profile of musculoskeletal symptoms has emerged. Moderate to severe musculoskeletal symptoms have led some women to discontinue therapy, compromising the survival benefit. The etiology of AI-related musculoskeletal symptoms is poorly understood, which challenges development of effective management strategies. The purpose of this article is to describe AI-related musculoskeletal symptoms, review possible causes, provide assessment guidelines, and recommend management strategies based on the best available evidence. Little evidence exists for effective management strategies of AI-related musculoskeletal symptoms, and randomized clinical trials are needed to establish effective interventions. A thorough musculoskeletal assessment can help guide clinical decision making for the best individual management approach. Providers need to manage symptoms with the best available evidence to minimize symptom distress and maximize adherence to AI therapy.
C1 [Park, So-Hyun; Knobf, M. Tish] Yale Univ, Sch Nursing, New Haven, CT 06536 USA.
   [Sutton, Karen M.] Yale Univ, Dept Orthoped Surg & Rehabil, New Haven, CT 06536 USA.
C3 Yale University; Yale University
RP Park, SH (corresponding author), Yale Univ, Sch Nursing, New Haven, CT 06536 USA.
EM so-hyun.park@yale.edu
CR Briot K, 2010, BREAST CANCER RES TR, V120, P127, DOI 10.1007/s10549-009-0692-7
   Burstein HJ, 2010, J CLIN ONCOL, V28, P3784, DOI 10.1200/JOP.000082
   CHRISTENSEN BV, 1992, ACTA ANAESTH SCAND, V36, P519, DOI 10.1111/j.1399-6576.1992.tb03511.x
   Crew Katherine D, 2007, J CANCER SURVIV, V1, P283, DOI 10.1007/s11764-007-0034-x
   Crew KD, 2007, J CLIN ONCOL, V25, P3877, DOI 10.1200/JCO.2007.10.7573
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Dent SF, 2011, BREAST CANCER RES TR, V126, P295, DOI 10.1007/s10549-011-1351-3
   Dietrich W, 2006, J SOC GYNECOL INVEST, V13, P512, DOI 10.1016/j.jsgi.2006.07.002
   Din OS, 2010, BREAST CANCER RES TR, V120, P525, DOI 10.1007/s10549-010-0757-7
   Dizdar O, 2009, J CLIN ONCOL, V27, P4955, DOI 10.1200/JCO.2008.20.5435
   Dowsett M, 2010, J CLIN ONCOL, V28, P509, DOI 10.1200/JCO.2009.23.1274
   Ernst E, 2011, PAIN, V152, P755, DOI 10.1016/j.pain.2010.11.004
   Ezzo J, 2001, ARTHRITIS RHEUM, V44, P819, DOI 10.1002/1529-0131(200104)44:4<819::AID-ANR138>3.3.CO;2-G
   Fernihough JK, 1999, ARTHRITIS RHEUM, V42, P2103, DOI 10.1002/1529-0131(199910)42:10<2103::AID-ANR10>3.0.CO;2-S
   Freedman RA, 2010, BREAST, V19, P69, DOI 10.1016/j.breast.2009.11.009
   Guise TA, 2010, CURR MED RES OPIN, V26, P6
   Hall H, 2011, PAIN, V152, P711, DOI 10.1016/j.pain.2011.01.039
   Henry NL, 2008, BREAST CANCER RES TR, V111, P365, DOI 10.1007/s10549-007-9774-6
   Henry NL, 2012, J CLIN ONCOL, V30, P936, DOI 10.1200/JCO.2011.38.0261
   Henry NL, 2011, BREAST CANCER RES TR, V125, P751, DOI 10.1007/s10549-010-1206-3
   Ingle JN, 2010, J CLIN ONCOL, V28, P4674, DOI 10.1200/JCO.2010.28.5064
   Jones SE, 2007, J CLIN ONCOL, V25, P4765, DOI 10.1200/JCO.2007.10.8274
   Josefsson ML, 2010, BREAST, V19, P76, DOI 10.1016/j.breast.2009.12.010
   Khan QJ, 2010, BREAST CANCER RES TR, V119, P111, DOI 10.1007/s10549-009-0495-x
   Mao JJ, 2009, CANCER, V115, P3631, DOI 10.1002/cncr.24419
   Miaskowski C, 2008, CLIN J ONCOL NURS, V12, P213, DOI 10.1188/08.CJON.213-221
   Millar A, 2009, ACSMS RESOURCES MANU, V0, P661
   Morales L, 2008, J CLIN ONCOL, V26, P3147, DOI 10.1200/JCO.2007.15.4005
   Morales L, 2007, BREAST CANCER RES TR, V104, P87, DOI 10.1007/s10549-006-9394-6
   Offit K, 2010, J CLIN ONCOL, V28, P4665, DOI 10.1200/JCO.2010.31.2926
   Presant CA, 2007, CLIN BREAST CANCER, V7, P775, DOI 10.3816/CBC.2007.n.038
   Prieto-Alhambra D, 2011, BREAST CANCER RES TR, V125, P869, DOI 10.1007/s10549-010-1075-9
   Sugamata N, 1999, INT J ONCOL, V14, P259
   Takeda W, 1994, ARTHRITIS CARE RES, V7, P118, DOI 10.1002/art.1790070304
   Vanderschueren D, 1997, ENDOCRINOLOGY, V138, P2301, DOI 10.1210/en.138.6.2301
   Waltman NL, 2009, CANCER NURS, V32, P143, DOI 10.1097/01.NCC.0000339262.44560.92
   Zhang YQ, 1998, ARTHRITIS RHEUM, V41, P1867, DOI 10.1002/1529-0131(199810)41:10<1867::AID-ART20>3.3.CO;2-N
NR 37
TC 10
Z9 12
U1 0
U2 8
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 1092-1095
EI 1538-067X
J9 CLIN J ONCOL NURS
JI Clin. J. Oncol. Nurs.
PD JUN 15
PY 2012
VL 16
IS 3
BP 260
EP 266
DI 10.1188/12.CJON.260-266
PG 7
WC Oncology; Nursing
SC Oncology; Nursing
GA 953BI
UT WOS:000304841500007
PM 22641317
DA 2026-01-16
ER

PT J
AU Cha, MH
   Nam, TS
   Kwak, Y
   Lee, H
   Lee, BH
AF Cha, Myeoung Hoon
   Nam, Taick Sang
   Kwak, Yongho
   Lee, Hyejung
   Lee, Bae Hwan
TI Changes in cytokine expression after electroacupuncture in neuropathic rats.
SO Evidence-based complementary and alternative medicine : eCAM
LA English
DT Journal Article
AB The production of proinflammatory cytokines including interleukin-1 (IL-1),  interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) plays a key role in  chronic pain such as neuropathic pain. We investigated changes in cytokine  expression in injured peripheral nerves and dorsal root ganglia (DRG) following  electroacupuncture (EA) treatment. Neuropathic pain was induced by peripheral  nerve injury to the left hind limb of Sprague-Dawley rats under pentobarbital  anesthesia. Two weeks later, the nerve-injured rats were treated by EA for 10  minutes. The expression levels of IL-1β, IL-6, and TNF-α in peripheral nerves and  DRG of neuropathic rats were significantly increased in nerve-injured rats.  However, after EA, the cytokine expression levels were noticeably decreased in  peripheral nerves and DRG. These results suggest that EA stimulation can reduce  the levels of proinflamtory cytokines elevated after nerve injury.
C1 Department of Physiology and Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, P.O. Box 8044, Seoul 120-752, Republic of Korea.
NR 0
TC 0
SN 1741-428
EI 1741-427
J9 Evid Based Complement Alternat Med
PD MAR 29
PY 2012
VL 2012
IS 
BP 792765
EP 792765
DI 10.1155/2012/792765
PG 0
UT PubMed:22454684
PM 22454684
DA 2012-03-29
ER

PT J
AU Wang, CZ
   He, H
   Wang, XY
   Yuan, CS
AF Wang, Chong-Zhi
   He, Hui
   Wang, Xiaoyu
   Yuan, Chun-Su
TI Trends in Scientific Publications of Chinese Medicine
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Traditional Chinese Medicine; TCM; Complementary and Alternative Medicine; CAM; American Journal of Chinese Medicine; AJCM; Publication Trends; Journal Impact Factor; Herbal Medicine; Inflammation; Cancer Research
ID anoectochilus-formosanus; ganoderma-lucidum; active components; tai chi; acupuncture; antioxidant; ginseng; pain; osteoarthritis; complementary
AB Traditional Chinese medicine (TCM) is an important component of complementary and alternative medicine (CAM). The fast economic growth of mainland China in the past two decades has promoted the use of TCM beyond Chinese-speaking countries. Chinese researchers have published more TCM research studies in CAM-related professional journals, including the American Journal of Chinese Medicine (AJCM), the highest impact journal in Chinese medicine. The consistent increase of the impact factor of the AJCM suggests a growth in TCM popularity. This study analyzed articles published in the AJCM between 2004 and 2011. Our data show that while enthusiasm towards cardiovascular, nervous system and inflammation related research remained high, more herbal investigations and cancer studies were published. Furthermore, a reduction in TCM formulation studies was replaced by increasing botanical single constituent research. Examples of frequently cited studies, including those before 2004, are presented. These data are not only important to the scientific community for recognition of trends in TCM research, but also for providing information to TCM researchers who are targeting potentially highly cited studies.
C1 [Wang, Chong-Zhi] Univ Chicago, Pritzker Sch Med, Tang Ctr Herbal Med Res, Chicago, IL 60637 USA.
   [Wang, Chong-Zhi] Univ Chicago, Pritzker Sch Med, Dept Anesthesia & Crit Care, Chicago, IL 60637 USA.
C3 University of Chicago; University of Chicago
RP Wang, CZ (corresponding author), Univ Chicago, Pritzker Sch Med, Tang Ctr Herbal Med Res, 5841 S Maryland Ave,MC 4028, Chicago, IL 60637 USA.
EM CWang@dacc.uchicago.edu
FU NIH/NCCAM [P01 AT004418, K01 AT005362]
CR Bian Zhao-Xiang, 2006, ZHONG XI YI JIE HE XUE BAO, V4, P120
   Carpenter RJ, 2010, AM J CHINESE MED, V38, P839, DOI 10.1142/S0192415X10008287
   Chan E, 2010, AM J CHINESE MED, V38, P815, DOI 10.1142/S0192415X10008263
   Chang HC, 2002, AM J CHINESE MED, V30, P307, DOI 10.1142/S0192415X02000223
   Chen MJ, 2010, AM J CHINESE MED, V38, P1131, DOI 10.1142/S0192415X10008524
   Cheung F, 2011, NATURE, V480, PS94, DOI 10.1038/480S94a
   COAN RM, 1980, AM J CHINESE MED, V8, P181, DOI 10.1142/S0192415X80000141
   Dagenais Simon, 2006, ZHONG XI YI JIE HE XUE BAO, V4, P455, DOI 10.3736/jcim20060504
   Ernst E, 2011, AM J CHINESE MED, V39, P423, DOI 10.1142/S0192415X11008920
   Hsieh CH, 2010, AM J CHINESE MED, V38, P675, DOI 10.1142/S0192415X10008147
   Hsu WH, 2010, AM J CHINESE MED, V38, P661, DOI 10.1142/S0192415X10008135
   Huang ST, 2005, AM J CHINESE MED, V33, P157, DOI 10.1142/S0192415X0500276X
   ISI Web of Knowledge, 2012, J CITATION REPORTS Q, V0, P0
   Jang HI, 2010, AM J CHINESE MED, V38, P949, DOI 10.1142/S0192415X10008378
   Kim SJ, 2011, AM J CHINESE MED, V39, P587, DOI 10.1142/S0192415X11009056
   Kuo YC, 1996, AM J CHINESE MED, V24, P111, DOI 10.1142/S0192415X96000165
   Kwon YB, 2001, AM J CHINESE MED, V29, P187, DOI 10.1142/S0192415X01000228
   Lee HZ, 2011, AM J CHINESE MED, V39, P201, DOI 10.1142/S0192415X11008750
   LEI XL, 1986, AM J CHINESE MED, V14, P145, DOI 10.1142/S0192415X86000235
   Li J, 2010, AM J CHINESE MED, V38, P569, DOI 10.1142/S0192415X10008068
   Li L, 2010, AM J CHINESE MED, V38, P449, DOI 10.1142/S0192415X1000797X
   Li SP, 2011, J PHARMACEUT BIOMED, V55, P802, DOI 10.1016/j.jpba.2010.12.011
   Liao HF, 2010, AM J CHINESE MED, V38, P173, DOI 10.1142/S0192415X10007749
   Lin CC, 1996, AM J CHINESE MED, V24, P31, DOI 10.1142/S0192415X96000050
   Lin CC, 2000, AM J CHINESE MED, V28, P87, DOI 10.1142/S0192415X00000118
   Lin JG, 2008, AM J CHINESE MED, V36, P635, DOI 10.1142/S0192415X08006107
   Lin JG, 2012, AM J CHINESE MED, V40, P219, DOI 10.1142/S0192415X12500176
   Lin JG, 1999, AM J CHINESE MED, V27, P265, DOI 10.1142/S0192415X99000306
   LIN JM, 1993, AM J CHINESE MED, V21, P59, DOI 10.1142/S0192415X9300008X
   Maciaszek J, 2010, AM J CHINESE MED, V38, P219, DOI 10.1142/S0192415X10007798
   MARGOLIN A, 1993, AM J CHINESE MED, V21, P103, DOI 10.1142/S0192415X93000133
   Su SL, 2010, AM J CHINESE MED, V38, P777, DOI 10.1142/S0192415X10008238
   Sun MY, 2010, AM J CHINESE MED, V38, P849, DOI 10.1142/S0192415X10008299
   Tang NY, 2010, AM J CHINESE MED, V38, P51, DOI 10.1142/S0192415X10007786
   THOMAS M, 1991, AM J CHINESE MED, V19, P95, DOI 10.1142/S0192415X91000156
   Tian JH, 2010, AM J CHINESE MED, V38, P15, DOI 10.1142/S0192415X10007646
   Vincent A, 2010, AM J CHINESE MED, V38, P695, DOI 10.1142/S0192415X10008160
   Wang CZ, 2007, AM J CHINESE MED, V35, P543, DOI 10.1142/S0192415X07005053
   Wang CZ, 2012, AM J CHINESE MED, V40, P657, DOI 10.1142/S0192415X12500498
   Wang CZ, 2011, AM J CHINESE MED, V39, P1161, DOI 10.1142/S0192415X11009470
   Wang J, 2011, AM J CHINESE MED, V39, P651, DOI 10.1142/S0192415X11009093
   Wetzel MS, 2003, ANN INTERN MED, V138, P191, DOI 10.7326/0003-4819-138-3-200302040-00011
   Wong CK, 2005, AM J CHINESE MED, V33, P381, DOI 10.1142/S0192415X05002990
   Wright PA, 2011, AM J CHINESE MED, V39, P461, DOI 10.1142/S0192415X11008968
   Wu JA, 2001, AM J CHINESE MED, V29, P69, DOI 10.1142/S0192415X01000083
   Wu SJ, 2010, AM J CHINESE MED, V38, P99, DOI 10.1142/S0192415X10007695
   WU WL, 1991, AM J CHINESE MED, V19, P207, DOI 10.1142/S0192415X91000284
   Xie JT, 2005, AM J CHINESE MED, V33, P397, DOI 10.1142/S0192415X05003004
   Xu M, 2010, AM J CHINESE MED, V38, P401, DOI 10.1142/S0192415X10007932
   Xu ZT, 2011, AM J CHINESE MED, V39, P15, DOI 10.1142/S0192415X11008610
   Xutian S, 2012, AM J CHINESE MED, V40, P231, DOI 10.1142/S0192415X12500188
   Xutian S, 2009, AM J CHINESE MED, V37, P411, DOI 10.1142/S0192415X09006941
   Yin YY, 2010, AM J CHINESE MED, V38, P517, DOI 10.1142/S0192415X10008020
   Zakaria ZA, 2011, AM J CHINESE MED, V39, P183, DOI 10.1142/S0192415X11008749
   Zeng XX, 2011, AM J CHINESE MED, V39, P1061, DOI 10.1142/S0192415X11009408
   Zhen Z, 2011, AM J CHINESE MED, V39, P53, DOI 10.1142/S0192415X11008646
   ZHOU W, 1990, AM J CHINESE MED, V18, P19, DOI 10.1142/S0192415X90000046
NR 57
TC 20
Z9 23
U1 4
U2 74
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192-415X
EI 1793-6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PD JUN 15
PY 2012
VL 40
IS 6
BP 1099
EP 1108
DI 10.1142/S0192415X12500814
PG 10
WC Integrative & Complementary Medicine; Medicine, General & Internal
SC Integrative & Complementary Medicine; General & Internal Medicine
GA 052PN
UT WOS:000312210400001
PM 23227784
DA 2026-01-16
ER

PT J
AU Choi, TY
   Lee, MS
   Kim, TH
   Zaslawski, C
   Ernst, E
AF Choi, Tae-Young
   Lee, Myeong Soo
   Kim, Tae-Hun
   Zaslawski, Christopher
   Ernst, Edzard
TI Acupuncture for the treatment of cancer pain: a systematic review of randomised
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Journal Article
AB PURPOSE: Controlling cancer-related pain is an important component in the  palliative care of cancer patients. The objective of this review was to assess  the effectiveness of acupuncture for treating cancer pain. METHODS: Fourteen  databases were searched from their inception through April 2011. Randomised  clinical trials (RCTs) were included if acupuncture was used as the sole  treatment or as a part of a combination therapy for cancer pain. Studies were  included if they were controlled with a placebo or controlled against a  drug-therapy or no-treatment group. The Cochrane criteria were used to assess the  risk of bias. RESULTS: A total of 15 RCTs met our inclusion criteria. All of the  included RCTs were associated with a high risk of bias. The majority of  acupuncture treatments or combination therapies with analgesics exhibited  favourable effects compared with conventional treatments in individual studies.  However, a meta-analysis suggested that acupuncture did not generate a better  effect than drug therapy (n = 886; risk ratio (RR), 1.12; 95% CI 0.98 to 1.28; P  = 0.09). The comparison between acupuncture plus drug therapy and drug therapy  alone demonstrated a significant difference in favour of the combination therapy  (n = 437; RR, 1.36; 95% CI 1.13 to 1.64; P = 0.003). The results of this  systematic review provide no strong evidence for the effectiveness of acupuncture  in the management of cancer pain. CONCLUSION: The total number of RCTs included  in the analysis and their methodological quality were too low to draw firm  conclusions. Future rigorous RCTs will be necessary to assess the clinical  efficacy of acupuncture in this area.
C1 Medical Research Division, Korea Institute of Oriental Medicine, Daejeon, 305-811, South Korea.
NR 0
TC 0
SN 1433-733
EI 
J9 Support Care Cancer
PD MAR 27
PY 2012
VL 20
IS 6
BP 1147
EP 58
DI 10.1007/s00520-012-1432-9
PG -1089
WC Acupuncture Therapy; methods; Analgesics; administration & dosage; Combined Modality Therapy; Humans; Neoplasms; complications; Pain; etiology; Pain Management; methods; Palliative Care; methods; Randomized Controlled Trials as Topic; Treatment Outcome
UT PubMed:22447366
PM 22447366
DA 2012-03-27
ER

PT J
AU Mao, JJ
   Leed, R
   Bowman, MA
   Desai, K
   Bramble, M
   Armstrong, K
   Barg, F
AF Mao, Jun J
   Leed, Rana
   Bowman, Marjorie A
   Desai, Krupali
   Bramble, Manuel
   Armstrong, Katrina
   Barg, Frances
TI Acupuncture for hot flashes: decision making by breast cancer survivors.
SO Journal of the American Board of Family Medicine : JABFM
LA English
DT Journal Article
AB PURPOSE: Hot flashes (HFs) are a particularly common and distressing symptom  among breast cancer survivors (BCSs). Given its low rate of side effects,  acupuncture shows promise as a therapeutic approach for HFs, but little is known  about BCS's decision making about the use of acupuncture. This study seeks to  identify attitudes and beliefs about using acupuncture for HFs by BCSs. METHODS:  Using the Theory of Planned Behavior (TPB) as a conceptual framework, we  conducted semistructured interviews among women with stage I-III breast cancer  who had finished primary treatment and were currently experiencing HFs.  Interviews were taped, transcribed, and coded. We used a modified grounded theory  approach to analyze the data. RESULTS: Twenty-five BCSs (13 whites/12 African  American) participated in the study. Respondents stated that their intended use  of acupuncture for HFs would be dependent on (1) expected therapeutic effects  (eg, pain relief, energy); (2) practical concerns (eg, fear of needles,  practitioner experience, time commitment); and (3) source of decision  support/validation (eg, family members, physicians, self). Although constructs in  the TPB accounted for many decision factors, respondents identified 2 major  themes outside of the TPB: (1) viewing acupuncture as a natural alternative to  medications, and (2) assessing the degree of HFs as bothersome enough in the  context of other medical comorbidities to trigger the need for therapy.  CONCLUSION: BCSs expressed varied expected therapeutic benefits, practical  concerns, and decision support, emphasizing the "natural appeal" and symptom  appraisal as key determinants when using acupuncture for HFs. Incorporating these  factors in counseling BCSs may promote patient-centered communication, leading to  improved hot flash management and quality of life.
C1 Department of Family Medicine and Community Health, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. maoj@uphs.upenn.edu
NR 0
TC 0
SN 1558-711
EI 1557-262
J9 J Am Board Fam Med
PD MAY 10
PY 2012
VL 25
IS 3
BP 323
EP 32
DI 10.3122/jabfm.2012.03.110165
PG -291
WC Acupuncture Therapy; methods; Adult; Aged; Breast Neoplasms; complications; Decision Making; Decision Support Techniques; Female; Health Knowledge, Attitudes, Practice; Hot Flashes; etiology; Humans; Interview, Psychological; Middle Aged; Survivors; Time Factors; Women's Health
UT PubMed:22570396
PM 22570396
DA 2012-05-10
ER

PT J
AU Zick, SM
   Wyatt, GK
   Murphy, SL
   Arnedt, JT
   Sen, A
   Harris, RE
AF Zick, Suzanna Maria
   Wyatt, Gwen Karilyn
   Murphy, Susan Lynn
   Arnedt, J. Todd
   Sen, Ananda
   Harris, Richard Edmund
TI Acupressure for persistent cancer-related fatigue in breast cancer survivors (AcuCrft): a study protocol for a randomized controlled trial
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Acupressure; Persistent fatigue; Breast cancer; Cancer survivor; Sleep quality; Ecological momentary assessment; Traditional Chinese Medicine; Actigraphy
ID quality-of-life; stage renal-disease; physical-activity; sleep; osteoarthritis; prevalence; pain; association; depression; actigraphy
AB Background: Despite high levels of clinically significant persistent cancer related fatigue in breast cancer survivors few treatments are currently available and most pose a significant burden on the part of the woman. Acupressure, a component of Traditional Chinese Medicine, has been shown to decrease fatigue levels by as much as 70% in cancer survivors while being inexpensive, non-toxic and an easy to use intervention. The primary aim of this study was to determine the efficacy of two types of self-administered acupressure (relaxation acupressure and stimulating acupressure), compared to standard of care on fatigue severity. Secondary aims were to evaluate the efficacy of two types of acupressure on sleep and kinetic parameters required for implementation of acupressure in a clinical setting; The purpose of this paper is to share the methodology used including challenges and insights. Methods/design: This study is a three group, randomized clinical trial. 375 breast cancer survivors at least 12 months after completion of cancer treatments, with moderate to severe persistent fatigue, are being randomized to one of 3 groups: self-administered relaxation acupressure; self-administered stimulating acupressure; or standard of care. Participants are assessed at baseline, 3 weeks, and 6 weeks followed by a 4-week follow-up period. The primary aim is to examine the effect of 6-weeks of relaxation acupressure compared to stimulatory acupressure or standard of care on fatigue as assessed by: weekly self-report using the Brief Fatigue Inventory; objective daytime physical activity on actigraph; or fatigue patterns assessed 4-times daily using a visual analog scale. Secondary endpoints include depression, anxiety, self-efficacy, and sleep quality. Discussion: This study has the potential to develop a low-cost, self-care intervention for the most troubling of late-term effects in breast cancer populations, fatigue. The methods used may lend constructive ideas to other investigators working with this population and/or intervention.
C1 [Zick, Suzanna Maria] Univ Michigan, Dept Family Med, Ann Arbor, MI 48105 USA.
   [Wyatt, Gwen Karilyn] Michigan State Univ, E Lansing, MI 48824 USA.
   [Murphy, Susan Lynn] Univ Michigan, Inst Gerontol, Ann Arbor, MI 48104 USA.
   [Murphy, Susan Lynn] VA Ann Arbor Hlth Care Syst, GRECC, Ann Arbor, MI 48104 USA.
   [Arnedt, J. Todd] Univ Michigan, Ann Arbor, MI 48103 USA.
   [Sen, Ananda] Univ Michigan, Dept Biostat, Dept Family Med, Ann Arbor, MI 48104 USA.
   [Harris, Richard Edmund] Univ Michigan, Dept Anesthesiol, Ann Arbor, MI 48105 USA.
C3 University of Michigan System; University of Michigan; Michigan State University; University of Michigan System; University of Michigan; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan
RP Zick, SM (corresponding author), Univ Michigan, Dept Family Med, 24 Frank Lloyd Wright Dr, Ann Arbor, MI 48105 USA.
EM szick@med.umich.edu
FU NIH [R01CA151445]
CR Alexander S, 2009, EUR J CANCER, V45, P384, DOI 10.1016/j.ejca.2008.09.010
   Ancoli-Israel S, 2003, SLEEP, V26, P342, DOI 10.1093/sleep/26.3.342
   Unknown -, 2012, CLIN PRACT GUID ONC, V0, P0
   Unknown -, 2012, CANCER FACTS AND FIGURES 2012, V0, P0
   Berger AM, 2009, PSYCHO-ONCOLOGY, V18, P634, DOI 10.1002/pon.1438
   Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006
   Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3
   BORKOVEC TD, 1972, J BEHAV THER EXP PSY, V3, P257, DOI 10.1016/0005-7916(72)90045-6
   Bower Julienne E, 2006, CLIN ADV HEMATOL ONCOL, V4, P828
   Gärtner R, 2009, JAMA-J AM MED ASSOC, V302, P1985, DOI 10.1001/jama.2009.1568
   Groenvold M, 2007, BREAST CANCER RES TR, V105, P209, DOI 10.1007/s10549-006-9447-x
   Harris RE, 2005, J ALTERN COMPLEM MED, V11, P673, DOI 10.1089/acm.2005.11.673
   Jerusalem M, 1992, SELF EFFICACY, V0, P195
   Kim SH, 2008, J PAIN SYMPTOM MANAG, V35, P644, DOI 10.1016/j.jpainsymman.2007.08.012
   Kuhnt S, 2009, ONKOLOGIE, V32, P312, DOI 10.1159/000215943
   Littner M, 2003, SLEEP, V26, P337, DOI 10.1093/sleep/26.3.337
   Mehnert A, 2007, PATIENT EDUC COUNS, V66, P108, DOI 10.1016/j.pec.2006.11.005
   Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N
   Montazeri A, 2008, J EXP CLIN CANC RES, V27, P0, DOI 10.1186/1756-9966-27-32
   Murphy SL, 2008, ARTHRIT RHEUM-ARTHR, V59, P1480, DOI 10.1002/art.24105
   Murphy SL, 2008, ARTHRIT RHEUM-ARTHR, V59, P849, DOI 10.1002/art.23710
   Murphy SL, 2008, AM J OCCUP THER, V62, P329, DOI 10.5014/ajot.62.3.329
   Murphy SL, 2009, PREV MED, V48, P108, DOI 10.1016/j.ypmed.2008.12.001
   Mustian KM, 2007, ONCOLOGIST, V12, P52, DOI 10.1634/theoncologist.12-S1-52
   Netzer NC, 1999, ANN INTERN MED, V131, P485, DOI 10.7326/0003-4819-131-7-199910050-00002
   Reid-Arndt SA, 2010, PSYCHO-ONCOLOGY, V19, P535, DOI 10.1002/pon.1581
   Savard J, 2001, J CLIN ONCOL, V19, P895, DOI 10.1200/JCO.2001.19.3.895
   SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749
   Stone AA, 1999, SCI SELF REPORT IMPL, V0, P0, DOI DOI 10.4324/9781410601261
   Tittle Mary Beth, 2003, ONCOL NURS FORUM, V30, P325, DOI 10.1188/03.ONF.325-330
   Tryon WW, 2004, SLEEP, V27, P158, DOI 10.1093/sleep/27.1.158
   Tsay SL, 2004, INT J NURS STUD, V41, P99, DOI 10.1016/S0020-7489(03)00079-8
   Tsay SL, 2003, INT J NURS STUD, V40, P1, DOI 10.1016/S0020-7489(02)00019-6
   U.S. Department of Health and Human Services National Institutes of Health, 2010, COMM TERM CRIT ADV E, V0, P0
   Wyatt G, 1996, J NURS MEAS, V4, P153
   Zick SM, 2011, EVID-BASED COMPL ALT, V2011, P0, DOI 10.1155/2011/142913
NR 36
TC 16
Z9 23
U1 1
U2 41
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472-6882
EI 
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD AUG 21
PY 2012
VL 12
IS 
BP 
EP 
DI 10.1186/1472-6882-12-132
PG 14
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 041DL
UT WOS:000311376700001
PM 22909076
DA 2026-01-16
ER

PT J
AU Yang, CM
   Chen, NC
   Shen, HC
   Chou, CH
   Yeh, PS
   Lin, HJ
   Chang, CY
   Cheng, TJ
   Lin, KC
AF Yang, Chun-Ming
   Chen, Nan-Cheng
   Shen, Hsiu-Chu
   Chou, Chi-Ho
   Yeh, Poh-Shiow
   Lin, Huey-Juan
   Chang, Chia-Yu
   Cheng, Tain-Junn
   Lin, Kao-Chang
TI [Guideline of neuropathic pain treatment and dilemma from neurological point of
SO Acta neurologica Taiwanica
LA chi
DT Journal Article
AB Neuropathic pain is a complicated symptomatic disease as migraine in recent  years. Not because the pain character differed from the nociceptive inflammatory  symptoms but because of its complexity of mechanisms. Though peripheral  sensitization, ectopic discharge, central sensitization, central re-organization  and loss of inhibition play part of roles in mechanisms, however, based on this  mechanistic treatment, the outcome still disappointed physicians and patients,  exampled as central post-stroke central pain (CPSP). The pain reduction is far  less than the expectation from patients and physician's under-treatment  frequently occur due to the fear of adverse effects or off-label use of these  anti-neuropathic pain drugs. Therefore, a multidisciplinary procedure including  non-pharmacological management, rehabilitation program, careful explanation,  stepwise pain reduction, daily diary record, and tailored individual planning for  medications are helpful in treating this kind of sufferers. Pharmacological  treatment is the mainstream in post-herpetic neuralgia (PHN), diabetic peripheral  neuropathic pain (DPNP), central post-stroke pain (CPSP), trigeminal neuralgia  (TN), complex regional pain syndrome (CRPS), cancer pain, failed back syndrome  etc, while polypharmacy is still the major prescriptions facing such kind of  miserable patients. The tricyclic antidepressants (TCA), gamma- aminobutyric acid  (GABA), voltage-dependent calcium channel blockers, selective non-epinephrine  reuptake inhibitor (SNRI), opioid or morphine etc, are still evidence-based  medicines (EBM) but with different outcome for individuals. Acupuncture is to  some extend effective in Taiwanese people with perceived evidence or placebo. The  Taiwan guidance for total pain management and review of EBM in treating  neuropathic pain from neurological point of view will be introduced in this  manuscript.
C1 Department of Neurology, Chi Mei Medical Center, Taiwan.
NR 0
TC 0
SN 
EI 1028-768
J9 Acta Neurol Taiwan
PD DEC 1
PY 2012
VL 21
IS 3
BP 136
EP 44
DI 
PG -92
WC Analgesics; therapeutic use; Guidelines as Topic; Humans; Neuralgia; etiology
UT PubMed:23196735
PM 23196735
DA 2012-12-01
ER

PT J
AU D'Alessandro, E
   de, Brito C
   Cecatto, R
   Saul, M
   Atta, JA
   Lin, CA
AF D'Alessandro, Eduardo
   de Brito, Christina
   Cecatto, Rebeca
   Saul, Maira
   Atta, Jose Antonio
   Lin, Chin An
TI Evaluation of acupuncture for cancer symptoms in a cancer institute in Brazil.
SO Acupuncture in medicine : journal of the British Medical Acupuncture Society
LA English
DT Journal Article
AB INTRODUCTION: Acupuncture has been progressively included in the practice of  mainstream medicine in recent decades. The State of Sao Paulo Cancer Institute is  a public hospital established in 2008 and its acupuncture service follows the  experience and model of several oncology centres in the USA, aiming to optimise  the treatment of symptoms such as postoperative pain, oncological pain,  neuropathic pain, nausea, vomiting, xerostomia and fatigue induced by  chemotherapy. This paper describes the population given acupuncture treatment and  the effects of the intervention on symptom management. METHODS: One hundred and  eighty-three patients from our service were enrolled in the study. Baseline and  final symptom intensity was recorded using a visual analogue score (VAS) ranging  from 0 to 10 cm, with a higher score meaning higher symptom intensity. RESULTS:  Fifty-four (29.50%) were receiving active treatment with chemotherapy and/or  radiotherapy, 29 (15.85%) were receiving hormone therapy and 100 (54.65%) were  considered to be in remission. The main symptoms were: oncological pain in 44  (24.04%), chemotoxicity in 34 (18.6%), lumbar pain in 53 (28.96%) and chronic  postoperative pain in 54 (28.4%). The mean (SD) initial symptom score was 7.04  (1.8), which was reduced to 2.56 (2.75) after treatment (p<0.001), an improvement  of 63.6% in control of the symptoms. Further analysis of the data showed that the  effect was similar in different indications for acupuncture treatment.  CONCLUSIONS: Use of acupuncture may have improved symptom control in patients  enrolled in this study.
C1 Department of Internal Medicine, Sao Paulo State Institute of Cancer, São Paulo, SP 05403-000, Brazil. e.g.dalessandro@gmail.com
NR 0
TC 0
SN 1759-987
EI 
J9 Acupunct Med
PD NOV 3
PY 2012
VL 31
IS 1
BP 23
EP 6
DI 10.1136/acupmed-2012-010206
PG -17
WC Academies and Institutes; Acupuncture Therapy; Adult; Aged; Aged, 80 and over; Brazil; Female; Humans; Lumbar Vertebrae; Male; Middle Aged; Musculoskeletal Pain; therapy; Neoplasms; complications; Pain Management; Pain, Postoperative; therapy; Treatment Outcome
UT PubMed:23117345
PM 23117345
DA 2012-11-03
ER

PT J
AU Cha, MH
   Nam, TS
   Kwak, Y
   Lee, H
   Lee, BH
AF Cha, Myeoung Hoon
   Nam, Taick Sang
   Kwak, Yongho
   Lee, Hyejung
   Lee, Bae Hwan
TI Changes in Cytokine Expression after Electroacupuncture in Neuropathic Rats
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID hiv-1 envelope glycoprotein; temporal expression; anti-hyperalgesia; messenger-rna; nerve injury; animal-model; pain; activation; acupuncture; allodynia
AB The production of proinflammatory cytokines including interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) plays a key role in chronic pain such as neuropathic pain. We investigated changes in cytokine expression in injured peripheral nerves and dorsal root ganglia (DRG) following electroacupuncture (EA) treatment. Neuropathic pain was induced by peripheral nerve injury to the left hind limb of Sprague-Dawley rats under pentobarbital anesthesia. Two weeks later, the nerve-injured rats were treated by EA for 10 minutes. The expression levels of IL-1 beta, IL-6, and TNF-alpha in peripheral nerves and DRG of neuropathic rats were significantly increased in nerve-injured rats. However, after EA, the cytokine expression levels were noticeably decreased in peripheral nerves and DRG. These results suggest that EA stimulation can reduce the levels of proinflamtory cytokines elevated after nerve injury.
C1 [Cha, Myeoung Hoon; Nam, Taick Sang; Kwak, Yongho; Lee, Bae Hwan] Yonsei Univ, Coll Med, Dept Physiol, Seoul 120752, South Korea.
   [Cha, Myeoung Hoon; Nam, Taick Sang; Kwak, Yongho; Lee, Bae Hwan] Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea.
   [Lee, Hyejung] Kyung Hee Univ, Acupuncture & Meridian Sci Res Ctr, Seoul 130701, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Kyung Hee University
RP Lee, BH (corresponding author), Yonsei Univ, Coll Med, Dept Physiol, POB 8044, Seoul 120752, South Korea.
EM bhlee@yuhs.ac
FU National Research Foundation (NRF) of Korea; Ministry of Education, Science and Technology [2005-0049404]
CR Arruda JL, 1998, MOL BRAIN RES, V62, P228, DOI 10.1016/S0169-328X(98)00257-5
   Cha MH, 2006, YONSEI MED J, V47, P359, DOI 10.3349/ymj.2006.47.3.359
   Cha MH, 2010, NEUROL RES, V32, PS96, DOI 10.1179/016164109X12537002794363
   CHENG RSS, 1981, BRAIN RES, V215, P77
   Compston A, 1997, J ANAT, V190, P161, DOI 10.1046/j.1469-7580.1997.19020161.x
   DeLeo JA, 1997, BRAIN RES, V759, P50, DOI 10.1016/S0006-8993(97)00209-6
   DeLeo JA, 2001, PAIN, V90, P1, DOI 10.1016/S0304-3959(00)00490-5
   HAN JS, 1982, ANNU REV PHARMACOL, V22, P193, DOI 10.1146/annurev.pa.22.040182.001205
   Holguin A, 2004, PAIN, V110, P517, DOI 10.1016/j.pain.2004.02.018
   Kim SK, 2005, EXP NEUROL, V195, P430, DOI 10.1016/j.expneurol.2005.06.018
   Lee BH, 2000, NEUROREPORT, V11, P657, DOI 10.1097/00001756-200003200-00002
   Lee HL, 2004, NEUROREPORT, V15, P2807
   Lisak RP, 1997, J INFECT DIS, V176, PS173, DOI 10.1086/513788
   Mayer DJ, 2000, PROG BRAIN RES, V122, P457
   Milligan ED, 2001, J NEUROSCI, V21, P2808, DOI 10.1523/JNEUROSCI.21-08-02808.2001
   Milligan ED, 2000, BRAIN RES, V861, P105, DOI 10.1016/S0006-8993(00)02050-3
   Oh JH, 2006, INT J NEUROSCI, V116, P1139, DOI 10.1080/00207450500513948
   Pittler MH, 2008, CLIN J PAIN, V24, P731, DOI 10.1097/AJP.0b013e3181759231
   Rothman SM, 2009, J PAIN, V10, P90, DOI 10.1016/j.jpain.2008.07.008
   Shamash S, 2002, J NEUROSCI, V22, P3052, DOI 10.1523/JNEUROSCI.22-08-03052.2002
   Song MJ, 2009, BRAIN RES BULL, V78, P335, DOI 10.1016/j.brainresbull.2008.10.009
   Sorkin LS, 2000, J PERIPHER NERV SYST, V5, P96, DOI 10.1046/j.1529-8027.2000.00012.x
   Szekanecz Z, 2000, ARTHRITIS RHEUM, V43, P1266, DOI 10.1002/1529-0131(200006)43:6<1266::AID-ANR9>3.0.CO;2-P
   Winkelstein BA, 2001, J COMP NEUROL, V439, P127
   Yonehara N, 2001, NEUROSCI RES, V40, P45, DOI 10.1016/S0168-0102(01)00207-3
   Zhang RX, 2007, ANESTH ANALG, V105, P1482, DOI 10.1213/01.ane.0000284705.34629.c5
   Zhang RX, 2004, BRAIN RES, V1020, P12, DOI 10.1016/j.brainres.2004.05.067
   Zijlstra FJ, 2003, MEDIAT INFLAMM, V12, P59, DOI 10.1080/0962935031000114943
NR 28
TC 28
Z9 32
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD JUN 15
PY 2012
VL 2012
IS 
BP 
EP 
DI 10.1155/2012/792765
PG 6
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 906VS
UT WOS:000301377600001
PM 22454684
DA 2026-01-16
ER

PT J
AU Ackerman, SL
   Lown, EA
   Dvorak, CC
   Dunn, EA
   Abrams, DI
   Horn, BN
   Degelman, M
   Cowan, MJ
   Mehling, WE
AF Ackerman, Sara L.
   Lown, E. Anne
   Dvorak, Christopher C.
   Dunn, Elizabeth A.
   Abrams, Donald I.
   Horn, Biljana N.
   Degelman, Marcia
   Cowan, Morton J.
   Mehling, Wolf E.
TI Massage for Children Undergoing Hematopoietic Cell Transplantation: A Qualitative Report
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID posttraumatic-stress-disorder; childhood-cancer; support program; survivors; therapy; acupuncture; chemotherapy; disability; management; symptoms
AB Background. No in-depth qualitative research exists about the effects of therapeutic massage with children hospitalized to undergo hematopoietic cell transplantation (HCT). The objective of this study is to describe parent caregivers' experience of the effects of massage/acupressure for their children undergoing HCT. Methods. We conducted a qualitative analysis of open-ended interviews with 15 parents of children in the intervention arm of a massage/acupressure trial. Children received both practitioner and parent-provided massage/acupressure. Results. Parents reported that their child experienced relief from pain and nausea, relaxation, and greater ease falling asleep. They also reported increased caregiver competence and closeness with their child as a result of learning and performing massage/acupressure. Parents supported a semistandardized massage protocol. Conclusion. Massage/acupressure may support symptom relief and promote relaxation and sleep among pediatric HCT patients if administered with attention to individual patients' needs and hospital routines and may relieve stress among parents, improve caregiver competence, and enhance the sense of connection between parent and child.
C1 [Abrams, Donald I.; Degelman, Marcia; Mehling, Wolf E.] Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94115 USA.
   [Ackerman, Sara L.] Univ Calif San Francisco, Dept Gen Internal Med, San Francisco, CA 94143 USA.
   [Lown, E. Anne] Alcohol Res Grp EAL, Emeryville, CA 94608 USA.
   [Lown, E. Anne] Univ Calif San Francisco, Dept Physiol Nursing, Sch Nursing, San Francisco, CA 94143 USA.
   [Dvorak, Christopher C.; Dunn, Elizabeth A.; Horn, Biljana N.; Cowan, Morton J.] Univ Calif San Francisco, Div Blood & Marrow Transplant, Dept Pediat, San Francisco, CA 94143 USA.
   [Abrams, Donald I.] Univ Calif San Francisco, Dept Med Hematol & Oncol, San Francisco, CA 94115 USA.
   [Mehling, Wolf E.] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA.
C3 University of California System; University of California San Francisco; University of California System; University of California San Francisco; Alcohol Research Group; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco
RP Mehling, WE (corresponding author), Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94115 USA.
EM mehlingw@ocim.ucsf.edu
FU Community Foundation Sonoma County, Santa Rosa, California
CR Ahles TA, 1999, J PAIN SYMPTOM MANAG, V18, P157, DOI 10.1016/S0885-3924(99)00061-5
   Unknown -, 2007, MANUAL ACUPUNCTURE, V0, P0
   Unknown -, 2009, NATL HLTH STAT REPOR, V0, P0
   Barlow JH, 2008, J PSYCHOSOM RES, V64, P55, DOI 10.1016/j.jpsychores.2007.06.006
   Billhult A, 2001, CANCER NURS, V24, P180, DOI 10.1097/00002820-200106000-00003
   Billhult Annika, 2007, CLIN NURS RES, V16, P85, DOI 10.1177/1054773806298488
   Brown RT, 2003, J TRAUMA STRESS, V16, P309, DOI 10.1023/A:1024465415620
   Calvert R, 2002, THE HISTORY OF MASSAGE: AN ILLUSTRATED SURVEY FROM AROUND THE WORLD, V0, P0
   Coffey A, 1996, MAKING SENSE OF QUALITATIVE DATA, V0, P26
   Dibble S L, 2000, ONCOL NURS FORUM, V27, P41
   Ernst E, 2009, SUPPORT CARE CANCER, V17, P333, DOI 10.1007/s00520-008-0569-z
   Ezzo J, 2005, J CLIN ONCOL, V23, P7188, DOI 10.1200/JCO.2005.06.028
   FIELD T, 1995, J DEV BEHAV PEDIATR, V16, P105
   Groopman J, 1998, HEALING HELL, V0, P0
   Hughes D, 2008, ONCOL NURS FORUM, V35, P431, DOI 10.1188/08.ONF.431-442
   Kazak AE, 2004, J PEDIATR PSYCHOL, V29, P211, DOI 10.1093/jpepsy/jsh022
   Kazak AE, 2005, J PEDIATR PSYCHOL, V30, P29, DOI 10.1093/jpepsy/jsi013
   Kempson D, 2009, HOME HLTH CARE MAN P, V21, P117, DOI 10.1177/1084822308325782
   Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003
   Mehling WE, 2007, J PAIN SYMPTOM MANAG, V33, P258, DOI 10.1016/j.jpainsymman.2006.09.016
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P228, DOI 10.1016/j.ctim.2006.09.009
   Myers Cynthia D, 2008, J SOC INTEGR ONCOL, V6, P19
   Phipps Sean, 2002, PEDIATR REHABIL, V5, P223
   Phipps S, 2010, CANCER-AM CANCER SOC, V116, P3924, DOI 10.1002/cncr.25415
   Pöder U, 2008, PSYCHO-ONCOLOGY, V17, P430, DOI 10.1002/pon.1263
   Post-White J, 2009, J PEDIATR ONCOL NURS, V26, P16, DOI 10.1177/1043454208323295
   Rourke MT, 2007, PEDIATR BLOOD CANCER, V49, P177, DOI 10.1002/pbc.20942
   SCHEPER-HUGHES N, 1987, MEDICAL ANTHROPOLOGY QUARTERLY, V1, P6, DOI 10.1525/maq.1987.1.1.02a00020
   Snöbohm C, 2010, PSYCHO-ONCOLOGY, V19, P863, DOI 10.1002/pon.1632
   Sturgeon M, 2009, J ALTERN COMPLEM MED, V15, P373, DOI 10.1089/acm.2008.0399
   Wilkie D J, 2000, HOSP J, V15, P31
   Williams HL, 2005, COMPLEMENT THER MED, V13, P107, DOI 10.1016/j.ctim.2005.03.007
   Zeltzer LK, 2009, J CLIN ONCOL, V27, P2396, DOI 10.1200/JCO.2008.21.1433
NR 36
TC 20
Z9 26
U1 0
U2 21
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD JUN 15
PY 2012
VL 2012
IS 
BP 
EP 
DI 10.1155/2012/792042
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 906VP
UT WOS:000301377200001
PM 22474526
DA 2026-01-16
ER

PT J
AU Park, JW
   Jeon, JH
   Yoon, J
   Jung, TY
   Kwon, KR
   Cho, CK
   Lee, YW
   Sagar, S
   Wong, R
   Yoo, HS
AF Park, Jae-Woo
   Jeon, Ju-Hyun
   Yoon, Jeungwon
   Jung, Tae-Young
   Kwon, Ki-Rok
   Cho, Chong-Kwan
   Lee, Yeon-Weol
   Sagar, Stephen
   Wong, Raimond
   Yoo, Hwa-Seung
TI Effects of Sweet Bee Venom Pharmacopuncture Treatment for Chemotherapy-Induced Peripheral Neuropathy: A Case Series
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE sweet bee venom pharmacopuncture; chemotherapy-induced peripheral neuropathy; VAS; melittin; Korean medicine; safety
ID cancer; inflammation; acupuncture; apipuncture; therapy; pain
AB Objective. This is a case series reporting safety and degree of response to 1 dose level of sweet bee venom pharmacopuncture (SBVP) or melittin as a symptom-control therapy for chemotherapy-induced peripheral neuropathy (CIPN). Setting. All treatments were conducted at the East West Cancer Center (EWCC), Dunsan Oriental Hospital, Daejeon University, Republic of Korea, an institution that uses complementary therapies for cancer patients. Methods. Five consecutive patients with CIPN were referred to the EWCC from March 20, 2010, to April 10, 2010. Patients with World Health Organization Chemotherapy-Induced Peripheral Neuropathy (WHO CIPN) grade 2 or more were treated with SBVP for 3 treatment sessions over a 1-week period. Measures of efficacy and safety. Validated Visual Analog System (VAS) pain scale, WHO CIPN grade, and Functional Assessment of Cancer Therapy-General (FACT-G) were compared before and after the 1-week course of treatment. To ensure the safety of SBVP, pretreatment skin response tests were given to patients to avoid any potential anaphylactic adverse effects. All patients were closely examined for any allergenic responses following each treatment session. Results. One patient discontinued treatment after the first session, and 4 patients completed all treatment sessions. Using each patient as their own comparator, marked improvements of VAS, WHO CIPN grade, and physical section scores of FACT-G were seen in 3 patients. Most important, there were no related adverse side effects found. Conclusion. This safety results of the SBVP therapy merits further investigations in a larger size trial for it to develop into a potential intervention for managing CIPN symptoms. This study will be extended to a dose-response evaluation to further establish safety and response, prior to a randomized trial.
C1 [Park, Jae-Woo; Jeon, Ju-Hyun; Yoon, Jeungwon; Jung, Tae-Young; Cho, Chong-Kwan; Lee, Yeon-Weol; Yoo, Hwa-Seung] Daejeon Univ, Taejon, South Korea.
   [Kwon, Ki-Rok] Korean Pharmacopuncture Inst, Seoul, South Korea.
   [Sagar, Stephen; Wong, Raimond] McMaster Univ, Hamilton, ON, Canada.
C3 Daejeon University; McMaster University
RP Yoo, HS (corresponding author), Daejeon Univ, EW Canc Ctr, Dunsan Oriental Hosp, 1136 Dunsan Dong, Taejon, South Korea.
EM altyhs@dju.kr
CR CARLSSON AM, 1983, PAIN, V16, P87, DOI 10.1016/0304-3959(83)90088-X
   Cavaletti G, 2002, EUR J CANCER, V38, P1832, DOI 10.1016/S0959-8049(02)00229-0
   Cella D, 1997, MANUAL FUNCTIONAL AS, V0, P0
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   CHAUDHRY V, 1994, ANN NEUROL, V35, P304, DOI 10.1002/ana.410350310
   Chaudhry V, 2003, NEUROLOGY, V60, P337, DOI 10.1212/01.WNL.0000043691.53710.53
   Choi YC, 2006, J PHARMACOPUNCT, V9, P105
   DOH WS, 1995, J KOR ACUP MOX SOC, V12, P211
   Hammack JE, 2002, PAIN, V98, P195, DOI 10.1016/S0304-3959(02)00047-7
   Hausheer FH, 2006, SEMIN ONCOL, V33, P15, DOI 10.1053/j.seminoncol.2005.12.010
   Kang KS, 2009, J PHARMACOPUNCT, V12, P33, DOI 10.3831/KPI.2009.12.4.033
   Kim YJ, 2009, J PHARMACOPUNCT, V12, P5, DOI 10.3831/KPI.2009.12.4.005
   Kim YS, 2005, EVID-BASED COMPL ALT, V2, P325, DOI 10.1093/ecam/neh102
   Korean Pharmacopuncture Institute Academic Committee, 2008, PHARM, V0, P167
   Koyama N, 2007, PAIN RES, V22, P35, DOI 10.11154/pain.22.35
   KWON GR, 1998, P C KOR MED, V0, P130
   Kwon KR, 2008, PHARMACOPUNCTUROLOGY, V0, P0
   Lee JD, 2005, EVID-BASED COMPL ALT, V2, P79, DOI 10.1093/ecam/neh070
   Lee JH, 2001, J VET MED SCI, V63, P251, DOI 10.1292/jvms.63.251
   Lee JS, 2006, J PHARMACOPUNCT, V9, P61
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
   Moon DO, 2007, INT IMMUNOPHARMACOL, V7, P1092, DOI 10.1016/j.intimp.2007.04.005
   Münstedt K, 2005, AM BEE J, V145, P665
   Ocean AJ, 2004, SUPPORT CARE CANCER, V12, P619, DOI 10.1007/s00520-004-0657-7
   Park HJ, 2004, ARTHRITIS RHEUM-US, V50, P3504, DOI 10.1002/art.20626
   Roh DH, 2004, J PAIN, V5, P297, DOI 10.1016/j.jpain.2004.05.003
   Rok KK, 2006, J PHARMACOPUNCT, V9, P79
   Verstappen CCP, 2003, DRUGS, V63, P1549, DOI 10.2165/00003495-200363150-00003
   WANG OH, 2001, J KOR ACU MOX SOC, V18, P35
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Yoo HS, 2008, J PHARMACOPUNCT, V11, P21, DOI 10.3831/KPI.2008.11.1.021
NR 32
TC 40
Z9 43
U1 0
U2 18
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN 15
PY 2012
VL 11
IS 2
BP 166
EP 171
DI 10.1177/1534735411413265
PG 6
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA 953QF
UT WOS:000304885400009
PM 21715371
DA 2026-01-16
ER

PT J
AU Lu, W
   Matulonis, UA
   Dunn, JE
   Lee, H
   Doherty-Gilman, A
   Dean-Clower, E
   Goodman, A
   Davis, RB
   Buring, J
   Wayne, P
   Rosenthal, DS
   Penson, RT
AF Lu, Weidong
   Matulonis, Ursula A
   Dunn, Julie E
   Lee, Hang
   Doherty-Gilman, Anne
   Dean-Clower, Elizabeth
   Goodman, Annekathryn
   Davis, Roger B
   Buring, Julie
   Wayne, Peter
   Rosenthal, David S
   Penson, Richard T
TI The Feasibility and Effects of Acupuncture on Quality of Life Scores During
SO Medical acupuncture
LA English
DT Journal Article
DE Acupuncture; Chemotherapy; EORTC; Neutropenia; Ovarian Cancer; Quality of Life; Randomized Controlled Trial
AB BACKGROUND: Within a pilot trial regarding chemotherapy-induced neutropenia, the  secondary aim of the main study was explored. This involved measuring the  effects-as shown on two key measurement scales reflecting quality of life  (QoL)-of verum versus sham acupuncture on patients with ovarian cancer during  chemotherapy. OBJECTIVE: The aim of this substudy was to determine the  feasibility of determining the effects of verum acupuncture versus sham  acupuncture on QoL in patients with ovarian cancer during chemotherapy. DESIGN:  This was a randomized, sham-controlled trial. SETTING: The trial was conducted at  two cancer centers. PATIENTS: Patients with ovarian cancer (N=21) who were  receiving chemotherapy-primarily intravenous carboplatin and  paclitaxel-participated in this substudy. INTERVENTION: The participants were  given either active or sham acupuncture 1 week prior to cycle 2 of chemotherapy.  There were ten sessions of acupuncture, with manual and electro-stimulation over  a 4-week period. MAIN OUTCOME MEASURES: The European Organization for Research  and Treatment of Cancer-Quality-of-Life Questionnaire-Core 30 Item  (EORTC-QLQ-C30) and the Quality of Life Questionnaire-Ovarian Cancer Module-28  Item (QLQ-OV28) were administered to the patients at baseline and at the end of  their acupuncture sessions. RESULTS: Of the original 21, 15 patients (71%)  completed the study, and 93% of them completed the questionnaires. The  EORTC-QLQ-C30 subscores were improved in the acupuncture arm, including the mean  scores of social function (SF), pain, and insomnia (p=0.05). However, after  adjusting for baseline differences, only the SF score was significantly higher in  the active acupuncture arm, compared with the sham acupuncture arm (p=0.03).  CONCLUSIONS: It appears feasible to conduct a randomized sham-controlled  acupuncture trial measuring QoL for patients with ovarian cancer who are  undergoing chemotherapy. Acupuncture may have a role in improving QoL during  chemotherapy.
C1 Leonard P. Zakim Center for Integrative Therapies, Dana-Farber Cancer Institute , Boston, MA. 
   The New England School of Acupuncture , Newton, MA.
   Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA.
   The New England School of Acupuncture , Newton, MA.
   Biostatistics Center, Massachusetts General Hospital , Boston, MA.
   Leonard P. Zakim Center for Integrative Therapies, Dana-Farber Cancer Institute , Boston, MA.
   Leonard P. Zakim Center for Integrative Therapies, Dana-Farber Cancer Institute , Boston, MA.
   Department of Gynecologic Oncology & Medicine, Massachusetts General Hospital , Boston, MA.
   Osher Center for Integrative Medicine, Harvard Medical School and Brigham and Women's Hospital , Boston, MA.
   Osher Center for Integrative Medicine, Harvard Medical School and Brigham and Women's Hospital , Boston, MA.
   Osher Center for Integrative Medicine, Harvard Medical School and Brigham and Women's Hospital , Boston, MA.
   Leonard P. Zakim Center for Integrative Therapies, Dana-Farber Cancer Institute , Boston, MA.
   Department of Gynecologic Oncology & Medicine, Massachusetts General Hospital , Boston, MA.
NR 0
TC 0
SN 1933-659
EI 1933-658
J9 Med Acupunct
PD DEC 1
PY 2012
VL 24
IS 4
BP 233
EP 240
DI 10.1089/acu.2012.0904
PG 7
UT PubMed:24761165
PM 24761165
DA 2012-12-01
ER

PT J
AU Su, TF
   Zhao, YQ
   Zhang, LH
   Peng, M
   Wu, CH
   Pei, L
   Tian, B
   Zhang, J
   Shi, J
   Pan, HL
   Li, M
AF Su, T. -F.
   Zhao, Y. -Q.
   Zhang, L. -H.
   Peng, M.
   Wu, C. -H.
   Pei, L.
   Tian, B.
   Zhang, J.
   Shi, J.
   Pan, H. -L.
   Li, M.
TI Electroacupuncture reduces the expression of proinflammatory cytokines in inflamed skin tissues through activation of cannabinoid CB2 receptors
SO EUROPEAN JOURNAL OF PAIN
LA English
DT Article
ID nerve growth-factor; necrosis-factor-alpha; rat sensory neurons; gene-related peptide; dorsal-root ganglia; inflammatory hyperalgesia; peripheral inflammation; cutaneous hyperalgesia; t-lymphocytes; spinal-cord
AB Endogenous cannabinoids and peripheral cannabinoid CB2 receptors (CB2Rs) are involved in the antinociceptive effect of electroacupuncture (EA) on inflammatory pain. However, it is not clear how CB2R activation contributes to the antinociceptive effect of EA. The major proinflammatory cytokines, such as tumour necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta) and IL-6, are involved in inflammatory pain. Here we determined the effects of CB2R activation and EA on the expression level of IL-1 beta, IL-6 and TNF-alpha in inflamed skin tissues. Inflammatory pain was induced by injection of complete Freund's adjuvant into the left hindpaw of rats. Thermal hyperalgesia was tested with a radiant heat stimulus, and mechanical allodynia was quantified using von Frey filaments. The mRNA and protein levels of IL-1 beta, IL-6 and TNF-alpha in inflamed skin tissues were measured using real-time polymerase chain reaction and Western blot, respectively. Local injection of the selective CB2R agonist AM1241 or EA applied to GB30 and GB34 significantly reduced thermal hyperalgesia and mechanical allodynia induced by tissue inflammation. The specific CB2R antagonist AM630 significantly attenuated the antinociceptive effect of EA. Furthermore, EA or AM1241 treatment significantly decreased the mRNA and protein levels of IL-1 beta, IL-6 and TNF-alpha in inflamed skin tissues. In addition, pretreatment with AM630 significantly reversed the inhibitory effect of EA on these cytokine levels in inflamed skin tissues. Our results suggest that EA reduces inflammatory pain and proinflammatory cytokines in inflamed skin tissues through activation of CB2Rs.
C1 [Su, T. -F.; Zhao, Y. -Q.; Zhang, L. -H.; Peng, M.; Wu, C. -H.; Pei, L.; Tian, B.; Zhang, J.; Shi, J.; Li, M.] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Neurobiol, Wuhan 430030, Peoples R China.
   [Su, T. -F.; Zhao, Y. -Q.; Zhang, L. -H.; Peng, M.; Wu, C. -H.; Pei, L.; Tian, B.; Zhang, J.; Shi, J.; Li, M.] Huazhong Univ Sci & Technol, Tongji Med Coll, Key Lab Neurol Dis Hubei Prov, Wuhan 430030, Peoples R China.
   [Pan, H. -L.] Univ Texas MD Anderson Canc, Dept Anesthesiol & Perioperat Med, Houston, TX 77030 USA.
C3 Huazhong University of Science & Technology; Huazhong University of Science & Technology; University of Texas System; UTMD Anderson Cancer Center
RP Li, M (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Neurobiol, 13 Hangkong Rd, Wuhan 430030, Peoples R China.
EM liman7322@hotmail.com
FU National Natural Science Foundation of China [30600832]; Scientific Research Foundation for the Returned Overseas Chinese Scholars of State Education Ministry [2008890]; Fundamental Research Funds for the Central Universities (HUST) [2010JC065]
CR AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5
   Berdyshev EV, 1997, EUR J PHARMACOL, V330, P231, DOI 10.1016/S0014-2999(97)01007-8
   Chagnon F, 2005, CIRC RES, V96, P1095, DOI 10.1161/01.RES.0000168327.22888.4d
   Chang YH, 2001, J CELL BIOCHEM, V81, P715, DOI 10.1002/jcb.1103
   Chen L, 2009, J PAIN, V10, P732, DOI 10.1016/j.jpain.2008.12.012
   CLEMENTJONES V, 1980, LANCET, V2, P946
   Cook CD, 2006, PHYSIOL BEHAV, V87, P552, DOI 10.1016/j.physbeh.2005.12.005
   Copray JCVM, 2001, J NEUROIMMUNOL, V118, P203, DOI 10.1016/S0165-5728(01)00324-1
   CUNHA FQ, 1992, BRIT J PHARMACOL, V107, P660, DOI 10.1111/j.1476-5381.1992.tb14503.x
   Dallos A, 2006, NEUROPEPTIDES, V40, P251, DOI 10.1016/j.npep.2006.06.002
   Delettieres Dreanina, 2004, CLIN DEV IMMUNOL, V11, P253, DOI 10.1080/17402520400001686
   Du Jing, 2008, ZHEN CI YAN JIU, V33, P37
   FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376
   FERREIRA SH, 1988, NATURE, V334, P698, DOI 10.1038/334698a0
   Fu X, 2007, NEUROSCIENCE, V144, P275, DOI 10.1016/j.neuroscience.2006.09.016
   FUKUOKA H, 1994, BRAIN RES, V657, P133, DOI 10.1016/0006-8993(94)90960-1
   GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x
   Gutierrez T, 2007, BRIT J PHARMACOL, V150, P153, DOI 10.1038/sj.bjp.0706984
   HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7
   Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297
   Hohmann AG, 2004, J PHARMACOL EXP THER, V308, P446, DOI 10.1124/jpet.103.060079
   Hohmann AG, 1999, NEUROSCIENCE, V90, P923, DOI 10.1016/S0306-4522(98)00524-7
   Ibrahim MM, 2005, P NATL ACAD SCI USA, V102, P3093, DOI 10.1073/pnas.0409888102
   Junger H, 2000, PAIN, V85, P145, DOI 10.1016/S0304-3959(99)00262-6
   KUNO K, 1994, J LEUKOCYTE BIOL, V56, P542, DOI 10.1002/jlb.56.5.542
   Kupczyk P, 2009, EXP DERMATOL, V18, P669, DOI 10.1111/j.1600-0625.2009.00923.x
   KUPPER TS, 1989, ANN NY ACAD SCI, V557, P454
   LEE JH, 1993, PAIN, V52, P11, DOI 10.1016/0304-3959(93)90109-3
   Levy ASA, 2009, W INDIAN MED J, V58, P295
   Li Jun-Jun, 2007, ZHEN CI YAN JIU, V32, P9
   Li WW, 2009, PAIN, V144, P303, DOI 10.1016/j.pain.2009.04.033
   Liu Fei, 2006, ZHONGGUO ZHEN JIU, V26, P436
   Malan TP, 2001, PAIN, V93, P239, DOI 10.1016/S0304-3959(01)00321-9
   MCMAHON SB, 1995, NAT MED, V1, P774, DOI 10.1038/nm0895-774
   MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0
   Nackley AG, 2004, J NEUROPHYSIOL, V92, P3562, DOI 10.1152/jn.00886.2003
   Nicol GD, 1997, J NEUROSCI, V17, P975
   Obreja O, 2005, BRAIN, V128, P1634, DOI 10.1093/brain/awh490
   Obreja O, 2002, FASEB J, V16, P1497, DOI 10.1096/fj.02-0101com
   Oprée A, 2000, J NEUROSCI, V20, P6289, DOI 10.1523/JNEUROSCI.20-16-06289.2000
   Parada CA, 2003, EUR J NEUROSCI, V17, P1847, DOI 10.1046/j.1460-9568.2003.02626.x
   PEETS JM, 1978, NATURE, V273, P675, DOI 10.1038/273675a0
   Quartilho A, 2003, ANESTHESIOLOGY, V99, P955, DOI 10.1097/00000542-200310000-00031
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Ross RA, 1999, BRIT J PHARMACOL, V126, P665, DOI 10.1038/sj.bjp.0702351
   SAFIEHGARABEDIAN B, 1995, BRIT J PHARMACOL, V115, P1265, DOI 10.1111/j.1476-5381.1995.tb15035.x
   Sekido R, 2004, AM J CHINESE MED, V32, P269, DOI 10.1142/S0192415X04001928
   Suzuki S, 1999, J CEREBR BLOOD F MET, V19, P1256, DOI 10.1097/00004647-199911000-00010
   Tewari-Singh N, 2009, TOXICOL SCI, V108, P194, DOI 10.1093/toxsci/kfn261
   VILLIGER PM, 1991, J IMMUNOL, V146, P550
   VONFLIEDNER V, 1992, CELL IMMUNOL, V139, P198, DOI 10.1016/0008-8749(92)90112-3
   Wang LN, 2006, BRAIN RES, V1120, P46, DOI 10.1016/j.brainres.2006.08.077
   Woolf CJ, 1997, BRIT J PHARMACOL, V121, P417, DOI 10.1038/sj.bjp.0701148
   WOOLF CJ, 1994, NEUROSCIENCE, V62, P327, DOI 10.1016/0306-4522(94)90366-2
   Xu XJ, 1997, CYTOKINE, V9, P1028, DOI 10.1006/cyto.1997.0243
   Yang B, 2005, KIDNEY INT, V68, P2050, DOI 10.1111/j.1523-1755.2005.00662.x
   Yao BB, 2008, BRIT J PHARMACOL, V153, P390, DOI 10.1038/sj.bjp.0707568
   Yung KT, 2005, AM J CHINESE MED, V33, P759, DOI 10.1142/S0192415X05003302
   Zhang J, 2010, J PAIN, V11, P1250, DOI 10.1016/j.jpain.2010.02.013
   Zhang RX, 2007, ANESTH ANALG, V105, P1482, DOI 10.1213/01.ane.0000284705.34629.c5
   Zhang RX, 2004, BRAIN RES, V1020, P12, DOI 10.1016/j.brainres.2004.05.067
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 62
TC 72
Z9 90
U1 0
U2 33
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1090-3801
EI 1532-2149
J9 EUR J PAIN
JI Eur. J. Pain
PD MAY 15
PY 2012
VL 16
IS 5
BP 624
EP 635
DI 10.1002/j.1532-2149.2011.00055.x
PG 12
WC Anesthesiology; Clinical Neurology; Neurosciences
SC Anesthesiology; Neurosciences & Neurology
GA 980OC
UT WOS:000306901700002
PM 22337285
DA 2026-01-16
ER

PT J
AU Deng, G
   Wong, WD
   Guillem, J
   Chan, Y
   Affuso, T
   Yeung, KS
   Coleton, M
   Sjoberg, D
   Vickers, A
   Cassileth, B
AF Deng, Gary
   Wong, W Douglas
   Guillem, Jose
   Chan, Yi
   Affuso, Theresa
   Yeung, K Simon
   Coleton, Marci
   Sjoberg, Daniel
   Vickers, Andrew
   Cassileth, Barrie
TI A phase II, randomized, controlled trial of acupuncture for reduction of
SO Annals of surgical oncology
LA English
DT Journal Article
AB PURPOSE: Postoperative ileus (POI) prolongs hospital stay and increases risk of  postoperative complications. We conducted a randomized, sham-controlled trial to  evaluate whether acupuncture reduces POI more effectively than sham acupuncture.  METHODS: Colon cancer patients undergoing elective colectomy were randomized to  receive 30 min of true or sham acupuncture twice daily during their first 3  postoperative days. GI-3 (the later of the following two events: time that the  patient first tolerated solid food, AND time that the patient first passed flatus  OR a bowel movement) and GI-2 (the later of the following two events: time  patient first tolerated solid food AND time patient first passed a bowel  movement) were determined. Pain, nausea, vomiting, and use of pain medications  were evaluated daily for the first 3 postoperative days. RESULTS: Ninety patients  were randomized. Eighty-one received the allocated intervention: 39 in the true  acupuncture group and 42 in the sham acupuncture group, all evaluated for the  primary endpoint. The mean time to GI-3 was 149 h [standard deviation (SD) 71 h]  and 146 (SD 62 h) after surgery for the acupuncture group and the sham  acupuncture group (difference between means -2 h; 95 % confidence interval -31,  26; p = 0.9). No significant differences were found between groups for secondary  endpoints. CONCLUSIONS: True acupuncture as provided in this study did not reduce  POI more significantly than sham acupuncture. The study was limited by a standard  deviation much larger than expected, suggesting that a study with a larger sample  size might be required.
C1 Integrative Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. dengg@mskcc.org
NR 0
TC 0
SN 1534-468
EI 1068-926
J9 Ann Surg Oncol
PD NOV 29
PY 2012
VL 20
IS 4
BP 1164
EP 9
DI 10.1245/s10434-012-2759-7
PG -1155
WC Acupuncture; Colectomy; adverse effects; Colonic Neoplasms; surgery; Female; Follow-Up Studies; Humans; Ileus; etiology; Length of Stay; Male; Middle Aged; Neoplasm Staging; Postoperative Complications; Prognosis; Prospective Studies; Survival Rate
UT PubMed:23188543
PM 23188543
DA 2012-11-29
ER

PT J
AU Schumann, S
   Lauche, R
   Hohmann, C
   Zirbes, T
   Dobos, G
   Saha, FJ
AF Schumann, Stefan
   Lauche, Romy
   Hohmann, Claudia
   Zirbes, Thomas
   Dobos, Gustav
   Saha, Felix Joyonto
TI [Development of lipoma following a single cupping massage - a case report].
SO Forschende Komplementarmedizin (2006)
LA ger
DT Journal Article
AB BACKGROUND: The cupping massage is a form of bloodless cupping. This type of  cupping is particularly used to treat muscular tension and musculoskeletal pain,  such as chronic neck pain; however the data records on mechanisms and potential  side effects are not satisfactory. CASE REPORT: In a study on the effectiveness  of cupping massage in patients with chronic neck pain, one patient showed a  formation of a lipoma in the cupping area after the first treatment session.  CONCLUSION: Because of the short time interval between therapy and development of  the lipoma, a primary cause is not realistic. This adverse event has not been  described in the literature before, and the present report describes the case in  summary.
C1 Lehrstuhl für Naturheilkunde der Alfried Krupp von Bohlen und Halbach-Stiftung, Universität Duisburg-Essen, Deutschland.
NR 0
TC 0
SN 1661-412
EI 
J9 Forsch Komplementmed
PD SEP 12
PY 2012
VL 19
IS 4
BP 202
EP 5
DI 10.1159/000341869
PG -197
WC Acupuncture Therapy; adverse effects; Aged; Chronic Disease; Clinical Trials as Topic; Diagnosis, Differential; Female; Humans; Lipoma; diagnosis; Massage; adverse effects; Neck Pain; therapy; Shoulder; surgery; Soft Tissue Neoplasms; diagnosis; Ultrasonography
UT PubMed:22964987
PM 22964987
DA 2012-09-12
ER

PT J
AU Mehling, WE
   Lown, EA
   Dvorak, CC
   Cowan, MJ
   Horn, BN
   Dunn, EA
   Acree, M
   Abrams, DI
   Hecht, FM
AF Mehling, Wolf E.
   Lown, E. Anne
   Dvorak, Christopher C.
   Cowan, Morton J.
   Horn, Biljana N.
   Dunn, Elizabeth A.
   Acree, Michael
   Abrams, Donald I.
   Hecht, Frederick M.
TI Hematopoietic Cell Transplant and Use of Massage for Improved Symptom Management: Results from a Pilot Randomized Control Trial
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID posttraumatic stress symptoms; childhood-cancer; nursing intervention; integrative medicine; pediatric cancer; support program; breast-cancer; children; therapy; nausea
AB Background. Pediatric hematopoietic cell transplant (HCT) is a lifesaving treatment that often results in physical and psychological discomfort. An acupressure-massage intervention may improve symptom management in this setting. Methods. This randomized controlled pilot trial compared a combined massage-acupressure intervention to usual care. Children were offered three practitioner-provided sessions per week throughout hospitalization. Parents were trained to provide additional acupressure as needed. Symptoms were assessed using nurses' reports and two questionnaires, the behavioral affective and somatic experiences scale and the Peds quality of life cancer module. Results. We enrolled 23 children, ages 5 to 18. Children receiving the intervention reported fewer days of mucositis (Hedges' g effect size ES = 0.63), lower overall symptom burden (ES = 0.26), feeling less tired and run-down (ES = 0.86), having fewer moderate/severe symptoms of pain, nausea, and fatigue (ES = 0.62), and less pain (ES = 0.42). The intervention group showed trends toward increasing contentness/serenity (ES = +0.50) and decreasing depression (ES = -0.45), but not decreased anxiety (ES = +0.42). Differences were not statistically significant. Discussion. Feasibility of studying massage-acupressure was established in children undergoing HCT. Larger studies are needed to test the efficacy of such interventions in reducing HCT-associated symptoms in children.
C1 [Mehling, Wolf E.; Acree, Michael; Abrams, Donald I.; Hecht, Frederick M.] Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94115 USA.
   [Mehling, Wolf E.] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94115 USA.
   [Lown, E. Anne] Inst Publ Hlth, Alcohol Res Grp, Emeryville, CA 94608 USA.
   [Dvorak, Christopher C.; Cowan, Morton J.; Horn, Biljana N.; Dunn, Elizabeth A.] Univ Calif San Francisco, Dept Pediat, Blood & Marrow Transplant Div, San Francisco, CA 94143 USA.
   [Abrams, Donald I.] Univ Calif San Francisco, Dept Med Hematol & Oncol, San Francisco, CA 94110 USA.
   [Hecht, Frederick M.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94115 USA.
C3 University of California System; University of California San Francisco; University of California System; University of California San Francisco; Alcohol Research Group; Public Health Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco
RP Mehling, WE (corresponding author), Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94115 USA.
EM mehlingw@ocim.ucsf.edu
FU Community Foundation Sonoma County, Santa Rosa California
CR Ackerman S, 2010, MASSAGE CHILDREN UND, V0, P0
   Ahles TA, 1999, J PAIN SYMPTOM MANAG, V18, P157, DOI 10.1016/S0885-3924(99)00061-5
   American Massage Therapy Association, 2003, MEMB SERV 2003, V0, P0
   Unknown -, 1994, DSM 4, V0, P0
   Barlow J H, 2007, PSYCHOL HEALTH MED, V12, P64, DOI 10.1080/13548500600580931
   Barlow JH, 2008, J PSYCHOSOM RES, V64, P55, DOI 10.1016/j.jpsychores.2007.06.006
   Beider S, 2007, EVID-BASED COMPL ALT, V4, P23, DOI 10.1093/ecam/nel068
   Billhult A, 2001, CANCER NURS, V24, P180, DOI 10.1097/00002820-200106000-00003
   Billhult A, 2007, J ALTERN COMPLEM MED, V13, P53, DOI 10.1089/acm.2006.6049
   Billhult Annika, 2009, COMPLEMENT THER CLIN PRACT, V15, P96, DOI 10.1016/j.ctcp.2008.10.003
   BLOTCKY AD, 1985, J PEDIATR PSYCHOL, V10, P479, DOI 10.1093/jpepsy/10.4.479
   Bower JE, 2009, CLIN CANCER RES, V15, P5534, DOI 10.1158/1078-0432.CCR-08-2584
   BROWN RT, 1993, J AM ACAD CHILD PSY, V32, P554, DOI 10.1097/00004583-199305000-00010
   Cassileth BR, 2004, J PAIN SYMPTOM MANAG, V28, P244, DOI 10.1016/j.jpainsymman.2003.12.016
   CASSILETH PA, 1993, J CLIN ONCOL, V11, P314, DOI 10.1200/JCO.1993.11.2.314
   Chao LF, 2009, BREAST CANCER RES TR, V118, P255, DOI 10.1007/s10549-009-0533-8
   Corbin Lisa, 2005, CANCER CONTROL, V12, P158
   Corner Jessica, 1995, INT J PALLIAT NURS, V1, P67, DOI 10.12968/ijpn.1995.1.2.67
   Dibble S L, 2000, ONCOL NURS FORUM, V27, P41
   Dolgin MJ, 1996, CANC FAMILY, V0, P0
   Dune LS, 2006, EXPLORE-NY, V2, P314, DOI 10.1016/j.explore.2006.04.004
   Ezzo JM, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002285.pub2
   Ezzo J, 2006, J ALTERN COMPLEM MED, V12, P489, DOI 10.1089/acm.2006.12.489
   Fellowes D, 2004, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858
   FERRELLTORRY AT, 1993, CANCER NURS, V16, P93
   Field T, 2002, MED CLIN N AM, V86, P163, DOI 10.1016/S0025-7125(03)00078-6
   FIELD T, 1995, J DEV BEHAV PEDIATR, V16, P105
   FIFE B, 1987, SOC SCI MED, V24, P159, DOI 10.1016/0277-9536(87)90248-6
   FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1007/BF00974317
   Fredrickson BL, 2003, J PERS SOC PSYCHOL, V84, P365, DOI 10.1037/0022-3514.84.2.365
   Fuemmeler BF, 2005, CHILD HEALTH CARE, V34, P289, DOI 10.1207/s15326888chc3404_4
   Gardani G, 2007, MINERVA MED, V98, P665
   Grealish L, 2000, CANCER NURS, V23, P237, DOI 10.1097/00002820-200006000-00012
   Green BL, 2004, TRAUMA HLTH PHYS HLT, V0, P247
   Hernandez-Reif M, 2004, J PSYCHOSOM RES, V57, P45, DOI 10.1016/S0022-3999(03)00500-2
   Jane SW, 2008, CANCER NURS, V31, PE24, DOI 10.1097/01.NCC.0000339242.51291.85
   Jane SW, 2009, J PAIN SYMPTOM MANAG, V37, P754, DOI 10.1016/j.jpainsymman.2008.04.021
   Jones Emily, 2008, J SOC INTEGR ONCOL, V6, P141
   Kazak AE, 2004, J PEDIATR PSYCHOL, V29, P211, DOI 10.1093/jpepsy/jsh022
   Kazak AE, 2005, J PEDIATR PSYCHOL, V30, P29, DOI 10.1093/jpepsy/jsi013
   Kim Y, 2008, J AGING HEALTH, V20, P483, DOI 10.1177/0898264308317533
   Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003
   Logan RM, 2007, CANCER TREAT REV, V33, P448, DOI 10.1016/j.ctrv.2007.03.001
   Lown EA, 2011, P AM PSYCH SOC C AN, V0, P0
   Maciocia G, 1989, THE FOUNDATIONS OF CHINESE MEDICINE: A COMPREHENSIVE TEXT FOR ACUPUNCTURISTS AND HERBALISTS, V0, P0
   MAGNI G, 1986, ACTA PAEDIATR SCAND, V75, P283, DOI 10.1111/j.1651-2227.1986.tb10200.x
   Mehling WE, 2007, J PAIN SYMPTOM MANAG, V33, P258, DOI 10.1016/j.jpainsymman.2006.09.016
   Mertens AC, 2008, PEDIATR BLOOD CANCER, V50, P90, DOI 10.1002/pbc.21177
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P228, DOI 10.1016/j.ctim.2006.09.009
   Moyer CA, 2004, PSYCHOL BULL, V130, P3, DOI 10.1037/0033-2909.130.1.3
   Myers Cynthia D, 2008, J SOC INTEGR ONCOL, V6, P19
   Phipps S, 1999, INT J CANCER, V0, P18
   Phipps S, 1994, J PEDIATR ONCOL NURS, V11, P109, DOI 10.1177/104345429401100305
   Phipps Sean, 2002, PEDIATR REHABIL, V5, P223
   Phipps S, 2010, CANCER-AM CANCER SOC, V116, P3924, DOI 10.1002/cncr.25415
   Pöder U, 2008, PSYCHO-ONCOLOGY, V17, P430, DOI 10.1002/pon.1263
   Post-White J, 2009, J PEDIATR ONCOL NURS, V26, P16, DOI 10.1177/1043454208323295
   Post-White Janice, 2003, INTEGR CANCER THER, V2, P332, DOI 10.1177/1534735403259064
   RADLOFF L S, 1977, APPLIED PSYCHOLOGICAL MEASUREMENT, V1, P385, DOI 10.1177/014662167700100306
   Rexilius Stephanie J, 2002, ONCOL NURS FORUM, V29, PE35, DOI 10.1188/02.ONF.E35-E44
   Sanders Jean E, 1997, P357, V0, P0
   Shafer AB, 2006, J CLIN PSYCHOL, V62, P123, DOI 10.1002/jclp.20213
   Shanghai College of Traditional Medicine, 1981, ACUP COMPR TEXT, V0, P0
   Sherman Karen J, 2006, BMC COMPLEMENT ALTERN MED, V6, P24, DOI 10.1186/1472-6882-6-24
   Shin YH, 2004, CANCER NURS, V27, P267, DOI 10.1097/00002820-200407000-00002
   Sloper P, 2000, J PEDIATR PSYCHOL, V25, P79, DOI 10.1093/jpepsy/25.2.79
   Streitberger K, 2006, AUTON NEUROSCI-BASIC, V129, P107, DOI 10.1016/j.autneu.2006.07.015
   Stuber ML, 1997, PEDIATRICS, V100, P958, DOI 10.1542/peds.100.6.958
   Sundberg T, 2007, BMC HEALTH SERV RES, V7, P0, DOI 10.1186/1472-6963-7-107
   Sundberg T, 2009, BMC COMPLEM ALTERN M, V9, P0, DOI 10.1186/1472-6882-9-33
   van der Riet P, 1999, AUST J HOLIST NURS, V6, P4
   Varni JW, 2004, J DEV BEHAV PEDIATR, V25, P239, DOI 10.1097/00004703-200408000-00003
   Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428
   Williams HL, 2005, COMPLEMENT THER MED, V13, P107, DOI 10.1016/j.ctim.2005.03.007
   Yim YK, 2007, EVID-BASED COMPL ALT, V4, P51, DOI 10.1093/ecam/nel054
NR 75
TC 24
Z9 33
U1 0
U2 28
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD JUN 15
PY 2012
VL 2012
IS 
BP 
EP 
DI 10.1155/2012/450150
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 906RI
UT WOS:000301364400001
PM 22454665
DA 2026-01-16
ER

PT J
AU Su, TF
   Zhao, YQ
   Zhang, LH
   Peng, M
   Wu, CH
   Pei, L
   Tian, B
   Zhang, J
   Shi, J
   Pan, HL
   Li, M
AF Su, T-F
   Zhao, Y-Q
   Zhang, L-H
   Peng, M
   Wu, C-H
   Pei, L
   Tian, B
   Zhang, J
   Shi, J
   Pan, H-L
   Li, M
TI Electroacupuncture reduces the expression of proinflammatory cytokines in
SO European journal of pain (London, England)
LA English
DT Journal Article
AB Endogenous cannabinoids and peripheral cannabinoid CB2 receptors (CB2Rs) are  involved in the antinociceptive effect of electroacupuncture (EA) on inflammatory  pain. However, it is not clear how CB2R activation contributes to the  antinociceptive effect of EA. The major proinflammatory cytokines, such as tumour  necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and IL-6, are involved in  inflammatory pain. Here we determined the effects of CB2R activation and EA on  the expression level of IL-1β, IL-6 and TNF-α in inflamed skin tissues.  Inflammatory pain was induced by injection of complete Freund's adjuvant into the  left hindpaw of rats. Thermal hyperalgesia was tested with a radiant heat  stimulus, and mechanical allodynia was quantified using von Frey filaments. The  mRNA and protein levels of IL-1β, IL-6 and TNF-α in inflamed skin tissues were  measured using real-time polymerase chain reaction and Western blot,  respectively. Local injection of the selective CB2R agonist AM1241 or EA applied  to GB30 and GB34 significantly reduced thermal hyperalgesia and mechanical  allodynia induced by tissue inflammation. The specific CB2R antagonist AM630  significantly attenuated the antinociceptive effect of EA. Furthermore, EA or  AM1241 treatment significantly decreased the mRNA and protein levels of IL-1β,  IL-6 and TNF-α in inflamed skin tissues. In addition, pretreatment with AM630  significantly reversed the inhibitory effect of EA on these cytokine levels in  inflamed skin tissues. Our results suggest that EA reduces inflammatory pain and  proinflammatory cytokines in inflamed skin tissues through activation of CB2Rs.
C1 Department of Neurobiology and Key Laboratory of Neurological Diseases of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology,Wuhan, China.
NR 0
TC 0
SN 1532-214
EI 
J9 Eur J Pain
PD FEB 18
PY 2012
VL 16
IS 5
BP 624
EP 35
DI 10.1002/j.1532-2149.2011.00055.x
PG -589
WC Animals; Cannabinoids; pharmacology; Electroacupuncture; Hyperalgesia; chemically induced; Indoles; pharmacology; Inflammation; metabolism; Interleukin-1beta; genetics; Interleukin-6; genetics; Male; Pain Management; methods; Pain Measurement; RNA, Messenger; genetics; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB2; agonists; Skin; drug effects; Tumor Necrosis Factor-alpha; genetics
UT PubMed:22337285
PM 22337285
DA 2012-02-18
ER

PT J
AU Tong, YY
   He, W
   Yang, C
   Zhang, B
   Du, J
   Zhao, YK
AF Tong, Yuan-yuan
   He, Wei
   Yang, Ce
   Zhang, Bin
   Du, Jian
   Zhao, Ying-kai
TI [Analysis of the status and trends of international research in complementary and
SO Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
LA chi
DT Journal Article
AB OBJECTIVE: To have an overview of the international status and trends of  complementary and alternative medicine (CAM) research, and to provide a reference  tool for researchers. METHODS: Taking PubMed as the retrieval source, and using  the methods of informetrics analysis (such as Price's Law of exponential growth,  Bradford's law) and text mining (association rules), CAM articles published  between 1998 and 2010 were statistically analyzed on, for example, document  growth, core journals and active fields. RESULTS: The literature about CAM  research published between 1998 and 2010 showed the trends of exponential growth  in quantity. Regional distribution of literature was extensive; China and the  United States were the two major sources. Forty-five periodicals were selected  from core journals based on Bradford's law of scattering; some colleges and  schools constituted the main force in research on CAM. The active fields mainly  focus on (1) acupuncture research; (2) phytotherapy research; (3) mind-body  medicine; (4) integrative medicine; (5) treatment and prevention of key  conditions such as neoplasm, low back pain, mental disorder and chronic diseases.  CONCLUSION: (1) CAM research has attracted attention from all over the world, and  it will enter a rapid development stage in the future; (2) Treatment and  prevention of neoplasm is a consistent key subject and research field in global  CAM research; (3) Elucidating clinical effects, mechanisms of action, and safety  of major CAM methods constitutes the most important task; (4) Studies on  mind-body medicine have increased in recent years, so clinical evaluation and  studies of mind-body interventions should be supported; (5) Research has been  done increasingly for identification of the clinical effects and biological  mechanisms of CAM interventions in symptom management; (6) Research on CAM will  stimulate the development of modern medical model; (7) TCM is an active  discipline of CAM, and China will thus face increasing challenges.
C1 Intelligence Center on Traditional Chinese Medicine, Institute of Information on Traditional Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing100700, China. tongyy@mail.cintcm.ac.cn.
NR 0
TC 0
SN 
EI 1672-197
J9 Zhong Xi Yi Jie He Xue Bao
PD JUN 19
PY 2012
VL 10
IS 6
BP 597
EP 603
DI 10.3736/jcim20120601
PG 6
WC Bibliometrics; Biomedical Research; trends; Complementary Therapies; Integrative Medicine
UT PubMed:22704406
PM 22704406
DA 2012-06-19
ER

PT J
AU Saw, CLL
   Chew, L
   Goh, C
AF Saw, Constance L. L.
   Chew, Lita
   Goh, Cynthia
TI Recent Non-Interventional Advances in Cancer Pain and Singaporean Patients
SO ANNALS ACADEMY OF MEDICINE SINGAPORE
LA English
DT Review
DE Cancer outpatients; Complementary therapies; Non-pharmacological pain treatments; Pain prevalence
ID celiac plexus block; alternative medicine; data metaanalysis; acupuncture; management; massage; complementary; therapy; oncology; electroacupuncture
AB Introduction: Pain is a common symptom in cancer patients, but very little information about the prevalence, severity, and treatment of pain in cancer patients in Singapore is available. Therefore, our prospective survey in the National Cancer Centre (NCC) outpatients is incorporated in this report. In addition, a review concerning the recent advances on non-interventional pain management in cancer treatment, which is relevant in the context, is discussed. Materials and Methods: For the prospective survey, a questionnaire was distributed for self-administration by patients while waiting for consultation at the NCC outpatient departments. Literature searches on advances in pain management were conducted, reviewed and discussed. Results: In the last decade, there have been advances in pain pharmacology ranging from wider therapeutic options and management approaches to novel delivery techniques. Acupuncture and massage therapy became increasingly popular among cancer patients. Some clinical trials of acupuncture show benefits in palliation of cancer pain. From the prospective survey, 41.2% of the responders reported pain in the past week, and only 70.8% talked to their doctors about their pain. One third of the patients received analgesics. Of these, 86.5% said that they were taking the prescribed medications, however, 37.4% admitted to having difficulties taking them. Non-drug methods were used by 25.4% of the patients. Medicated oil, cream or gel was used by 49.3%; only 2.6% reported use of Chinese herbs. Conclusion: Pain is a significant symptom in outpatients attending a cancer centre, affecting 41.2% of the patients. Although majority of patients who suffered from pain reported this to doctors, much more medical effort is needed to help patients to relieve their pain and proper complementary therapy could be considered.
C1 [Saw, Constance L. L.] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, Piscataway, NJ 08854 USA.
   [Saw, Constance L. L.; Chew, Lita] Natl Canc Ctr, Dept Pharm, Singapore, Singapore.
   [Goh, Cynthia] Natl Canc Ctr, Dept Palliat Med, Singapore, Singapore.
C3 Rutgers University System; Rutgers University New Brunswick; National Cancer Centre Singapore (NCCS); National Cancer Centre Singapore (NCCS)
RP Saw, CLL (corresponding author), Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, 160 Frelinghuysen Rd, Piscataway, NJ 08854 USA.
EM constancesaw@gmail.com
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Alshemmari S, 2010, AM J HOSP PALLIAT ME, V27, P446, DOI 10.1177/1049909110362438
   Unknown -, 1986, CANC PAIN REL, V0, P0
   Brogan Shane, 2010, J SUPPORT ONCOL, V8, P52
   Carlsson CPO, 2001, CLIN J PAIN, V17, P296, DOI 10.1097/00002508-200112000-00003
   Chang VT, 2006, J PALLIAT MED, V9, P1414, DOI 10.1089/jpm.2006.9.1414
   Chaplan SR, 2010, TRANSLATIONAL PAIN R, V0, P0
   Cleeland CS, 1997, ANN INTERN MED, V127, P813, DOI 10.7326/0003-4819-127-9-199711010-00006
   Corbin LW, 2009, J PALLIAT MED, V12, P7, DOI 10.1089/jpm.2008.0198
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Deng Gary, 2006, J SOC INTEGR ONCOL, V4, P86
   Droney Joanne, 2009, J PAIN RES, V2, P135
   Dunigan BJ, 2011, BODY IMAGE, V8, P411, DOI 10.1016/j.bodyim.2011.06.004
   Ernst E, 2009, SUPPORT CARE CANCER, V17, P333, DOI 10.1007/s00520-008-0569-z
   Ezzo JM, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002285.pub2
   FISCHER MV, 1984, ACUPUNCTURE ELECTRO, V9, P11
   Gansler T, 2008, CANCER-AM CANCER SOC, V113, P1048, DOI 10.1002/cncr.23659
   Gottschling S, 2008, KLIN PADIATR, V220, P365, DOI 10.1055/s-0028-1086039
   Guindon J, 2007, DRUGS, V67, P2121, DOI 10.2165/00003495-200767150-00002
   HAN JS, 1984, NEUROPHARMACOLOGY, V23, P1
   Jannetto PJ, 2010, GENOME MED, V2, P0, DOI 10.1186/gm187
   JAYARATNAM F J, 1988, SMJ SINGAPORE MEDICAL JOURNAL, V29, P557
   Jindal V, 2008, J PEDIAT HEMATOL ONC, V30, P431, DOI 10.1097/MPH.0b013e318165b2cc
   Johnson CD, 2009, PANCREATOLOGY, V9, P755, DOI 10.1159/000199441
   Kasai S, 2008, N-S ARCH PHARMACOL, V377, P269, DOI 10.1007/s00210-007-0205-3
   Kim SK, 2006, J PHYSIOL SCI, V56, P259, DOI 10.2170/physiolsci.SC002706
   Krishna LKR, 2010, ANN ACAD MED SINGAP, V39, P790
   Kvorning N, 2010, PAIN MED, V11, P1126, DOI 10.1111/j.1526-4637.2010.00878.x
   Law LAF, 2008, J PAIN, V9, P714, DOI 10.1016/j.jpain.2008.03.009
   Li A, 2011, EVID-BASED COMPL ALT, V2011, P0
   LI QS, 1994, CHINESE MED J-PEKING, V107, P289
   Lin JG, 2008, AM J CHINESE MED, V36, P635, DOI 10.1142/S0192415X08006107
   Mehling WE, 2007, J PAIN SYMPTOM MANAG, V33, P258, DOI 10.1016/j.jpainsymman.2006.09.016
   Mercadante S, 2006, CANCER TREAT REV, V32, P304, DOI 10.1016/j.ctrv.2006.03.001
   Minton O, 2007, J PAIN SYMPTOM MANAG, V33, P115, DOI 10.1016/j.jpainsymman.2006.09.011
   Mitra R, 2012, AM J HOSP PALLIAT ME, V29, P70, DOI 10.1177/1049909111413256
   Okuyama T, 2004, JPN J CLIN ONCOL, V34, P37, DOI 10.1093/jjco/hyh004
   Olaku O, 2011, EUR J CANCER, V47, P508, DOI 10.1016/j.ejca.2010.11.018
   Ouchi Y, 2006, NEUROSCI LETT, V407, P131, DOI 10.1016/j.neulet.2006.08.037
   Pan CX, 2000, J PAIN SYMPTOM MANAG, V20, P374, DOI 10.1016/S0885-3924(00)00190-1
   Portenoy Russell K, 2010, J OPIOID MANAG, V6, P97
   Raphael J, 2010, PAIN MED, V11, P872, DOI 10.1111/j.1526-4637.2010.00841.x
   Riley J, 2006, SUPPORT CARE CANCER, V14, P56, DOI 10.1007/s00520-005-0843-2
   Siu A, 2007, CNS DRUG REV, V13, P96, DOI 10.1111/j.1527-3458.2007.00006.x
   So WKW, 2009, ONCOL NURS FORUM, V36, P405, DOI 10.1188/09.ONF.E205-E214
   Spichiger E, 2011, EUR J ONCOL NURS, V15, P95, DOI 10.1016/j.ejon.2010.06.005
   Standish LJ, 2008, AM J HOSP PALLIAT ME, V25, P298, DOI 10.1177/1049909108315916
   Stefaniak T, 2005, EJSO-EUR J SURG ONC, V31, P768, DOI 10.1016/j.ejso.2005.03.012
   Tay WKJ, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P191
   Tay W, 2009, ANN ACAD MED SINGAP, V38, P989
   Valeberg BT, 2008, EUR J PAIN, V12, P582, DOI 10.1016/j.ejpain.2007.09.004
   Vickers AJ, 2010, TRIALS, V11, P0, DOI 10.1186/1745-6215-11-90
   Vickers AJ, 2009, ACUPUNCT MED, V27, P126, DOI 10.1136/aim.2009.001313
   Wagner-Johnston ND, 2010, J PAIN SYMPTOM MANAG, V39, P180, DOI 10.1016/j.jpainsymman.2009.06.012
   Xu L, 2007, INTEGR CANCER THER, V6, P208, DOI 10.1177/1534735407305705
   Zareba G, 2009, DRUG TODAY, V45, P445, DOI 10.1358/dot.2009.45.6.1385751
   Zhao ZL, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq045
NR 57
TC 1
Z9 2
U1 0
U2 13
PU ACAD MEDICINE SINGAPORE
PI REPUBLIC SINGAPORE
PA 142 NEIL RD, REPUBLIC SINGAPORE 088871, SINGAPORE
SN 0304-4602
EI 
J9 ANN ACAD MED SINGAP
JI Ann. Acad. Med. Singap.
PD SEP 15
PY 2012
VL 41
IS 9
BP 407
EP 416
DI 
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 024HI
UT WOS:000310099900006
PM 23052435
DA 2026-01-16
ER

PT J
AU Hurlow, A
   Bennett, MI
   Robb, KA
   Johnson, MI
   Simpson, KH
   Oxberry, SG
AF Hurlow, Adam
   Bennett, Michael I.
   Robb, Karen A.
   Johnson, Mark I.
   Simpson, Karen H.
   Oxberry, Stephen G.
TI Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Pain Management; Neoplasms [complications]; Pain [etiology]; Randomized Controlled Trials as Topic; Transcutaneous Electric Nerve Stimulation [methods]; Adult; Humans
ID management; medicine; laser
AB Background Cancer-related pain is complex and multi-dimensional but the mainstay of cancer pain management has predominantly used a biomedical approach. There is a need for non-pharmacological and innovative approaches. Transcutaneous Electric Nerve Stimulation (TENS) may have a role in pain management but the effectiveness of TENS is currently unknown. This is an update of the original review published in Issue 3, 2008. Objectives The aim of this systematic review was to determine the effectiveness of TENS for cancer-related pain in adults. Search methods The initial review searched The Cochrane Library, MEDLINE, EMBASE, CINAHL, PsychINFO, AMED and PEDRO databases in April 2008. We performed an updated search of CENTRAL, MEDLINE, EMBASE, CINAHL and PEDRO databases in November 2011. Selection criteria We included only randomised controlled trials (RCTS) investigating the use of TENS for the management of cancer-related pain in adults. Data collection and analysis The search strategy identified a further two studies for possible inclusion. One of the review authors screened each abstract using a study eligibility tool. Where eligibility could not be determined, a second author assessed the full paper. One author used a standardised data extraction sheet to collect information on the studies and independently assess the quality of the studies using the validated five-point Oxford Quality Scale. The small sample sizes and differences in patient study populations of the three included studies (two from the original review and a third included in this update) prevented meta-analysis. For the original review the search strategy identified 37 possible published studies; we divided these between two pairs of review authors who decided on study selection; all four review authors discussed and agreed final scores. Main results Only one additional RCT met the eligibility criteria (24 participants) for this updated review. Although this was a feasibility study, not designed to investigate intervention effect, it suggested that TENS may improve bone pain on movement in a cancer population. The initial review identified two RCTs (64 participants) therefore this review now includes a total of three RCTs (88 participants). These studies were heterogenous with respect to study population, sample size, study design, methodological quality, mode of TENS, treatment duration, method of administration and outcome measures used. In one RCT, there were no significant differences between TENS and placebo in women with chronic pain secondary to breast cancer treatment. In the other RCT, there were no significant differences between acupuncture-type TENS and sham in palliative care patients; this study was underpowered. Authors' conclusions Despite the one additional RCT, the results of this updated systematic review remain inconclusive due to a lack of suitable RCTs. Large multi-centre RCTs are required to assess the value of TENS in the management of cancer-related pain in adults.
C1 [Hurlow, Adam] Leeds Teaching Hosp NHS Trust, Palliat Care Team, Leeds, W Yorkshire, England.
   [Bennett, Michael I.] Univ Leeds, Leeds Inst Hlth Sci, Leeds, W Yorkshire, England.
   [Robb, Karen A.] Barts Hosp, Physiotherapy Dept, London, England.
   [Johnson, Mark I.] Leeds Metropolitan Univ, Fac Hlth & Social Sci, Leeds LS1 3HE, W Yorkshire, England.
   [Simpson, Karen H.] Leeds Teaching Hosp NHS Trust, Chron Pain Team, Leeds, W Yorkshire, England.
   [Oxberry, Stephen G.] Kirkwood Hosp, Huddersfield, W Yorkshire, England.
C3 University of Leeds; University of Leeds; Leeds Beckett University; University of Leeds
RP Hurlow, A (corresponding author), Leeds Teaching Hosp NHS Trust, Palliat Care Team, Leeds, W Yorkshire, England.
EM adamhurlow@yahoo.co.uk
FU Cochrane Pain, Palliative and Supportive Care; Barts; Tower Hamlets PCT, UK; London NHS Trust
CR AVELLANOSA AM, 1982, J MED, V13, P203
   Bennett MI, 2010, J PAIN, V11, P351, DOI 10.1016/j.jpain.2009.08.002
   BILD E, 1990, REVISTA MEDICO-CHIRURGICALA SOCIETATII DI MEDICI SI NATURALISTI DIN IASI, V94, P407
   Bjordal JM, 2003, EUR J PAIN, V7, P181, DOI 10.1016/S1090-3801(02)00098-8
   Bonakdar R, 2004, PATIENT CARE NU 0909, V0, P9
   Brosseau L, 2003, COCHRANE DATABASE SYST REV, V0, PCD004377
   Cata JP, 2004, J PAIN SYMPTOM MANAG, V27, P72, DOI 10.1016/j.jpainsymman.2003.05.007
   COOPERMAN AM, 1975, SURG FORUM, V26, P77
   CROMPTON AC, 1992, BRIT J OBSTET GYNAEC, V99, P492, DOI 10.1111/j.1471-0528.1992.tb13788.x
   De Pinto Mario, 2006, ANESTHESIOL CLIN, V24, P19, DOI 10.1016/j.atc.2005.12.006
   DeSantana Josimari M, 2008, CURR RHEUMATOL REP, V10, P492
   DILDIN AS, 1985, VOP ONKOL+, V31, P33
   Dowswell T, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007214.pub2
   Evtiukhin A I, 1998, VOPR ONKOL, V44, P229
   Filshie J, 2000, CANC PAIN MANAGEMENT, V0, P0
   Gadsby JG, 1997, COMPLEMENTARY THER MED, V5, P13, DOI 10.1016/S0965-2299(97)80084-2
   Hakl L, 1989, DTSCH Z AKUPUNK, V32, P10
   Hamza MA, 1999, ANESTHESIOLOGY, V91, P1232, DOI 10.1097/00000542-199911000-00012
   Hasun R, 1988, SCHMERZ PAIN DOULEUR, V9, P234
   Hidderley Margaret, 1997, INT J PALLIAT NURS, V3, P185, DOI 10.12968/ijpn.1997.3.4.185
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Johnson M, 2008, CANC PAIN, V2nd, P0
   Johnson MI, 2011, EXPERT REV NEUROTHER, V11, P735, DOI 10.1586/ern.11.48
   Johnson MI, 2001, PAIN REV, V8, P121, DOI 10.1191/0968130201pr182ra
   Johnson MI, 2008, ELECTROTHERAPY EVIDE, V12th, P0
   Jones I, 2009, BJA EDUC, V9, P130, DOI 10.1093/bjaceaccp/mkp021
   Khadilkar A, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003008.pub3
   Kim PS, 2005, SEMIN ONCOL, V32, P194, DOI 10.1053/j.seminoncol.2005.01.001
   Kroeling P, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004251.pub4
   LAMER TJ, 1994, MAYO CLIN PROC, V69, P473, DOI 10.1016/S0025-6196(12)61647-4
   Lange A, 1995, KRANKENGYMNASTIQUE, V47, P338
   Librach SL, 1988, PALLIATIVE MED, V2, P15
   LONG DM, 1991, STEREOT FUNCT NEUROS, V56, P2, DOI 10.1159/000099388
   McCaffery M, 1992, HOSP J, V8, P121
   MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971
   Miguel R, 2000, CANCER CONTROL, V7, P149
   Mulvey MR, 2010, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007264.pub2
   NAVEAU S, 1992, GASTROEN CLIN BIOL, V16, P8
   Nnoaham KE, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003222.pub2
   Oosterwijk RFA, 1994, CRITICAL REV PHYS RE, V6, P219
   OSTROWSKI MJ, 1979, BRIT J CLIN PRACT, V33, P157
   Pan CX, 2000, J PAIN SYMPTOM MANAG, V20, P374, DOI 10.1016/S0885-3924(00)00190-1
   Patt R B, 1990, AM J HOSP PALLIAT CARE, V7, P30, DOI 10.1177/104990919000700608
   Patt R B, 1992, AM J HOSP PALLIAT CARE, V9, P41, DOI 10.1177/104990919200900604
   Picaza J A, 1975, SURG NEUROL, V4, P105
   Proctor M, 1996, COCHRANE DATABASE SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002123
   Rafter J, 1986, TENS CANC PAIN, V0, P0
   Raphael J, 2010, PAIN MED, V11, P872, DOI 10.1111/j.1526-4637.2010.00841.x
   Reeve J, 1996, INT J TECHNOL ASSESS, V12, P299, DOI 10.1017/S026646230000965X
   Reuss R, 1985, PHYS THERAPY CLIN MA, V5, P26
   Robb K, 2003, CHARTERED SOC PHYSIO, V0, P125
   Robb KA, 2004, PPA NEWS, V17, P26
   Robb KA, 2007, J PAIN SYMPTOM MANAG, V33, P410, DOI 10.1016/j.jpainsymman.2006.09.020
   Rutjes AWS, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002823.pub2
   Rutkowski B, 1980, POL TYG LEK, V35, P1865
   Sang CN, 2003, J PAIN SYMPTOM MANAG, V25, P64, DOI 10.1016/S0885-3924(02)00541-9
   Searle RD, 2008, PALLIATIVE MED, V22, P878, DOI 10.1177/0269216308096719
   Sharp SM, 2003, RES PRACTITIONER, V4, P134
   Sima L, 2009, J CLIN ONCOL, V27, P0
   Simpson K, 2000, CANC PAIN MANAGEMENT, V1, P0
   Sloan Paul A, 2004, J SUPPORT ONCOL, V2, P491
   Tonkin J, 1998, PHYSIOTHERAPY FRONTL, V4, P18
   Turk DC, 1998, PAIN, V74, P247, DOI 10.1016/S0304-3959(97)00187-5
   Urba SG, 1996, CLIN GERIATR MED, V12, P301
   Ventafridda V, 1979, ADV PAIN RES THER, V2, P509
   Walsh DM, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006142.pub2
   Walsh DM, 1997, TENS CLIN APPL RELAT, V0, P0
   Weinstein SM, 1994, PHYS MED REHABIL, V8, P279
   WEN HL, 1977, MOD MED ASIA, V13, P12
NR 70
TC 99
Z9 117
U1 1
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PD JUN 15
PY 2012
VL 0
IS 3
BP 
EP 
DI 10.1002/14651858.CD006276.pub3
PG 29
WC Medicine, General & Internal
SC General & Internal Medicine
GA 908QQ
UT WOS:000301505600060
PM 22419313
DA 2026-01-16
ER

PT J
AU Zhang, ZD
   Wang, CS
   Gu, GY
   Li, HP
   Zhao, HF
   Wang, K
   Han, F
   Wang, GN
AF Zhang, Zhaodi
   Wang, Changsong
   Gu, Guangying
   Li, Huiping
   Zhao, Haifang
   Wang, Kun
   Han, Fei
   Wang, Guonian
TI The Effects of Electroacupuncture at the ST36 (Zusanli) Acupoint on Cancer Pain and Transient Receptor Potential Vanilloid Subfamily 1 Expression in Walker 256 Tumor-Baearing Rats
SO ANESTHESIA AND ANALGESIA
LA English
DT Article
ID low-frequency electroacupuncture; induced inflammatory pain; postoperative pain; neuropathic pain; analgesic requirement; mechanical allodynia; messenger-rna; model; hyperalgesia; trpv1
AB BACKGROUND: Several studies have addressed the expression of transient receptor potential vanilloid subfamily 1(TRPV1) playing an important role in the generation of cancer pain. Electroacupuncture (EA) is an effective method of acupuncture shown to attenuate different kinds of pain such as inflammatory, neuropathic, and cancer. In this study, we investigated the effect of EA on cancer pain caused by intraplantar injection of Walker 256 carcinoma cells and cancer-driven TRPV1 expression in the dorsal root ganglions (DRGs). METHODS: Rats were randomly divided into 4 groups: the nontumor cell inoculation group (normal control, n = 8); Walker 256 carcinoma cell inoculation group (tumor control, n = 8); sham point electrical stimulation treatment with Walker 256 carcinoma cell inoculation group (SES, n = 8); EA treatment with Walker 256 carcinoma cell inoculation group (EA, n = 8). The time courses of thermal, mechanical sensitivity, and spontaneous nocifensive behavior were determined. In addition, TRPV1 expression in DRGs was observed by quantitative real-time polymerase chain reaction and Western blotting. RESULTS: Injection of cancer cells decreased the paw withdrawal threshold, increased spontaneous nocifensive behavior, and induced significant thermal hyperalgesia that was attenuated by EA at the ST36 acupoint (2 Hz, 0.3 ms, <= 1 mA). TRPV1 mRNA and protein in DRGs were upregulated in the cancer pain model, and EA at ST36 acupoint counteracted the cancer-driven upregulation of TRPV1 expression in the corresponding DRGs. CONCLUSIONS: EA at ST36 could attenuate cancer-induced pain, at least in part, through suppressing TRPV1 mRNA and protein upregulation in the DRGs. (Anesth Analg 2012;114:879-85)
C1 [Zhang, Zhaodi; Gu, Guangying; Zhao, Haifang; Wang, Kun; Han, Fei; Wang, Guonian] Harbin Med Univ, Affiliated Hosp 3, Dept Anesthesiol, Harbin 150081, Peoples R China.
   [Wang, Changsong] Harbin Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Harbin 150081, Peoples R China.
   [Li, Huiping] Harbin Med Univ, Dept Anat, Harbin 150081, Peoples R China.
C3 Harbin Medical University; Harbin Medical University; Harbin Medical University
RP Wang, GN (corresponding author), Harbin Med Univ, Affiliated Hosp 3, Dept Anesthesiol, 6 Baojian Rd, Harbin 150081, Peoples R China.
EM guonian_wang@yahoo.cn
FU Outstanding Youth Science Foundation [JC2007716]; Education Bureau of Heilongjiang Province of China [1152hz33]
CR Aloe L, 2009, NEUROSCI LETT, V449, P173, DOI 10.1016/j.neulet.2008.11.003
   Asai H, 2005, PAIN, V117, P19, DOI 10.1016/j.pain.2005.05.010
   Baek YH, 2005, BRAIN RES, V1057, P181, DOI 10.1016/j.brainres.2005.07.014
   Brigatte P, 2007, J PAIN, V8, P412, DOI 10.1016/j.jpain.2006.11.006
   Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807
   Chen L, 1998, ANESTH ANALG, V87, P1129, DOI 10.1097/00000539-199811000-00028
   Chernyak GV, 2005, ANESTHESIOLOGY, V102, P1031, DOI 10.1097/00000542-200505000-00024
   Dai Y, 2004, J NEUROSCI, V24, P4293, DOI 10.1523/JNEUROSCI.0454-04.2004
   Coura LEF, 2011, ACUPUNCT MED, V29, P16, DOI 10.1136/aim.2010.003251
   Furuse S, 2009, ANESTHESIOLOGY, V111, P173, DOI 10.1097/ALN.0b013e3181a51e0d
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   Guo R, 1995, J TRADIT CHIN MED, V15, P262
   Huang C, 2008, NEUROCHEM RES, V33, P2107, DOI 10.1007/s11064-008-9721-x
   Jia YL, 2005, DRUG NEWS PERSPECT, V18, P165, DOI 10.1358/dnp.2005.18.3.892761
   Kim GH, 2010, NEUROL RES, V32, PS92, DOI 10.1179/016164109X12537002794327
   Kim JH, 2004, BRAIN RES, V998, P230, DOI 10.1016/j.brainres.2003.11.045
   Kim SK, 2005, EXP NEUROL, V195, P430, DOI 10.1016/j.expneurol.2005.06.018
   Koo ST, 2008, PAIN, V135, P11, DOI 10.1016/j.pain.2007.04.034
   Kotani N, 2001, ANESTHESIOLOGY, V95, P349, DOI 10.1097/00000542-200108000-00015
   Lau WK, 2010, NEUROSCIENCE, V170, P655, DOI 10.1016/j.neuroscience.2010.07.031
   Lee HJ, 2009, ACUPUNCTURE ELECTRO, V34, P27, DOI 10.3727/036012909803861095
   Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507
   Lin JG, 2002, PAIN, V99, P509, DOI 10.1016/S0304-3959(02)00261-0
   Mantyh PW, 2002, NAT REV CANCER, V2, P201, DOI 10.1038/nrc747
   Mao-Ying QL, 2006, EUR J PAIN, V10, P689, DOI 10.1016/j.ejpain.2005.11.001
   Menéndez L, 2002, J NEUROSCI METH, V113, P91, DOI 10.1016/S0165-0270(01)00483-6
   Miao XR, 2010, BMC CANCER, V10, P0, DOI 10.1186/1471-2407-10-216
   Nagamine K, 2006, J PAIN, V7, P659, DOI 10.1016/j.jpain.2006.02.013
   Nakanishi M, 2010, MOL BIOL CELL, V21, P2568, DOI 10.1091/mbc.E10-01-0049
   Nayebi AM, 2010, PAK J PHARM SCI, V23, P201
   Nayebi AM, 2009, PHARMACOL REP, V61, P453, DOI 10.1016/S1734-1140(09)70086-6
   Niiyama Y, 2007, NEUROSCIENCE, V148, P560, DOI 10.1016/j.neuroscience.2007.05.049
   Otis V, 2011, NEUROSCIENCE, V183, P221, DOI 10.1016/j.neuroscience.2011.03.052
   Puntambekar P, 2004, J NEUROSCI, V24, P3663, DOI 10.1523/JNEUROSCI.4773-03.2004
   Schmidt BL, 2010, MOL INTERV, V10, P164, DOI 10.1124/mi.10.3.7
   Shinoda M, 2008, J PAIN, V9, P687, DOI 10.1016/j.jpain.2008.02.007
   Sim Chin-Keng, 2002, ACUPUNCT MED, V20, P56
   Sun Y, 2008, BRIT J ANAESTH, V101, P151, DOI 10.1093/bja/aen146
   Tang NM, 1997, PAIN, V71, P71, DOI 10.1016/S0304-3959(97)03341-1
   Vickers Andrew J, 2006, BMC ANESTHESIOL, V6, P5, DOI 10.1186/1471-2253-6-5
   Wang K, 2009, ANESTH ANALG, V109, P1666, DOI 10.1213/ANE.0b013e3181b5a234
   Xu GY, 2007, GASTROENTEROLOGY, V133, P1282, DOI 10.1053/j.gastro.2007.06.015
   Xu S, 1995, J TRADIT CHIN MED, V15, P189
   Xu XJ, 2009, J NEUROSCI RES, V87, P482, DOI 10.1002/jnr.21844
   Yang EJ, 2011, RHEUMATOL INT, V31, P725, DOI 10.1007/s00296-010-1364-y
   Zhang H, 2007, J NEUROSCI, V27, P12067, DOI 10.1523/JNEUROSCI.0496-07.2007
   Zhang RX, 2008, EUR J PAIN, V12, P870, DOI 10.1016/j.ejpain.2007.12.006
   Zhang RX, 2007, ANESTH ANALG, V105, P1482, DOI 10.1213/01.ane.0000284705.34629.c5
   Zhang SP, 2004, BRAIN RES BULL, V62, P327, DOI 10.1016/j.brainresbull.2003.10.002
NR 49
TC 43
Z9 51
U1 2
U2 30
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
EI 
J9 ANESTH ANALG
JI Anesth. Analg.
PD APR 15
PY 2012
VL 114
IS 4
BP 879
EP 885
DI 10.1213/ANE.0b013e318246536d
PG 7
WC Anesthesiology
SC Anesthesiology
GA 912UL
UT WOS:000301826800026
PM 22253272
DA 2026-01-16
ER

PT J
AU Mehling, WE
   Lown, EA
   Dvorak, CC
   Cowan, MJ
   Horn, BN
   Dunn, EA
   Acree, M
   Abrams, DI
   Hecht, FM
AF Mehling, Wolf E
   Lown, E Anne
   Dvorak, Christopher C
   Cowan, Morton J
   Horn, Biljana N
   Dunn, Elizabeth A
   Acree, Michael
   Abrams, Donald I
   Hecht, Frederick M
TI Hematopoietic cell transplant and use of massage for improved symptom management:
SO Evidence-based complementary and alternative medicine : eCAM
LA English
DT Journal Article
AB Background. Pediatric hematopoietic cell transplant (HCT) is a lifesaving  treatment that often results in physical and psychological discomfort. An  acupressure-massage intervention may improve symptom management in this setting.  Methods. This randomized controlled pilot trial compared a combined  massage-acupressure intervention to usual care. Children were offered three  practitioner-provided sessions per week throughout hospitalization. Parents were  trained to provide additional acupressure as needed. Symptoms were assessed using  nurses' reports and two questionnaires, the behavioral affective and somatic  experiences scale and the Peds quality of life cancer module. Results. We  enrolled 23 children, ages 5 to 18. Children receiving the intervention reported  fewer days of mucositis (Hedges' g effect size ES = 0.63), lower overall symptom  burden (ES = 0.26), feeling less tired and run-down (ES = 0.86), having fewer  moderate/severe symptoms of pain, nausea, and fatigue (ES = 0.62), and less pain  (ES = 0.42). The intervention group showed trends toward increasing  contentness/serenity (ES = +0.50) and decreasing depression (ES = -0.45), but not  decreased anxiety (ES = +0.42). Differences were not statistically significant.  Discussion. Feasibility of studying massage-acupressure was established in  children undergoing HCT. Larger studies are needed to test the efficacy of such  interventions in reducing HCT-associated symptoms in children.
C1 Osher Center for Integrative Medicine, University of California, San Francisco, CA 94115, USA.
NR 0
TC 0
SN 1741-428
EI 1741-427
J9 Evid Based Complement Alternat Med
PD MAR 29
PY 2012
VL 2012
IS 
BP 450150
EP 450150
DI 10.1155/2012/450150
PG 0
UT PubMed:22454665
PM 22454665
DA 2012-03-29
ER

PT J
AU Rocha, ALL
   Reis, FM
   Petraglia, F
AF Rocha, Ana Luiza L.
   Reis, Fernando M.
   Petraglia, Felice
TI New trends for the medical treatment of endometriosis
SO EXPERT OPINION ON INVESTIGATIONAL DRUGS
LA English
DT Review
DE acupuncture; antiangiogenic therapy; antioxidant therapy; endometriosis; natural extracts; new treatment; omega-3; selective estrogen receptor modulator; statins; thiazolinedione; vitamins
ID endothelial growth-factor; chronic pelvic pain; progesterone-receptor modulator; simvastatin induces apoptosis; gamma agonist rosiglitazone; cancer cell-proliferation; cb1 cannabinoid receptor; nude-mouse model; stromal cells; in-vitro
AB Introduction: Endometriosis is a benign sex hormone-dependent gynecological disease, characterized by the presence and growth of endometrial tissue outside the uterus; it affects 10% of women of reproductive age and is associated with infertility and pain. Treatment of endometriosis involves conservative or radical surgery, or medical therapies. The goals for endometriosis treatment may be the relief of pain and/or a successful pregnancy achievement in infertile patients. Treatment must be individualized with a multidisciplinary approach. The classical treatments carry adverse side effects and in some cases a negative impact on quality of life. New agents promise a distinct perspective in endometriosis treatment. Areas covered: The aim of this paper is to systematically review the literature evidence of new medical treatments for endometriosis, defined as pharmacological treatments not yet commonly available and currently under investigation. Expert opinion: These new medical therapies would be used associated with surgical treatment and, in the future, will render possible the association of hormone therapy with non-hormonal treatment for endometriosis.
C1 [Rocha, Ana Luiza L.; Petraglia, Felice] Univ Siena, Dept Pediat Obstet & Reprod Med, Policlin Santa Maria alle Scotte, I-53100 Siena, Italy.
   [Rocha, Ana Luiza L.; Reis, Fernando M.] Univ Fed Minas Gerais, Dept Obstet & Gynecol, Belo Horizonte, MG, Brazil.
   [Rocha, Ana Luiza L.; Reis, Fernando M.] Natl Inst Hormones & Womens Hlth, Belo Horizonte, MG, Brazil.
C3 University of Siena; Universidade Federal de Minas Gerais
RP Petraglia, F (corresponding author), Univ Siena, Dept Pediat Obstet & Reprod Med, Policlin Santa Maria alle Scotte, Viale Bracci, I-53100 Siena, Italy.
EM petraglia@unisi.it
CR Ailawadi RK, 2004, FERTIL STERIL, V81, P290, DOI 10.1016/j.fertnstert.2003.09.029
   Akhmetshina A, 2009, ARTHRITIS RHEUM-US, V60, P1129, DOI 10.1002/art.24395
   Al Kadri H, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005997.pub2
   Altintas D, 2010, EUR J OBSTET GYN R B, V150, P84, DOI 10.1016/j.ejogrb.2010.02.004
   Amsterdam LL, 2005, FERTIL STERIL, V84, P300, DOI 10.1016/j.fertnstert.2005.02.018
   Anthony M, 2001, ANN NY ACAD SCI, V949, P261
   ARUMUGAM K, 1995, FERTIL STERIL, V63, P198, DOI 10.1016/S0015-0282(16)57320-8
   Aytan H, 2007, AUST NZ J OBSTET GYN, V47, P321, DOI 10.1111/j.1479-828X.2007.00744.x
   Baarine M, 2011, GENES NUTR, V6, P161, DOI 10.1007/s12263-011-0232-z
   Bahamondes L, 2007, CONTRACEPTION, V75, PS134, DOI 10.1016/j.contraception.2006.12.008
   Becker CM, 2011, AM J PATHOL, V178, P1782, DOI 10.1016/j.ajpath.2010.12.037
   Beretta P, 1998, FERTIL STERIL, V70, P1176, DOI 10.1016/S0015-0282(98)00385-9
   Berkley KJ, 2005, SCIENCE, V308, P1587, DOI 10.1126/science.1111445
   Berkley KJ, 2010, ENDOCRINOLOGY, V0, P2356
   BOUABOULA M, 1995, BIOCHEM J, V312, P637, DOI 10.1042/bj3120637
   Boucher A, 2001, BIOL REPROD, V65, P890, DOI 10.1095/biolreprod65.3.890
   Bruner-Tran KL, 2011, BIOL REPROD, V84, P106, DOI 10.1095/biolreprod.110.086744
   Bruner-Tran KL, 2009, J CLIN ENDOCR METAB, V94, P2489, DOI 10.1210/jc.2008-2802
   Bulun SE, 2009, NEW ENGL J MED, V360, P268, DOI 10.1056/NEJMra0804690
   Carli C, 2009, ENDOCRINOLOGY, V150, P3128, DOI 10.1210/en.2008-1088
   Carr B, 2011, 11 WORLD C END, V0, P176
   Chabbert-Buffet N, 2005, HUM REPROD UPDATE, V11, P293, DOI 10.1093/humupd/dmi002
   Chapron C, 2002, HUM REPROD UPDATE, V8, P591, DOI 10.1093/humupd/8.6.591
   Chegini N, 1999, MOL HUM REPROD, V5, P459, DOI 10.1093/molehr/5.5.459
   CHEN DB, 1995, HUM REPROD, V10, P2773, DOI 10.1093/oxfordjournals.humrep.a135790
   Chishima F, 2002, AM J REPROD IMMUNOL, V48, P50, DOI 10.1034/j.1600-0897.2002.01101.x
   Cho SJ, 2008, INT J CANCER, V123, P951, DOI 10.1002/ijc.23593
   Chwalisz K, 2005, ENDOCR REV, V26, P423, DOI 10.1210/er.2005-0001
   Chwalisz K, 2004, FERTIL STERIL, V82, PS83, DOI 10.1016/j.fertnstert.2004.07.212
   Chwalisz K, 2002, ANN NY ACAD SCI, V955, P373, DOI 10.1111/j.1749-6632.2002.tb02798.x
   Cobellis L, 2004, EUR J OBSTET GYN R B, V116, P100, DOI 10.1016/j.ejogrb.2004.02.007
   Collins NH, 2009, BIOL REPROD, V80, P375, DOI 10.1095/biolreprod.107.065375
   Cosín R, 2009, FERTIL STERIL, V92, P1214, DOI 10.1016/j.fertnstert.2008.08.079
   COVENS AL, 1988, FERTIL STERIL, V49, P698
   Critchley HOD, 2006, ENDOCRINOLOGY, V147, P744, DOI 10.1210/en.2005-1153
   De Petrocellis L, 1998, P NATL ACAD SCI USA, V95, P8375, DOI 10.1073/pnas.95.14.8375
   Defer N, 2009, FASEB J, V23, P2120, DOI 10.1096/fj.09-129478
   del Pulgar TG, 2002, BIOCHEM J, V363, P183, DOI 10.1042/0264-6021:3630183
   Delgado-Rosas F, 2011, REPRODUCTION, V142, P745, DOI 10.1530/REP-11-0223
   Delmas D, 2004, ONCOGENE, V23, P8979, DOI 10.1038/sj.onc.1208086
   Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200
   Delmas D, 2002, INT J MOL MED, V10, P193
   Delmas D, 2000, ONCOL REP, V7, P847
   Demirturk F, 2006, J SOC GYNECOL INVEST, V13, P58, DOI 10.1016/j.jsgi.2005.10.002
   Donnez J, 2002, GYNECOL OBSTET INVES, V54, P52, DOI 10.1159/000066295
   Dousset B, 2010, ANN SURG, V251, P887, DOI 10.1097/SLA.0b013e3181d9722d
   Ebert AD, 2005, EUR J OBSTET GYN R B, V122, P144, DOI 10.1016/j.ejogrb.2005.04.017
   Elden H, 2005, BMJ-BRIT MED J, V330, P761, DOI 10.1136/bmj.38397.507014.E0
   Esfandiari N, 2007, FERTIL STERIL, V87, P257, DOI 10.1016/j.fertnstert.2006.06.040
   Fauconnier A, 2005, HUM REPROD UPDATE, V11, P595, DOI 10.1093/humupd/dmi029
   Ferrero S, 2009, HUM REPROD, V24, P3033, DOI 10.1093/humrep/dep302
   Ferrero S, 2011, REPROD BIOL ENDOCRIN, V9, P0, DOI 10.1186/1477-7827-9-89
   Foyouzi N, 2004, FERTIL STERIL, V82, P1019, DOI 10.1016/j.fertnstert.2004.02.133
   Franzoni F, 2003, INT J CARDIOL, V90, P317, DOI 10.1016/S0167-5273(02)00577-6
   French L, 2005, AM FAM PHYSICIAN, V71, P285
   French Linda, 2008, PAEDIATR DRUGS, V10, P1, DOI 10.2165/00148581-200810010-00001
   Furman C, 2004, ATHEROSCLEROSIS, V174, P93, DOI 10.1016/j.atherosclerosis.2004.01.009
   Ricci AG, 2011, REPROD SCI, V18, P614, DOI 10.1177/1933719110395406
   Garcia-Gonzalez E, 2009, RHEUMATOLOGY, V48, P1050, DOI 10.1093/rheumatology/kep189
   Gazvani MR, 2001, FERTIL STERIL, V76, P717, DOI 10.1016/S0015-0282(01)01991-4
   GERHARD I, 1992, GYNECOL ENDOCRINOL, V6, P171
   Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5
   Giudice LC, 2010, NEW ENGL J MED, V362, P2389, DOI 10.1056/NEJMcp1000274
   Grow DR, 1996, J CLIN ENDOCR METAB, V81, P1933, DOI 10.1210/jc.81.5.1933
   Guindon J, 2008, BRIT J PHARMACOL, V153, P319, DOI 10.1038/sj.bjp.0707531
   Harel Z, 1996, AM J OBSTET GYNECOL, V174, P1335, DOI 10.1016/S0002-9378(96)70681-6
   Hefler LA, 2005, FERTIL STERIL, V84, P1033, DOI 10.1016/j.fertnstert.2005.04.059
   HELMS JM, 1987, OBSTET GYNECOL, V69, P51
   Herington JL, 2011, FERTIL STERIL, V95, P1295, DOI 10.1016/j.fertnstert.2010.09.017
   Highfield ES, 2006, J ALTERN COMPLEM MED, V12, P317, DOI 10.1089/acm.2006.12.317
   HODGEN GD, 1994, HUM REPROD, V9, P77, DOI 10.1093/humrep/9.suppl_1.77
   Howard FM, 2009, J MINIM INVAS GYN, V16, P540, DOI 10.1016/j.jmig.2009.06.017
   Huang Hong-Yuan, 2008, CHANG GUNG MED J, V31, P431
   Hudelist G, 2007, REPROD SCI, V14, P798, DOI 10.1177/1933719107309120
   Huirne JAF, 2001, LANCET, V358, P1793, DOI 10.1016/S0140-6736(01)06797-6
   Hull ML, 2005, HUM REPROD, V20, P350, DOI 10.1093/humrep/deh611
   Imesch P, 2011, FERTIL STERIL, V95, P1579, DOI 10.1016/j.fertnstert.2010.12.058
   Jackson LW, 2005, HUM REPROD, V20, P2014, DOI 10.1093/humrep/dei001
   Julien B, 2005, GASTROENTEROLOGY, V128, P742, DOI 10.1053/j.gastro.2004.12.050
   KAUPPILA A, 1979, PROSTAG OTH LIPID M, V18, P655, DOI 10.1016/0090-6980(79)90033-9
   KAUPPILA A, 1985, OBSTET GYNECOL, V65, P379
   Kennedy S, 2005, HUM REPROD, V20, P2698, DOI 10.1093/humrep/dei135
   Kitawaki J, 1997, BIOL REPROD, V57, P514, DOI 10.1095/biolreprod57.3.514
   Kitawaki J, 1999, FERTIL STERIL, V72, P1100, DOI 10.1016/S0015-0282(99)00424-0
   Klein TW, 2005, NAT REV IMMUNOL, V5, P400, DOI 10.1038/nri1602
   Kulak Jr J, 2011, ENDOCRINOLOGY, V0, P0
   Lançon A, 2004, BIOCHEM BIOPH RES CO, V316, P1132, DOI 10.1016/j.bbrc.2004.02.164
   Lancon A, 2007, DRUG METAB DISPOS, V35, P699, DOI 10.1124/dmd.106.013664
   Laschke MW, 2006, BRIT J PHARMACOL, V149, P137, DOI 10.1038/sj.bjp.0706857
   Laschke MW, 2008, HUM REPROD, V23, P2308, DOI 10.1093/humrep/den245
   Laschke MW, 2007, HUM REPROD UPDATE, V13, P331, DOI 10.1093/humupd/dmm006
   Laschke MW, 2006, HUM REPROD, V21, P262, DOI 10.1093/humrep/dei308
   Lazzeri L, 2011, 11 WORLD C END, V0, P181
   Lebovic DI, 2007, FERTIL STERIL, V88, P1108, DOI 10.1016/j.fertnstert.2006.12.072
   Lebovic DI, 2010, ENDOCRINOLOGY, V151, P1846, DOI 10.1210/en.2009-1076
   Lebovic DI, 2004, FERTIL STERIL, V82, P1008, DOI 10.1016/j.fertnstert.2004.02.148
   Lian F, 2007, CHIN J INTEGR MED, V13, P109, DOI 10.1007/s11655-007-0109-6
   Lossl K, 2009, EUR J OBSTET GYN R B, V144, P48, DOI 10.1016/j.ejogrb.2009.02.001
   Luisi S, 2009, GYNECOL ENDOCRINOL, V25, P734, DOI 10.3109/09513590903159664
   Lund I, 2006, ACTA OBSTET GYN SCAN, V85, P12, DOI 10.1080/00016340500317153
   Machado DE, 2008, FERTIL STERIL, V90, P148, DOI 10.1016/j.fertnstert.2007.05.076
   Machado DE, 2010, FERTIL STERIL, V93, P2674, DOI 10.1016/j.fertnstert.2009.11.037
   Madauss KP, 2007, MOL ENDOCRINOL, V21, P1066, DOI 10.1210/me.2006-0524
   Marel AK, 2008, MOL NUTR FOOD RES, V52, P538, DOI 10.1002/mnfr.200700185
   Mckinnon BD, 2011, 11 WORLD C END, V0, P182
   McLaren J, 2000, HUM REPROD UPDATE, V6, P45, DOI 10.1093/humupd/6.1.45
   Melck D, 2000, ENDOCRINOLOGY, V141, P118, DOI 10.1210/en.141.1.118
   Meresman GF, 2005, FERTIL STERIL, V84, P459, DOI 10.1016/j.fertnstert.2005.01.137
   Michalski CW, 2008, PLOS ONE, V3, P0, DOI 10.1371/journal.pone.0001701
   Mier-Cabrera J, 2008, INT J GYNECOL OBSTET, V100, P252, DOI 10.1016/j.ijgo.2007.08.018
   Mier-Cabrera J, 2009, REPROD BIOL ENDOCRIN, V7, P0, DOI 10.1186/1477-7827-7-54
   Mier-Cabrera J, 2011, BJOG-INT J OBSTET GY, V118, P6, DOI 10.1111/j.1471-0528.2010.02777.x
   Milingos S, 2003, ANN NY ACAD SCI, V997, P269, DOI 10.1196/annals.1290.030
   MOORE J, 2004, THE COCHRANE LIBRARY, V0, P0
   Moravek MB, 2009, GYNECOL OBSTET INVES, V68, P167, DOI 10.1159/000230713
   Muñoz-Luque J, 2008, J PHARMACOL EXP THER, V324, P475, DOI 10.1124/jpet.107.131896
   Murphy AA, 1998, FERTIL STERIL, V69, P1092, DOI 10.1016/S0015-0282(98)00087-9
   Nap AW, 2004, HUM REPROD, V19, P2180, DOI 10.1093/humrep/deh408
   Nasu K, 2001, MOL HUM REPROD, V7, P741, DOI 10.1093/molehr/7.8.741
   Netsu S, 2008, FERTIL STERIL, V90, P1496, DOI 10.1016/j.fertnstert.2007.08.014
   Noble LS, 1996, J CLIN ENDOCR METAB, V81, P174, DOI 10.1210/jc.81.1.174
   Novella-Maestre E, 2009, HUM REPROD, V24, P1025, DOI 10.1093/humrep/den499
   Novembri R, 2011, J ENDOMETR PELVIC PA, V3, P34, DOI 10.5301/JE.2011.8331
   Oktem M, 2007, HUM REPROD, V22, P1474, DOI 10.1093/humrep/del505
   Olivares C, 2011, FERTIL STERIL, V96, P428, DOI 10.1016/j.fertnstert.2011.05.063
   Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2
   Panina P, 2011, 11 WORLD C END, V0, P188
   Pezzuto JM, 2011, ANN NY ACAD SCI, V1215, P123, DOI 10.1111/j.1749-6632.2010.05849.x
   Piotrowski PC, 2006, BIOL REPROD, V75, P107, DOI 10.1095/biolreprod.106.051763
   Pouresmail Zahra, 2002, J TRADIT CHIN MED, V22, P205
   Prentice A, 2004, COCHRANE LIB, V0, P0
   Ramón LA, 2011, HUM REPROD, V26, P1082, DOI 10.1093/humrep/der025
   Razzi S, 2004, BJOG-INT J OBSTET GY, V111, P182, DOI 10.1046/j.1471-0528.2003.00038.x
   Remorgida V, 2007, FERTIL STERIL, V88, P724, DOI 10.1016/j.fertnstert.2006.12.027
   Remorgida V, 2007, AUST NZ J OBSTET GYN, V47, P222, DOI 10.1111/j.1479-828X.2007.00722.x
   Rossi M, 2005, REPRODUCTION, V130, P721, DOI 10.1530/rep.1.00688
   Rubi-Klein K, 2010, EUR J OBSTET GYN R B, V153, P90, DOI 10.1016/j.ejogrb.2010.06.023
   Rueda D, 2000, MOL PHARMACOL, V58, P814, DOI 10.1124/mol.58.4.814
   Saito T, 2003, ARZNEIMITTEL-FORSCH, V53, P507
   SELAK V, 2004, THE COCHRANE LIBRARY, V0, P0
   Sesti F, 2009, EUR J OBSTET GYN R B, V147, P72, DOI 10.1016/j.ejogrb.2009.07.003
   Sharma I, 2011, FERTIL STERIL, V95, P829, DOI 10.1016/j.fertnstert.2010.09.008
   Slayden OD, 1998, HUM REPROD, V13, P269, DOI 10.1093/humrep/13.2.269
   Smuc T, 2009, MOL CELL ENDOCRINOL, V301, P59, DOI 10.1016/j.mce.2008.07.020
   Sokalska A, 2010, J CLIN ENDOCR METAB, V95, P3453, DOI 10.1210/jc.2010-0072
   Soysal S, 2004, HUM REPROD, V19, P160, DOI 10.1093/humrep/deh035
   Spitz IM, 2010, CONTRACEPTION, V82, P442, DOI 10.1016/j.contraception.2009.12.012
   Stratton P, 2008, OBSTET GYNECOL, V111, P88, DOI 10.1097/01.AOG.0000297307.35024.b5
   Struthers RS, 2009, J CLIN ENDOCR METAB, V94, P545, DOI 10.1210/jc.2008-1695
   Stygar Denis, 2003, REPROD BIOL ENDOCRINOL, V1, P40
   Szekeres T, 2011, ANN NY ACAD SCI, V1215, P89, DOI 10.1111/j.1749-6632.2010.05864.x
   Tan XJ, 2002, FERTIL STERIL, V78, P148, DOI 10.1016/S0015-0282(02)03187-4
   Teixeira-Clerc F, 2006, NAT MED, V12, P671, DOI 10.1038/nm1421
   Tokushige N, 2006, HUM REPROD, V21, P3001, DOI 10.1093/humrep/del260
   Tsou K, 1996, NEUROSCIENCE, V70, P791, DOI 10.1016/S0306-4522(96)83015-6
   Van Langendonckt A, 2008, MOL HUM REPROD, V14, P259, DOI 10.1093/molehr/gan019
   Velasco I, 2006, MOL HUM REPROD, V12, P377, DOI 10.1093/molehr/gal041
   Vercellini P, 2003, AM J OBSTET GYNECOL, V188, P606, DOI 10.1067/mob.2003.7
   Vercellini P, 2008, BEST PRACT RES CL OB, V22, P275, DOI 10.1016/j.bpobgyn.2007.10.001
   Viganò P, 2006, J MOL ENDOCRINOL, V36, P415, DOI 10.1677/jme.1.01946
   Wassmann S, 2002, ARTERIOSCL THROM VAS, V22, P300, DOI 10.1161/hq0202.104081
   Wieser F, 2005, FERTIL STERIL, V84, PS192, DOI 10.1016/j.fertnstert.2005.07.480
   Wieser F, 2007, HUM REPROD UPDATE, V13, P487, DOI 10.1093/humupd/dmm015
   Wieser F, 2009, BIOL REPROD, V81, P371, DOI 10.1095/biolreprod.108.075069
   Wilson WRW, 2005, EUR J VASC ENDOVASC, V30, P259, DOI 10.1016/j.ejvs.2005.02.044
   WOLF JP, 1989, FERTIL STERIL, V52, P1055
   Wölfler MM, 2005, HUM REPROD, V20, P1702, DOI 10.1093/humrep/deh796
   Xu H, 2009, HUM REPROD, V24, P608, DOI 10.1093/humrep/den417
   Yang Dong-xia, 2006, CHIN J INTEGR MED, V12, P218
   Yao Z, 2005, J INVEST SURG, V18, P177, DOI 10.1080/08941930591004412
   Yavuz E, 2007, FERTIL STERIL, V88, P1129, DOI 10.1016/j.fertnstert.2007.01.010
NR 171
TC 47
Z9 52
U1 1
U2 43
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354-3784
EI 1744-7658
J9 EXPERT OPIN INV DRUG
JI Expert Opin. Investig. Drugs
PD JUL 15
PY 2012
VL 21
IS 7
BP 905
EP 919
DI 10.1517/13543784.2012.683783
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 958ND
UT WOS:000305244600002
PM 22568855
DA 2026-01-16
ER

PT J
AU Gavronsky, S
   Koeniger-Donohue, R
   Steller, J
   Hawkins, JW
AF Gavronsky, Stas
   Koeniger-Donohue, Rebecca
   Steller, Julie
   Hawkins, Joellen W.
TI Postoperative Pain: Acupuncture versus Percutaneous Electrical Nerve Stimulation
SO PAIN MANAGEMENT NURSING
LA English
DT Article
ID low-back-pain; reproductive health-care; visual analog scales; controlled-trial; electroacupuncture; questionnaire; management; therapy
AB The purpose of this study was to examine the effect of traditional acupuncture compared with acupuncture with percutaneous electrical nerve stimulation (PENS) on postoperative surgical pain relief in gynecologic oncology patients. Twenty postoperative gynecologic oncology patients were randomly assigned into the two groups, and the intervention was initiated within 24 hours after surgery. The patients in each group received four treatments in the subsequent 48 hours, with 12 hours between each-treatment. Either traditional acupuncture needles or acupuncture needles with a pulsed electric current were applied to stimulate the area of points Sp6 and Sp8 near the saphenous nerve. Pain measurement instruments included a visual analog scale and the McGill Pain Questionnaire. Although the PENS treatment group demonstrated a consistent decrease in pain with each treatment application compared with the traditional acupuncture group, after 48 hours both groups experienced equivalent pain relief. (C) 2012 by the American Society for Pain Management Nursing
C1 [Gavronsky, Stas; Koeniger-Donohue, Rebecca; Steller, Julie; Hawkins, Joellen W.] Simmons Coll, Sch Hlth Sci, Boston, MA 02115 USA.
C3 Simmons University
RP Koeniger-Donohue, R (corresponding author), Simmons Coll, Sch Hlth Sci, 300 Fenway, Boston, MA 02115 USA.
EM rdono1@gmail.com
CR Ahmed HE, 2000, HEADACHE, V40, P311, DOI 10.1046/j.1526-4610.2000.00046.x
   Anastasia JK, 2000, NURSING SPECTRU 0727, V0, P0
   Unknown -, 2009, STATE CERTIFICATION, V0, P0
   Aune A, 1998, SCAND J PRIM HEALTH, V16, P37
   Beal M W, 2000, HOLIST NURS PRACT, V15, P78
   Beal M W, 2000, HOLIST NURS PRACT, V14, P69
   Beal MW, 1998, J NURSE-MIDWIFERY, V43, P224, DOI 10.1016/S0091-2182(98)00009-3
   Beal MW, 1999, J NURSE-MIDWIFERY, V44, P217, DOI 10.1016/S0091-2182(99)00054-3
   CHRISTENSEN PA, 1993, BRIT J ANAESTH, V71, P835, DOI 10.1093/bja/71.6.835
   CHRISTENSEN PA, 1989, BRIT J ANAESTH, V62, P258, DOI 10.1093/bja/62.3.258
   Cramp FL, 2000, ARCH PHYS MED REHAB, V81, P324, DOI 10.1053/apmr.2000.0810324
   Crichton N, 2001, J CLIN NURS, V10, P706
   DELUZE C, 1992, BRIT MED J, V305, P1249, DOI 10.1136/bmj.305.6864.1249
   FLAHERTY SA, 1996, J AM ASS NURSE ANEST, V64, P133
   Ghoname ESA, 1999, JAMA-J AM MED ASSOC, V281, P818, DOI 10.1001/jama.281.9.818
   HOBBS B, 1994, COMPLEMENTARY THERAP, V2, P36
   Hudson T, 2005, TOWNSEND LETT DOCTOR, V269, P142
   Kaye V, 2002, TRANSCUTANEOUS ELECT, V0, P0
   Kendall D E, 2002, DAO OF CHINESE MEDICINE: UNDERSTANDING AN ANCIENT HEALING ART, V0, P0
   Kerr DP, 2003, CLIN J PAIN, V19, P364, DOI 10.1097/00002508-200311000-00004
   Keuler H, 1998, NURS PRACT FORUM, V9, P202
   Lewith G T, 1996, J ALTERN COMPLEMENT MED, V2, P79, DOI 10.1089/acm.1996.2.79
   Lin JG, 2002, PAIN, V99, P509, DOI 10.1016/S0304-3959(02)00261-0
   MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5
   MURRAY JB, 1995, J PSYCHOL, V129, P443, DOI 10.1080/00223980.1995.9914980
   Pomeroy VM, 2000, AGE AGEING, V29, P229, DOI 10.1093/ageing/29.3.229
   POULAIN P, 1997, ACUPUNCT MED, V15, P10
   Sherwood Gwen D, 2003, AORN J, V77, P377, DOI 10.1016/S0001-2092(06)61206-4
   Stephenson NL, 2000, APPL NURS RES, V13, P157, DOI 10.1053/apnr.2000.7658
   Weiner DK, 2003, J AM GERIATR SOC, V51, P599, DOI 10.1034/j.1600-0579.2003.00202.x
   WEWERS ME, 1990, RES NURS HEALTH, V13, P227, DOI 10.1002/nur.4770130405
   WILKIE DJ, 1990, NURS RES, V39, P36
   Wolfe HL, 2005, TOWNSEND LETT DOCTOR, V261, P85
   Wong RHL, 2006, ANN THORAC SURG, V81, P2031, DOI 10.1016/j.athoracsur.2005.12.064
NR 34
TC 21
Z9 24
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1524-9042
EI 1532-8635
J9 PAIN MANAG NURS
JI Pain Manag. Nurs.
PD SEP 15
PY 2012
VL 13
IS 3
BP 150
EP 156
DI 10.1016/j.pmn.2009.08.001
PG 7
WC Nursing
SC Nursing
GA 005YH
UT WOS:000308785500004
PM 22929602
DA 2026-01-16
ER

PT J
AU Wong, RK
   James, JL
   Sagar, S
   Wyatt, G
   Nguyen-Tân, PF
   Singh, AK
   Lukaszczyk, B
   Cardinale, F
   Yeh, AM
   Berk, L
AF Wong, Raimond K W
   James, Jennifer L
   Sagar, Stephen
   Wyatt, Gwen
   Nguyen-Tân, Phuc Felix
   Singh, Anurag K
   Lukaszczyk, Barbara
   Cardinale, Francis
   Yeh, Alexander M
   Berk, Lawrence
TI Phase 2 results from Radiation Therapy Oncology Group Study 0537: a phase 2/3
SO Cancer
LA English
DT Journal Article
AB BACKGROUND: In this phase 2 component of a multi-institutional, phase 2/3,  randomized trial, the authors assessed the feasibility and preliminary efficacy  of acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) in  reducing radiation-induced xerostomia. METHODS: Patients with cancer of the head  and neck who were 3 to 24 months from completing radiotherapy with or without  chemotherapy (RT ± C) and who were experiencing xerostomia symptoms with basal  whole saliva production ≥0.1 mL per minute and were without recurrence were  eligible. Patients received twice weekly ALTENS sessions (24 sessions over 12  weeks) using a proprietary electrical stimulation unit. The primary study  objective was to assess the feasibility of ALTENS treatment. Patients were  considered compliant if 19 of 24 ALTENS sessions were delivered, and the targeted  compliance rate was 85%. Secondary objectives measured treatment-related  toxicities and the effect of ALTENS on overall radiation-induced xerostomia  burden using the University of Michigan Xerostomia-Related Quality of Life Scale  (XeQOLS). RESULTS: Of 48 accrued patients, 47 were evaluable. The median age was  60 years, 84% of patients were men, 70% completed RT ± C for >12 months, and 21%  had previously received pilocarpine. Thirty-four patients completed all 24 ALTENS  sessions, 9 patients completed 20 to 23 sessions, and 1 patient completed 19  sessions, representing a 94% total compliance rate. Six-month XeQOLS scores were  available for 35 patients and indicated that 30 patients (86%) achieved a  positive treatment response with a mean ± standard deviation reduction of 35.9% ±  36.1%. Five patients developed grade 1 or 2 gastrointestinal toxicity, and 1 had  a grade 1 pain event. CONCLUSIONS: The current results indicated that ALTENS  treatment for radiation-induced xerostomia can be delivered uniformly in a  cooperative, multicenter setting and produces possible beneficial treatment  response. Given these results, the phase 3 component of this study was initiated.
C1 McMaster University, Department of Oncology, Juravinski Cancer Center, Hamilton, Ontario, Canada. raimond.wong@jcc.hhsc.ca
NR 0
TC 0
SN 1097-014
EI 0008-543
J9 Cancer
PD JAN 19
PY 2012
VL 118
IS 17
BP 4244
EP 52
DI 10.1002/cncr.27382
PG -4192
WC Acupuncture; methods; Adult; Aged; Aged, 80 and over; Female; Head and Neck Neoplasms; radiotherapy; Humans; Male; Middle Aged; Pilocarpine; therapeutic use; Quality of Life; Radiation Injuries; therapy; Radiotherapy; adverse effects; Transcutaneous Electric Nerve Stimulation; adverse effects; Xerostomia; etiology; Young Adult
UT PubMed:22252927
PM 22252927
DA 2012-01-19
ER

PT J
AU Campbell, CL
   Campbell, LC
AF Campbell, Cathy L.
   Campbell, Lisa C.
TI A systematic review of cognitive behavioral interventions in advanced cancer
SO PATIENT EDUCATION AND COUNSELING
LA English
DT Review
DE Advanced neoplasms; Cognitive-behavioral; Cognitive therapy; Psycho-educational interventions; Adults
ID quality-of-life; palliative care; psychological interventions; pain management; self-efficacy; distress; issue; caregivers; symptoms; survival
AB Objective: To systematically review cognitive behavioral interventions for people with advanced cancer. Methods: A literature search was conducted using Medline(C), CINAHL(C), and Psych-info(C). Inclusion criteria: studies were included in the review if they met the following criteria: (1) the design was a randomized clinical trial, (2) the study tested a cognitive behavioral therapy, including psycho-educational, alternative and complementary therapies (i.e. acupuncture, relaxation), expressive, support and skill building interventions, (3) participants were adults (18 years of age or older) with advanced cancer and the (4) outcomes were directly related to the patient with advanced cancer. Results: 11 studies met the inclusion criteria. Of the studies in the review: treatment effects were not statistically significant in most studies, methods were not consistently described, and samples had limited racial/ethnic diversity. Conclusion: The interpretation of the effectiveness of the CBIs was limited by major challenges to the internal validity of the studies included in the review. The lack of data about the efficacy of CBIs to support people with advanced cancer is a gap in the current knowledge base. Practice implications: Given the needs of people living with advanced cancer well-designed studies are needed to test interventions that will improve outcomes for people living with advanced cancer. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Campbell, Cathy L.] Univ Virginia, Sch Nursing, Dept Acute & Specialty Care, Charlottesville, VA 22903 USA.
   [Campbell, Lisa C.] E Carolina Univ, Dept Psychol, Greenville, NC 27858 USA.
C3 University of Virginia; University of North Carolina; East Carolina University
RP Campbell, CL (corresponding author), Univ Virginia, Sch Nursing, Dept Acute & Specialty Care, 202 Jeanette Lancaster Way,McLeod Hall, Charlottesville, VA 22903 USA.
EM clc5t@virginia.edu
FU NIH/NCI [5R01CA122704-04, 3R01CA122704-03S1]
CR Unknown -, 2011, CANCER FACTS AND FIGURES 2011, V0, P0
   Aubin M, 2006, ONCOL NURS FORUM, V33, P1183, DOI 10.1188/06.ONF.1183-1188
   Bahn D, 2001, NURS EDUC TODAY, V21, P110, DOI 10.1054/nedt.2000.0522
   Bakitas M, 2009, JAMA-J AM MED ASSOC, V302, P741, DOI 10.1001/jama.2009.1198
   BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191
   Bowers Libby, 2003, CLIN J ONCOL NURS, V7, P281, DOI 10.1188/03.CJON.281-288
   Breitbart W, 2010, PSYCHO-ONCOLOGY, V19, P21, DOI 10.1002/pon.1556
   Brown Jean K, 2002, ONCOL NURS FORUM, V29, P517, DOI 10.1188/02.ONF.517-532
   Buck HG, 2008, JOURNAL OF HOSPICE AND PALLIATIVE NURSING, V10, P91, DOI 10.1097/01.NJH.0000306737.08850.71
   Byock IR, 1996, CLIN GERIATR MED, V12, P237
   Campbell CL, 2007, JOURNAL OF HOSPICE PALLIATIVE NURSING, V9, P31, DOI 10.1097/00129191-2007
   Chambers SK, 2011, PATIENT EDUC COUNS, V85, PE75, DOI 10.1016/j.pec.2011.01.027
   Clapper TC, 2010, CLIN SIMUL NURS, V6, P0
   Devine E C, 1995, ONCOL NURS FORUM, V22, P1369
   Devine Elizabeth C, 2003, ONCOL NURS FORUM, V30, P75, DOI 10.1188/03.ONF.75-89
   Doorenbos A, 2006, NURS RES, V55, P161, DOI 10.1097/00006199-200605000-00002
   Flor H, 2004, PROG PAIN RES MANAG, V27, P47
   FOLKMAN S, 1980, J HEALTH SOC BEHAV, V21, P219, DOI 10.2307/2136617
   Frankl VE, 1963, MANS SEARCH FOR MEANING, V0, P0
   Gelman M, 1998, AUST NZ J PSYCHIAT, V32, P307
   Gibson CA, 2006, ANESTHESIOL CLIN N A, V24, P61, DOI 10.1016/j.atc.2005.12.001
   Given Barbara, 2009, ONCOL NURS FORUM, V36, PE293, DOI 10.1188/09.ONF.E293-E302
   Glass E, 2007, JOURNAL OF HOSPICE AND PALLIATIVE NURSING, V9, P15
   Goodwin PJ, 2001, NEW ENGL J MED, V345, P1719, DOI 10.1056/NEJMoa011871
   Henry M, 2010, PSYCHO-ONCOLOGY, V19, P1340, DOI 10.1002/pon.1764
   Kapo J, 2004, J PALLIAT MED S1, V8, P0
   KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L
   Keefe FJ, 2005, J PAIN SYMPTOM MANAG, V29, P263, DOI 10.1016/j.jpainsymman.2004.06.014
   Kolva E, 2011, J PAIN SYMPTOM MANAG, V42, P691, DOI 10.1016/j.jpainsymman.2011.01.013
   Kwekkeboom KL, 2010, ONCOL NURS FORUM, V37, P151
   Lauver DR, 2002, RES NURS HEALTH, V25, P246, DOI 10.1002/nur.10044
   Lavoy G, 1997, CALLINGS FINDING FOL, V0, P0
   Lepore SJ, 2006, ANN BEHAV MED, V32, P85, DOI 10.1207/s15324796abm3202_2
   Lloyd-Wiiams M, 2008, EUR J CANCER, V44, P1133, DOI 10.1016/j.ejca.2008.02.032
   Manne SL, 2006, ANN BEHAV MED, V32, P98, DOI 10.1207/s15324796abm3202_4
   McMillan SC, 2007, ONCOL NURS FORUM, V34, P313, DOI 10.1188/07.ONF.313-321
   Meyers FJ, 2011, J PALLIAT MED, V14, P465, DOI 10.1089/jpm.2010.0416
   Miller JJ, 2007, J PSYCHOSOC ONCOL, V25, P105, DOI 10.1300/J077v25n04_07
   Moorey S, 2009, PSYCHOL MED, V39, P713, DOI 10.1017/S0033291708004169
   Peppercorn JM, 2011, J CLIN ONCOL, V29, P755, DOI 10.1200/JCO.2010.33.1744
   Porter LS, 2011, CURR PAIN HEADACHE R, V15, P263, DOI 10.1007/s11916-011-0190-6
   Ransom S, 2006, RES NURS HEALTH, V29, P190, DOI 10.1002/nur.20129
   Ropka M E, 2001, ONCOL NURS FORUM, V28, P1585
   Savard Josee, 2006, PALLIAT SUPPORT CARE, V4, P219
   Sherwood P, 2005, ONCOL NURS FORUM, V32, P1190, DOI 10.1188/05.ONF.1190-1198
   SKINNER BF, 1958, J EXP ANAL BEHAV, V1, P371, DOI 10.1901/jeab.1958.1-371
   Steel JL, 2007, J PSYCHOSOC ONCOL, V25, P19, DOI 10.1300/J077v25n03_02
   Teunissen SCCM, 2007, PALLIATIVE MED, V21, P341, DOI 10.1177/0269216307079067
   Thekkumpurath P, 2008, J PAIN SYMPTOM MANAG, V36, P520, DOI 10.1016/j.jpainsymman.2007.11.010
   Virnig BA, 2009, HEALTH AFFAIR, V28, P160, DOI 10.1377/hlthaff.28.1.160
   Waters SJ, 2004, PROG PAIN RES MANAG, V27, P261
   Weber BA, 2004, PSYCHO-ONCOLOGY, V13, P47, DOI 10.1002/pon.718
   Younis T, 2007, J PALLIAT MED, V10, P381, DOI 10.1089/jpm.2006.0071
NR 56
TC 28
Z9 33
U1 0
U2 48
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
SN 0738-3991
EI 
J9 PATIENT EDUC COUNS
JI Patient Educ. Couns.
PD OCT 15
PY 2012
VL 89
IS 1
BP 15
EP 24
DI 10.1016/j.pec.2012.06.019
PG 10
WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary
SC Public, Environmental & Occupational Health; Social Sciences - Other Topics
GA 028KJ
UT WOS:000310420900005
PM 22796302
DA 2026-01-16
ER

PT J
AU Choi, TY
   Lee, MS
   Kim, TH
   Zaslawski, C
   Ernst, E
AF Choi, Tae-Young
   Lee, Myeong Soo
   Kim, Tae-Hun
   Zaslawski, Christopher
   Ernst, Edzard
TI Acupuncture for the treatment of cancer pain: a systematic review of randomised clinical trials
SO SUPPORTIVE CARE IN CANCER
LA English
DT Review
DE Acupuncture; Cancer pain; Systematic review; Complementary and alternative medicine
ID electroacupuncture; management; expression; issue
AB Controlling cancer-related pain is an important component in the palliative care of cancer patients. The objective of this review was to assess the effectiveness of acupuncture for treating cancer pain. Fourteen databases were searched from their inception through April 2011. Randomised clinical trials (RCTs) were included if acupuncture was used as the sole treatment or as a part of a combination therapy for cancer pain. Studies were included if they were controlled with a placebo or controlled against a drug-therapy or no-treatment group. The Cochrane criteria were used to assess the risk of bias. A total of 15 RCTs met our inclusion criteria. All of the included RCTs were associated with a high risk of bias. The majority of acupuncture treatments or combination therapies with analgesics exhibited favourable effects compared with conventional treatments in individual studies. However, a meta-analysis suggested that acupuncture did not generate a better effect than drug therapy (n = 886; risk ratio (RR), 1.12; 95% CI 0.98 to 1.28; P = 0.09). The comparison between acupuncture plus drug therapy and drug therapy alone demonstrated a significant difference in favour of the combination therapy (n = 437; RR, 1.36; 95% CI 1.13 to 1.64; P = 0.003). The results of this systematic review provide no strong evidence for the effectiveness of acupuncture in the management of cancer pain. The total number of RCTs included in the analysis and their methodological quality were too low to draw firm conclusions. Future rigorous RCTs will be necessary to assess the clinical efficacy of acupuncture in this area.
C1 [Choi, Tae-Young; Lee, Myeong Soo; Kim, Tae-Hun] Korea Inst Oriental Med, Div Med Res, Taejon 305811, South Korea.
   [Ernst, Edzard] Univ Exeter, Peninsula Med Sch, Exeter, Devon, England.
   [Zaslawski, Christopher] Univ Technol Sydney, Coll Tradit Chinese Med, Sydney, NSW 2007, Australia.
C3 Korea Institute of Oriental Medicine (KIOM); University of Exeter; University of Technology Sydney
RP Lee, MS (corresponding author), Korea Inst Oriental Med, Div Med Res, Taejon 305811, South Korea.
EM drmslee@gmail.com
FU Korea Institute of Oriental Medicine [K11111, K11130]
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   American College of Chest Physicians, 2007, J ALTERN COMPLEMENT, V13, P1049, DOI 10.1089/acm.2007.0703
   American Pain Society, 2008, PRINC AN US TREATM A, V0, P0
   Unknown -, 2010, LIAONING J TRAD CHINESE MED, V0, P0, DOI DOI 10.13192/J.LJTCM.2010.10.166.MIJP.061
   Unknown -, 2010, CLIN PRACT GUID ONC, V0, P0
   Unknown -, 2005, CHIN J INTEGRATED TR, V0, P0
   Unknown -, 2000, CHINESE ACUPUNCTURE, V0, P0
   Unknown -, 2000, ACUPUNCT RES, V0, P0
   Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001
   Burton AW, 2007, PAIN MED, V8, P189, DOI 10.1111/j.1526-4637.2006.00220.x
   Caraceni A, 2005, J PAIN SYMPTOM MANAG, V29, P507, DOI 10.1016/j.jpainsymman.2004.08.014
   Carr Daniel B, 2004, J NATL CANCER INST MONOGR, V0, P23
   Cassileth Barrie, 2007, CURR PAIN HEADACHE REP, V11, P265, DOI 10.1007/s11916-007-0202-8
   Chen Zhong-jie, 2008, ZHONGGUO ZHEN JIU, V28, P251
   Cleary JF, 2007, J PALLIAT MED, V10, P1369, DOI 10.1089/jpm.2007.9842
   Dang W, 1998, J TRADIT CHIN MED, V18, P31
   Ernst E, 1997, NATURE, V385, P480, DOI 10.1038/385480c0
   Ernst Edzard, 2010, J PAIN SYMPTOM MANAGE, V40, Pe3, DOI 10.1016/j.jpainsymman.2010.03.010
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Goudas LC, 2005, CANCER INVEST, V23, P182, DOI 10.1081/CNV-200050482
   Harris JD, 2008, CLIN J PAIN, V24, PS8, DOI 10.1097/AJP.0b013e31816b58eb
   Higgins J, 2011, COCHRANE COLLABORATI, V0, P0
   Hsieh RK, 2005, J FORMOS MED ASSOC, V104, P913
   [胡侠 Hu Xia], 2004, 中国针灸 CHINESE ACUPUNCTURE AND MOXIBUSTION, V24, P149
   Kaasa S, 2008, PALLIATIVE MED, V22, P301, DOI 10.1177/0269216308091918
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Koshy RC, 1998, SUPPORT CARE CANCER, V6, P430, DOI 10.1007/s005200050190
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Lee HJ, 2009, ACUPUNCTURE ELECTRO, V34, P27, DOI 10.3727/036012909803861095
   Mao-Ying QL, 2006, EUR J PAIN, V10, P689, DOI 10.1016/j.ejpain.2005.11.001
   Norheim A J, 1996, J ALTERN COMPLEMENT MED, V2, P291, DOI 10.1089/acm.1996.2.291
   Paley CA, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub2
   Peng Hao, 2010, ZHONG XI YI JIE HE XUE BAO, V8, P501
   Pittler MH, 2000, J CLIN EPIDEMIOL, V53, P485, DOI 10.1016/S0895-4356(99)00220-6
   Quigley C, 2008, CLIN EVID, V2008, P2408
   Richardson MA, 2000, J CLIN ONCOL, V18, P2505, DOI 10.1200/JCO.2000.18.13.2505
   Sabino Mary Ann C, 2005, J SUPPORT ONCOL, V3, P15
   SCHUG SA, 1992, DRUG SAFETY, V7, P200, DOI 10.2165/00002018-199207030-00005
   Soyannwo O, 2009, PAIN RES MANAG, V14, P349
   Stjernsward J, 1996, J PAIN SYMPTOM MANAG, V12, P65, DOI 10.1016/0885-3924(96)00109-1
   Wang Ju-yong, 2011, ZHONG XI YI JIE HE XUE BAO, V9, P129, DOI 10.3736/jcim20110202
   White A, 2008, AN INTRODUCTION TO WESTERN MEDICAL ACUPUNCTURE, V0, P0
   White A, 2009, ACUPUNCT MED, V27, P33, DOI 10.1136/aim.2008.000372
   Zhang RX, 2008, EUR J PAIN, V12, P870, DOI 10.1016/j.ejpain.2007.12.006
   Zhang RX, 2007, ANESTH ANALG, V105, P1482, DOI 10.1213/01.ane.0000284705.34629.c5
NR 55
TC 81
Z9 92
U1 0
U2 42
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD JUN 15
PY 2012
VL 20
IS 6
BP 1147
EP 1158
DI 10.1007/s00520-012-1432-9
PG 12
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 935PN
UT WOS:000303532000005
PM 22447366
DA 2026-01-16
ER

PT J
AU Collinge, W
   Kahn, J
   Walton, T
   Kozak, L
   Bauer-Wu, S
   Fletcher, K
   Yarnold, P
   Soltysik, R
AF Collinge, William
   Kahn, Janet
   Walton, Tracy
   Kozak, Leila
   Bauer-Wu, Susan
   Fletcher, Kenneth
   Yarnold, Paul
   Soltysik, Robert
TI Touch, Caring, and Cancer: randomized controlled trial of a multimedia caregiver
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Journal Article
AB PURPOSE: A randomized controlled trial was conducted to evaluate outcomes of a  multimedia instructional program for family caregivers in simple touch-based  techniques to provide comfort to cancer patients at home. METHODS: A multilingual  78-min DVD and 66-page manual were produced for homebased instruction. Content  addresses attitudes and communication about touch in cancer, psychological  preparation for giving and receiving touch, safety precautions, massage  techniques for comfort and relaxation, acupressure for specific cancer-related  symptoms, and practice in the home setting. Materials were produced in English,  Spanish, and Chinese versions. A community-based multiethnic sample of 97 adult  patient/caregiver dyads was randomized to experimental (massage) or attention  control (reading) groups for 4 weeks. Massage dyads received the program and  instructions to practice at least three times per week, while control caregivers  read to their patients for the same frequency. Self-report instruments assessed  change in symptom severity, quality of life, perceived stress, and caregiver  attitudes. RESULTS: Significant reductions in all symptoms occurred for patients  after both activities: 12-28 % reductions after reading vs. 29-44 % after  massage. Massage caregivers showed significant gains in confidence, comfort, and  self-efficacy using touch and massage as forms of caregiving. CONCLUSIONS:  Multimedia instruction in touch and massage methods may offer family members a  viable means of enhancing self-efficacy and satisfaction in caregiving while  decreasing patient pain, depression, and other symptoms. Family members may be  able to learn and apply safe and simple methods that increase patient comfort and  reduce distress.
C1 Collinge and Associates, Eugene, OR 79405, USA. william@collinge.org
NR 0
TC 0
SN 1433-733
EI 0941-435
J9 Support Care Cancer
PD DEC 25
PY 2012
VL 21
IS 5
BP 1405
EP 14
DI 10.1007/s00520-012-1682-6
PG -1391
WC Adolescent; Adult; Aged; Aged, 80 and over; Attitude to Health; Caregivers; education; Communication; Female; Humans; Male; Massage; education; Middle Aged; Multimedia; Neoplasms; pathology; Outcome Assessment, Health Care; Pain; etiology; Quality of Life; Reading; Self Efficacy; Severity of Illness Index; Stress, Psychological; etiology; Treatment Outcome; Young Adult
UT PubMed:23262808
PM 23262808
DA 2012-12-25
ER

PT J
AU Lin, LL
   Wang, YH
   Lai, CY
   Chau, CL
   Su, GC
   Yang, CY
   Lou, SY
   Chen, SK
   Hsu, KH
   Lai, YL
   Wu, WM
   Huang, JL
   Liao, CH
   Juan, HF
AF Lin, Li-Ling
   Wang, Ya-Hui
   Lai, Chi-Yu
   Chau, Chan-Lao
   Su, Guan-Chin
   Yang, Chun-Yi
   Lou, Shu-Ying
   Chen, Szu-Kai
   Hsu, Kuan-Hao
   Lai, Yen-Ling
   Wu, Wei-Ming
   Huang, Jian-Long
   Liao, Chih-Hsin
   Juan, Hsueh-Fen
TI Systems Biology of Meridians, Acupoints, and Chinese Herbs in Disease
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Review
ID prostate-cancer cells; gene-expression; proteomic analysis; american ginseng; medicinal herb; uncaria-rhynchophylla; acupuncture treatment; microarray analysis; parkinsons-disease; neuropathic pain
AB Meridians, acupoints, and Chinese herbs are important components of traditional Chinese medicine (TCM). They have been used for disease treatment and prevention and as alternative and complementary therapies. Systems biology integrates omics data, such as transcriptional, proteomic, and metabolomics data, in order to obtain a more global and complete picture of biological activity. To further understand the existence and functions of the three components above, we reviewed relevant research in the systems biology literature and found many recent studies that indicate the value of acupuncture and Chinese herbs. Acupuncture is useful in pain moderation and relieves various symptoms arising from acute spinal cord injury and acute ischemic stroke. Moreover, Chinese herbal extracts have been linked to wound repair, the alleviation of postmenopausal osteoporosis severity, and anti-tumor effects, among others. Different acupoints, variations in treatment duration, and herbal extracts can be used to alleviate various symptoms and conditions and to regulate biological pathways by altering gene and protein expression. Our paper demonstrates how systems biology has helped to establish a platform for investigating the efficacy of TCM in treating different diseases and improving treatment strategies.
C1 [Lin, Li-Ling; Lou, Shu-Ying; Lai, Yen-Ling; Liao, Chih-Hsin; Juan, Hsueh-Fen] Natl Taiwan Univ, Dept Life Sci, Taipei 106, Taiwan.
   [Wang, Ya-Hui; Lai, Chi-Yu] Natl Taiwan Univ, Grad Inst Epidemiol & Prevent Med, Taipei 100, Taiwan.
   [Chau, Chan-Lao] Natl Taiwan Univ, Dept Bioenvironm Syst Engn, Taipei 106, Taiwan.
   [Su, Guan-Chin; Yang, Chun-Yi] Natl Taiwan Univ, Inst Biochem Sci, Taipei 106, Taiwan.
   [Chen, Szu-Kai; Hsu, Kuan-Hao; Juan, Hsueh-Fen] Natl Taiwan Univ, Inst Mol & Cellular Biol, Taipei 106, Taiwan.
   [Wu, Wei-Ming] Natl Taiwan Univ, Dept Biochem Sci & Technol, Taipei 106, Taiwan.
   [Huang, Jian-Long; Juan, Hsueh-Fen] Natl Taiwan Univ, Grad Inst Biomed Elect & Bioinformat, Taipei 106, Taiwan.
C3 National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University
RP Juan, HF (corresponding author), Natl Taiwan Univ, Dept Life Sci, 1,Sect 4,Roosevelt Rd, Taipei 106, Taiwan.
EM yukijuan@ntu.edu.tw
FU National Taiwan University Cutting-Edge Steering Research Project [101R7602C3]; National Science Council of Taiwan [NSC99-2621-B-010-001-MY3, NSC99-2621-B-002-005-MY3]
CR Agnolet S, 2010, METABOLOMICS, V6, P292, DOI 10.1007/s11306-009-0195-x
   Bai LJ, 2010, MOL PAIN, V6, P0, DOI 10.1186/1744-8069-6-73
   Birch Stephen, 1999, UNDERSTANDING ACUPUN, V0, P0
   Butcher EC, 2004, NAT BIOTECHNOL, V22, P1253, DOI 10.1038/nbt1017
   Cantwell SL, 2010, TOP COMPANION ANIM M, V25, P53, DOI 10.1053/j.tcam.2009.10.006
   Chae Y, 2006, J PHYSIOL SCI, V56, P425, DOI 10.2170/physiolsci.RP010206
   Chan LS, 2009, EUR J PHARM SCI, V38, P370, DOI 10.1016/j.ejps.2009.08.008
   Chang FC, 2004, J BIOMED SCI, V11, P179, DOI 10.1159/000076030
   Cheng CH, 2010, NUTR CANCER, V62, P648, DOI 10.1080/01635581003605516
   Cheng KC, 2007, BMC GENOMICS, V8, P0, DOI 10.1186/1471-2164-8-411
   Cheng ZX, 2008, J ETHNOPHARMACOL, V120, P129, DOI 10.1016/j.jep.2008.07.030
   Choi YG, 2011, GENE, V481, P7, DOI 10.1016/j.gene.2011.03.006
   Choi YG, 2011, CELL MOL NEUROBIOL, V31, P377, DOI 10.1007/s10571-010-9629-2
   Chuang HY, 2010, ANNU REV CELL DEV BI, V26, P721, DOI 10.1146/annurev-cellbio-100109-104122
   Cojocaru Inimioara Mihaela, 2008, ROM J INTERN MED, V46, P77
   Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3
   DePeyer O, 2000, NATURE NEWS, V0, P0
   Ding XR, 2006, NEUROSCI LETT, V399, P11, DOI 10.1016/j.neulet.2006.01.067
   Fang JQ, 1999, IN VIVO, V13, P311
   Fu YC, 2005, J LIPID RES, V46, P1369, DOI 10.1194/jlr.M400373-JLR200
   Fulder S, 1996, HDB ALTERNATIVE COMP, V3rd, P0
   Fung Peter Chin Wan, 2009, CHIN MED, V4, P10, DOI 10.1186/1749-8546-4-10
   Gao YZ, 2007, AM J CHINESE MED, V35, P767, DOI 10.1142/S0192415X07005259
   Gözüm S, 2003, CANCER NURS, V26, P230
   Greenbaum D, 2001, GENOME RES, V11, P1463, DOI 10.1101/gr.207401
   Hall Robert, 2002, PLANT CELL, V14, P1437, DOI 10.1105/tpc.140720
   Han GC, 2007, J AGR FOOD CHEM, V55, P10641, DOI 10.1021/jf0722598
   Hara A, 2005, LIFE SCI, V77, P991, DOI 10.1016/j.lfs.2005.01.018
   Hong MS, 2010, NEUROL RES, V32, PS74, DOI 10.1179/016164109X12537002794165
   Hsu JW, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep107
   Hu CW, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0028329
   Hung YC, 2010, BBA-PROTEINS PROTEOM, V1804, P1310, DOI 10.1016/j.bbapap.2010.02.001
   Hung YC, 2009, J ETHNOPHARMACOL, V124, P463, DOI 10.1016/j.jep.2009.05.020
   Hussain SP, 2004, CANCER RES, V64, P6849, DOI 10.1158/0008-5472.CAN-04-2201
   Iizuka N, 2003, INT J CANCER, V107, P666, DOI 10.1002/ijc.11452
   Ito K, 2000, CIRC RES, V87, P588, DOI 10.1161/01.RES.87.7.588
   Jeon S, 2008, PROTEOMICS, V8, P4822, DOI 10.1002/pmic.200700955
   Jia J, 2010, BEHAV NEUROSCI, V124, P305, DOI 10.1037/a0018931
   Jia J, 2009, BEHAV BRAIN RES, V205, P214, DOI 10.1016/j.bbr.2009.06.024
   Jiang JH, 2011, INT J ONCOL, V38, P1675, DOI 10.3892/ijo.2011.996
   Jiang JH, 2010, INT J ONCOL, V37, P1529, DOI 10.3892/ijo_00000806
   Juan HF, 2012, SYSTEM BIOL APPL CAN, V0, P0
   Kang JX, 2005, CARCINOGENESIS, V26, P1934, DOI 10.1093/carcin/bgi154
   Kim CK, 2005, J NEUROIMMUNOL, V168, P144, DOI 10.1016/j.jneuroim.2005.07.005
   Kim SK, 2011, EVID-BASED COMPL ALT, V2011, P0
   Kim ST, 2010, J PHYSIOL SCI, V60, P27, DOI 10.1007/s12576-009-0061-7
   King ML, 2007, J EXP THER ONCOL, V6, P147
   Ko J, 2002, J BIOCHEM MOL BIOL, V35, P420
   Kong J, 2009, NEUROIMAGE, V47, P1066, DOI 10.1016/j.neuroimage.2009.05.087
   Konkimalla VB, 2008, NITRIC OXIDE-BIOL CH, V19, P184, DOI 10.1016/j.niox.2008.04.008
   Lai CY, 2010, VACCINE, V28, P4945, DOI 10.1016/j.vaccine.2010.05.037
   Langevin Helene M, 2002, ANATOMICAL RECORD, V269, P257, DOI 10.1002/ar.10185
   Lee J, 2003, J PHARMACOL SCI, V92, P70, DOI 10.1254/jphs.92.70
   Lee SMY, 2002, LIFE SCI, V71, P2267, DOI 10.1016/S0024-3205(02)01962-8
   Lemmon HR, 2012, J ETHNOPHARMACOL, V142, P1, DOI 10.1016/j.jep.2012.04.004
   Li HL, 2010, CANCER LETT, V297, P198, DOI 10.1016/j.canlet.2010.05.012
   Li HW, 2006, FASEB J, V20, P1748, DOI 10.1096/fj.06-5836fje
   Li M, 2007, INT J MOL MED, V19, P617
   Li WJ, 2010, NEUROSCI RES, V67, P307, DOI 10.1016/j.neures.2010.04.012
   Lin CC, 2012, BMC SYST BIOL, V6, P0, DOI 10.1186/1752-0509-6-18
   Lin CC, 2010, BMC SYST BIOL, V4, P0, DOI 10.1186/1752-0509-4-138
   Lin LL, 2012, J PROTEOMICS, V75, P3081, DOI 10.1016/j.jprot.2012.03.046
   Lin YL, 2006, MOL PHARMACOL, V70, P637, DOI 10.1124/mol.106.022327
   Lindsay RS, 2002, LANCET, V360, P57, DOI 10.1016/S0140-6736(02)09335-2
   LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H
   Lo WY, 2010, AM J CHINESE MED, V38, P745, DOI 10.1142/S0192415X10008214
   Luo XJ, 2008, INT J ONCOL, V32, P975, DOI 10.1007/978-3-540-77385-6
   Madsen MV, 2009, BMJ-BRIT MED J, V338, P0, DOI 10.1136/bmj.a3115
   Noureddine MA, 2005, MOVEMENT DISORD, V20, P1299, DOI 10.1002/mds.20573
   Oliver SG, 1998, TRENDS BIOTECHNOL, V16, P373, DOI 10.1016/S0167-7799(98)01214-1
   Pan SQ, 2011, EXP BIOL MED, V236, P325, DOI 10.1258/ebm.2011.010041
   Pham AN, 2010, J PHARMACOL EXP THER, V332, P949, DOI 10.1124/jpet.109.162248
   Praticò D, 2008, TRENDS PHARMACOL SCI, V29, P609, DOI 10.1016/j.tips.2008.09.001
   Prost-Squarcioni C, 2008, ANN DERMATOLOGIE V 2, V135, P1
   Reutelingsperger CPM, 1997, CELL MOL LIFE SCI, V53, P527, DOI 10.1007/s000180050067
   Richardson MA, 2000, J CLIN ONCOL, V18, P2505, DOI 10.1200/JCO.2000.18.13.2505
   Rudy Y, 2008, CIRCULATION, V118, P1202, DOI 10.1161/CIRCULATIONAHA.108.772715
   Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2
   Shiue HS, 2008, J ALTERN COMPLEM MED, V14, P689, DOI 10.1089/acm.2007.0669
   Shiue HS, 2010, J ALTERN COMPLEM MED, V16, P59, DOI 10.1089/acm.2009.0024
   Siebert JR, 2010, BMC NEUROSCI, V11, P0, DOI 10.1186/1471-2202-11-148
   Sliva D, 2004, MINI-REV MED CHEM, V4, P873, DOI 10.2174/1389557043403323
   Smith CA, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009232
   Sohn SH, 2010, CELL MOL NEUROBIOL, V30, P631, DOI 10.1007/s10571-009-9487-y
   Su SY, 2010, AM J CHINESE MED, V38, P1171, DOI 10.1142/S0192415X1000855X
   Sun Y, 2008, PHYTOTHER RES, V22, P267, DOI 10.1002/ptr.2291
   Sung HJ, 2004, PROTEOMICS, V4, P2805, DOI 10.1002/pmic.200300821
   Tan C, 2010, J ACUPUNCT MERIDIAN, V3, P173, DOI 10.1016/S2005-2901(10)60033-7
   Tan GG, 2011, BIOMED CHROMATOGR, V25, P1343, DOI 10.1002/bmc.1607
   Tseng CW, 2011, BMC SYST BIOL, V5, P0, DOI 10.1186/1752-0509-5-99
   Ulett GA, 1998, SOUTHERN MED J, V91, P1115, DOI 10.1097/00007611-199812000-00004
   Vlahcevic ZR, 1996, AM J PHYSIOL-GASTR L, V270, PG646, DOI 10.1152/ajpgi.1996.270.4.G646
   Wang EN, 2011, BMC MED GENOMICS, V4, P0, DOI 10.1186/1755-8794-4-38
   Wang F, 2006, CANCER CHEMOTH PHARM, V57, P389, DOI 10.1007/s00280-005-0047-y
   Wang H, 2011, PHYTOMEDICINE, V18, P163, DOI 10.1016/j.phymed.2010.06.011
   Wang LH, 1996, J NEUROSCI, V16, P6197
   Wang XY, 2011, J ETHNOPHARMACOL, V135, P662, DOI 10.1016/j.jep.2011.03.070
   Wang XY, 2009, J MOL NEUROSCI, V37, P97, DOI 10.1007/s12031-008-9095-1
   Westerhoff HV, 2004, NAT BIOTECHNOL, V22, P1249, DOI 10.1038/nbt1020
   Whichard ZL, 2010, BLOOD, V115, P2339, DOI 10.1182/blood-2009-08-215798
   Wojcikowski K, 2006, J LAB CLIN MED, V147, P160, DOI 10.1016/j.lab.2005.11.011
   Wolters H, 2002, J HEPATOL, V37, P556, DOI 10.1016/S0168-8278(02)00247-7
   Wu J, 2010, N-S ARCH PHARMACOL, V381, P83, DOI 10.1007/s00210-009-0461-5
   Xu X, 1991, ESSENTIALS TRADITION, V0, P0
   Xu Y, 2009, J PROTEOME RES, V8, P1585, DOI 10.1021/pr801001j
   Yan SK, 2009, MOL BIOSYST, V5, P1204, DOI 10.1039/b816407j
   Yaoita H, 2000, CARDIOVASC RES, V45, P630, DOI 10.1016/S0008-6363(99)00349-1
   Yoo JH, 2010, CANCER LETT, V289, P99, DOI 10.1016/j.canlet.2009.08.008
   Yuan Xiao-Chen, 2009, ZHEN CI YAN JIU, V34, P75
   Yue Patrick YK, 2005, ANGIOGENESIS, V8, P205, DOI 10.1007/s10456-005-9000-2
   Zhang Q, 2011, J ETHNOPHARMACOL, V138, P668, DOI 10.1016/j.jep.2011.08.080
   Zhang Q, 2009, ACTA PHARMACOL SIN, V30, P1674, DOI 10.1038/aps.2009.173
   Zhang Q, 2009, J NAT MED-TOKYO, V63, P304, DOI 10.1007/s11418-009-0337-5
   Zhang SP, 2004, BRAIN RES BULL, V62, P327, DOI 10.1016/j.brainresbull.2003.10.002
   Zhao H, 2006, WOUND REPAIR REGEN, V14, P593, DOI 10.1111/j.1743-6109.2006.00166.x
   Zhao H, 2012, EUR J DERMATOL, V22, P58, DOI 10.1684/ejd.2011.1599
NR 116
TC 18
Z9 22
U1 0
U2 42
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD JUN 15
PY 2012
VL 2012
IS 
BP 
EP 
DI 10.1155/2012/372670
PG 13
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 026NS
UT WOS:000310287200001
DA 2026-01-16
ER

PT J
AU Li, SQ
   Meng, LH
   Wang, YC
AF Li, Shu-Qing
   Meng, Ling-Hui
   Wang, Yun-Cang
TI [Acupuncture at Hegu (LI 4) for 18 cases of pain during CT-guided percutaneous
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD JUN 2
PY 2012
VL 32
IS 5
BP 451
EP 451
DI 
PG 0
WC Acupuncture Analgesia; Acupuncture Points; Adult; Aged; Aged, 80 and over; Catheter Ablation; Female; Humans; Liver Neoplasms; surgery; Male; Middle Aged; Pain Management
UT PubMed:22650137
PM 22650137
DA 2012-06-02
ER

PT J
AU Running, A
   Seright, T
AF Running, Alice
   Seright, Teresa
TI Integrative oncology: managing cancer pain with complementary and alternative
SO Current pain and headache reports
LA English
DT Review
AB For the projected 1,638,910 patients with a diagnosis of cancer this year, the  great majority of them (75-90 %) will experience cancer-related pain. A growing  number of these patients will turn to complementary and alternative therapies to  assist with the management of their pain and other cancer-related symptoms. The  World Health Organization's suggested approach to pain management begins with the  use of time honored opioids, but recommends the use of adjuvant therapies early  in the management process. Complementary and alternative therapies are being used  by more patients each year to assist with the management of their pain.  Practitioners and researchers must be aware of the evidence that exists to  support or refute the use of these therapies. In this manuscript we review  evidence from the recent past on complementary and alternative therapies for pain  with emphasis on more common modalities including acupuncture, bio-energy,  massage, and music.
C1 College of Nursing, Montana State University, Bozeman, MT 59717-3560, USA. alice.running@montana.edu
NR 0
TC 0
SN 1534-308
EI 
J9 Curr Pain Headache Rep
PD MAY 29
PY 2012
VL 16
IS 4
BP 325
EP 31
DI 10.1007/s11916-012-0275-x
PG -294
WC Acupuncture Therapy; Anxiety; diagnosis; Combined Modality Therapy; Complementary Therapies; methods; Evidence-Based Medicine; Female; Holistic Health; Humans; Male; Massage; Meditation; Music Therapy; Neoplasms; complications; Pain; diagnosis; Pain Management; methods; Patient Selection; Treatment Outcome
UT PubMed:22639181
PM 22639181
DA 2012-05-29
ER

PT J
AU Hurlow, A
   Bennett, MI
   Robb, KA
   Johnson, MI
   Simpson, KH
   Oxberry, SG
AF Hurlow, Adam
   Bennett, Michael I
   Robb, Karen A
   Johnson, Mark I
   Simpson, Karen H
   Oxberry, Stephen G
TI Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults.
SO The Cochrane database of systematic reviews
LA English
DT Journal Article
AB BACKGROUND: Cancer-related pain is complex and multi-dimensional but the mainstay  of cancer pain management has predominantly used a biomedical approach. There is  a need for non-pharmacological and innovative approaches. Transcutaneous Electric  Nerve Stimulation (TENS) may have a role in pain management but the effectiveness  of TENS is currently unknown. This is an update of the original review published  in Issue 3, 2008. OBJECTIVES: The aim of this systematic review was to determine  the effectiveness of TENS for cancer-related pain in adults. SEARCH METHODS: The  initial review searched The Cochrane Library, MEDLINE, EMBASE, CINAHL, PsychINFO,  AMED and PEDRO databases in April 2008. We performed an updated search of  CENTRAL, MEDLINE, EMBASE, CINAHL and PEDRO databases in November 2011. SELECTION  CRITERIA: We included only randomised controlled trials (RCTS) investigating the  use of TENS for the management of cancer-related pain in adults. DATA COLLECTION  AND ANALYSIS: The search strategy identified a further two studies for possible  inclusion. One of the review authors screened each abstract using a study  eligibility tool. Where eligibility could not be determined, a second author  assessed the full paper. One author used a standardised data extraction sheet to  collect information on the studies and independently assess the quality of the  studies using the validated five-point Oxford Quality Scale. The small sample  sizes and differences in patient study populations of the three included studies  (two from the original review and a third included in this update) prevented  meta-analysis. For the original review the search strategy identified 37 possible  published studies; we divided these between two pairs of review authors who  decided on study selection; all four review authors discussed and agreed final  scores. MAIN RESULTS: Only one additional RCT met the eligibility criteria (24  participants) for this updated review. Although this was a feasibility study, not  designed to investigate intervention effect, it suggested that TENS may improve  bone pain on movement in a cancer population. The initial review identified two  RCTs (64 participants) therefore this review now includes a total of three RCTs  (88 participants). These studies were heterogenous with respect to study  population, sample size, study design, methodological quality, mode of TENS,  treatment duration, method of administration and outcome measures used. In one  RCT, there were no significant differences between TENS and placebo in women with  chronic pain secondary to breast cancer treatment. In the other RCT, there were  no significant differences between acupuncture-type TENS and sham in palliative  care patients; this study was underpowered. AUTHORS' CONCLUSIONS: Despite the one  additional RCT, the results of this updated systematic review remain inconclusive  due to a lack of suitable RCTs. Large multi-centre RCTs are required to assess  the value of TENS in the management of cancer-related pain in adults.
C1 Palliative Care Team, Leeds Teaching Hospitals NHS Trust, Leeds, UK. adamhurlow@yahoo.co.uk.
NR 0
TC 0
SN 1469-493
EI 
J9 Cochrane Database Syst Rev
PD MAR 16
PY 2012
VL 2012
IS 3
BP CD006276
EP CD006276
DI 10.1002/14651858.CD006276.pub3
PG 1
WC Adult; Bone Diseases; therapy; Humans; Neoplasms; complications; Pain; etiology; Pain Management; methods; Randomized Controlled Trials as Topic; Transcutaneous Electric Nerve Stimulation; methods
UT PubMed:22419313
PM 22419313
DA 2012-03-16
ER

PT J
AU Gondim, DV
   Costa, JL
   Rocha, SS
   Brito, GA
   Ribeiro, Rde A
   Vale, ML
AF Gondim, Delane Viana
   Costa, Jéssyca Lima
   Rocha, Suellen Sousa
   Brito, Gerly Anne de Castro
   Ribeiro, Ronaldo de Albuquerque
   Vale, Mariana Lima
TI Antinociceptive and anti-inflammatory effects of electroacupuncture on
SO Canadian journal of physiology and pharmacology
LA English
DT Journal Article
AB This study investigated the antinociceptive and anti-inflammatory effects of  electroacupuncture (EA) on zymosan-induced acute arthritis of the rat  temporomandibular joint (TMJ). Male Wistar rats were injected with saline or  zymosan (control group; 2 mg) into the left TMJ. Low frequency EA (10 Hz, 30 min)  was performed at acupoints (LI4, LI11, ST36, ST44) or sham points 2 h after or  1 h before zymosan administration. Mechanical hypernociception was accessed by  the electronic Von Frey method after zymosan administration. Rats were sacrificed  6 h after zymosan administration and the joint was removed for histopathological  analysis, myeloperoxidase activity assessment, vascular permeability  observations, and immunohistochemical verification of inflammatory mediators. The  results showed that EA inhibited zymosan-induced hypernociception, compared with  the control group and with the sham group (p < 0.05). The results showed that EA  inhibited inflammatory parameters such as neutrophil migration, vascular  permeability, and tumour necrosis factor α (TNF-α), cyclooxygenase-2 (COX-2), and  inducible nitric oxide synthase (iNOS) expression in the TMJ compared with the  sham group (p < 0.05). Histopathological analysis showed that EA significantly  inhibited edema and periarticular infiltration (p < 0.05) compared with the  control and sham groups. EA at acupoints produced antinociceptive and  anti-inflammatory effects on zymosan-induced arthritis in the rat TMJ.
C1 Medical Sciences Post-Graduation, Federal University of Ceará (UFC), Fortaleza, Ceará, Brazil. delanegondim@yahoo.com.br
NR 0
TC 0
SN 1205-754
EI 
J9 Can J Physiol Pharmacol
PD MAR 27
PY 2012
VL 90
IS 4
BP 395
EP 405
DI 10.1139/y2012-003
PG 10
WC Acupuncture Points; Animals; Arthritis, Experimental; chemically induced; Capillary Permeability; drug effects; Edema; therapy; Electroacupuncture; methods; Inflammation; chemically induced; Inflammation Mediators; metabolism; Male; Nociceptive Pain; therapy; Peroxidase; metabolism; Rats; Temporomandibular Joint; metabolism; Zymosan
UT PubMed:22443108
PM 22443108
DA 2012-03-27
ER

PT J
AU Lin, JG
   Chen, YH
AF Lin, Jaung-Geng
   Chen, Yi-Hung
TI The Role of Acupuncture in Cancer Supportive Care
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Acupuncture; Cancer Care; Pain; Nausea; Vomiting; Xerostomia; Nervousness and Insomnia; Review
ID radiation-induced xerostomia; chemotherapy-induced nausea; auricular acupuncture; electroacupuncture; stimulation; analgesia; pain; dexamethasone; moxibustion; insomnia
AB Acupuncture has many beneficial effects during cancer therapy and has proven efficacy in the management of side effects induced by chemotherapy and radiotherapy. In this review, we discussed the benefits of acupuncture on cancer patients. In cancer pain management, acupuncture is effective for head and neck pain, waist pain, abdominal and chest pain. Many studies confirm the excellent efficacy of acupuncture against symptoms of vomiting and nausea, including those induced by chemotherapy and radiotherapy. Head and neck cancer patients receiving radiotherapy may develop xerostomia, which may be relieved by acupuncture. Acupuncture may also cause sedative and hypnotic effects in cancer patients for treating nervousness and insomnia.
C1 [Lin, Jaung-Geng] China Med Univ, Sch Chinese Med, Taichung 404, Taiwan.
   [Chen, Yi-Hung] China Med Univ, Grad Inst Acupuncture Sci, Taichung 404, Taiwan.
C3 China Medical University Taiwan; China Medical University Taiwan
RP Lin, JG (corresponding author), China Med Univ, Sch Chinese Med, 91 Hsueh Shih Rd, Taichung 404, Taiwan.
EM jglin@mail.cmu.edu.tw; yihungchen@mail.cmu.edu.tw
FU Committee on Chinese Medicine and Pharmacy, Department of Health, Taipei, Taiwan [CCMP 100-RD-31]; National Science Council, Taipei, Taiwan [NSC-100-2320-B-039-029-MY2]
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Unknown -, 2003, PARKINSONISM RELATED, V0, P0
   Caraceni A, 1999, PAIN, V82, P263, DOI 10.1016/S0304-3959(99)00073-1
   Carpenter RJ, 2010, AM J CHINESE MED, V38, P839, DOI 10.1142/S0192415X10008287
   Chang CS, 2010, AM J CHINESE MED, V38, P231, DOI 10.1142/S0192415X10007804
   Chang FC, 2004, J BIOMED SCI, V11, P179, DOI 10.1159/000076030
   Chen HY, 2007, J ALTERN COMPLEM MED, V13, P669, DOI 10.1089/acm.2006.6400
   CHENG R, 1979, LIFE SCI, V24, P1481, DOI 10.1016/0024-3205(79)90031-6
   Cheuk DKL, 2007, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005375.pub2
   Chiu JH, 2003, CAN J VET RES, V67, P94
   Chung A, 2003, CAN FAM PHYSICIAN, V49, P985
   CLEMENTJONES V, 1980, LANCET, V2, P946
   DREIZEN S, 1976, CANCER-AM CANCER SOC, V38, P273, DOI 10.1002/1097-0142(197607)38:1<273::AID-CNCR2820380141>3.0.CO;2-8
   Ernst E, 2007, AM J CHINESE MED, V35, P21, DOI 10.1142/S0192415X07004588
   FILSHIE J, 1988, CANCER SURV, V7, P161
   Braga FDF, 2011, BRAZ ORAL RES, V25, P180
   FRANZEN L, 1992, EUR J CANCER, V28A, P457, DOI 10.1016/S0959-8049(05)80076-0
   Griffin AM, 1996, ANN ONCOL, V7, P189
   Hau DM, 1999, AM J CHINESE MED, V27, P157, DOI 10.1142/S0192415X99000203
   Ioannidis JPA, 2000, J CLIN ONCOL, V18, P3409, DOI 10.1200/JCO.2000.18.19.3409
   Johnstone PAS, 2002, CANCER, V94, P1151, DOI 10.1002/cncr.10348
   Kimura K, 2006, AM J CHINESE MED, V34, P189, DOI 10.1142/S0192415X06003758
   KISER RS, 1983, LANCET, V2, P1394
   Kou W, 2007, AM J CHINESE MED, V35, P753, DOI 10.1142/S0192415X07005247
   Lee MS, 2010, AM J CHINESE MED, V38, P829, DOI 10.1142/S0192415X10008275
   Lin JG, 2009, AM J CHINESE MED, V37, P1
   Lin JG, 2008, AM J CHINESE MED, V36, P635, DOI 10.1142/S0192415X08006107
   Liu JH, 2004, NEUROSCI LETT, V356, P99, DOI 10.1016/j.neulet.2003.11.044
   LOVE RR, 1989, CANCER-AM CANCER SOC, V63, P604, DOI 10.1002/1097-0142(19890201)63:3<604::AID-CNCR2820630334>3.0.CO;2-2
   MAYER DJ, 1977, BRAIN RES, V121, P368, DOI 10.1016/0006-8993(77)90161-5
   Middlekauff HR, 2004, CLIN AUTON RES, V14, P113, DOI 10.1007/s10286-004-0171-5
   Mori H, 2002, NEUROSCI LETT, V320, P21, DOI 10.1016/S0304-3940(02)00012-5
   Moritaka K, 2010, AM J CHINESE MED, V38, P869, DOI 10.1142/S0192415X10008317
   Oleson T, 2002, NEUROREHABILITATION, V17, P49
   Osoba D, 1997, SUPPORT CARE CANCER, V5, P307, DOI 10.1007/s005200050078
   PERT A, 1981, BRAIN RES, V224, P83, DOI 10.1016/0006-8993(81)91118-5
   POMERANZ B, 1976, LIFE SCI, V19, P1757, DOI 10.1016/0024-3205(76)90084-9
   Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0
   Qiu Xingsheng, 2004, J TRADIT CHIN MED, V24, P56
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Roscoe JA, 2000, J PAIN SYMPTOM MANAG, V20, P113, DOI 10.1016/S0885-3924(00)00159-7
   Sekido R, 2003, AM J CHINESE MED, V31, P955, DOI 10.1142/S0192415X03001491
   Spence DW, 2004, J NEUROPSYCH CLIN N, V16, P19, DOI 10.1176/appi.neuropsych.16.1.19
   Streitberger K, 2003, CLIN CANCER RES, V9, P2538
   Sun HL, 2001, CHINESE ACUPUNCTURE, V21, P275
   Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321
   Vickers AJ, 2004, J CLIN ONCOL, V22, P1731, DOI 10.1200/JCO.2004.04.102
   Wang G, 2001, CHINESE ACUPUNCTURE, V21, P241
   Wen SL, 2011, AM J CHINESE MED, V39, P287, DOI 10.1142/S0192415X11008828
   Wong RKW, 2003, INT J RADIAT ONCOL, V57, P472, DOI 10.1016/S0360-3016(03)00572-8
   Wu J N, 1996, J ALTERN COMPLEMENT MED, V2, P19, DOI 10.1089/acm.1996.2.19
   Wu P, 2001, J TRADIT CHIN MED, V21, P68
   Yamaguchi N, 2007, EVID-BASED COMPL ALT, V4, P447, DOI 10.1093/ecam/nel107
NR 53
TC 31
Z9 35
U1 1
U2 39
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192-415X
EI 1793-6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PD JUN 15
PY 2012
VL 40
IS 2
BP 219
EP 229
DI 10.1142/S0192415X12500176
PG 11
WC Integrative & Complementary Medicine; Medicine, General & Internal
SC Integrative & Complementary Medicine; General & Internal Medicine
GA 908QH
UT WOS:000301504700001
PM 22419418
DA 2026-01-16
ER

PT J
AU Gavronsky, S
   Koeniger-Donohue, R
   Steller, J
   Hawkins, JW
AF Gavronsky, Stas
   Koeniger-Donohue, Rebecca
   Steller, Julie
   Hawkins, Joellen W
TI Postoperative pain: acupuncture versus percutaneous electrical nerve stimulation.
SO Pain management nursing : official journal of the American Society of Pain
LA English
DT Journal Article
AB The purpose of this study was to examine the effect of traditional acupuncture  compared with acupuncture with percutaneous electrical nerve stimulation (PENS)  on postoperative surgical pain relief in gynecologic oncology patients. Twenty  postoperative gynecologic oncology patients were randomly assigned into the two  groups, and the intervention was initiated within 24 hours after surgery. The  patients in each group received four treatments in the subsequent 48 hours, with  12 hours between each treatment. Either traditional acupuncture needles or  acupuncture needles with a pulsed electric current were applied to stimulate the  area of points Sp6 and Sp8 near the saphenous nerve. Pain measurement instruments  included a visual analog scale and the McGill Pain Questionnaire. Although the  PENS treatment group demonstrated a consistent decrease in pain with each  treatment application compared with the traditional acupuncture group, after 48  hours both groups experienced equivalent pain relief.
C1 School for Health Sciences, Simmons College, Boston, Massachusetts 02115, USA.
NR 0
TC 0
SN 1532-863
EI 
J9 Pain Manag Nurs
PD AUG 30
PY 2012
VL 13
IS 3
BP 150
EP 6
DI 10.1016/j.pmn.2009.08.001
PG -144
WC Acupuncture Analgesia; methods; Adult; Aged; Aged, 80 and over; Female; Gynecologic Surgical Procedures; nursing; Humans; Middle Aged; Pain Measurement; Pain, Postoperative; nursing; Perioperative Nursing; methods; Transcutaneous Electric Nerve Stimulation; methods; Treatment Outcome
UT PubMed:22929602
PM 22929602
DA 2012-08-30
ER

PT J
AU Walter, M
   Sammer, U
   Kessler, TM
AF Walter, M
   Sammer, U
   Kessler, T M
TI [Chronic pelvic pain syndrome: neurostimulation, neuromodulation and
SO Der Urologe. Ausg. A
LA ger
DT Journal Article
AB Chronic pelvic pain syndrome (CPPS) is defined by the European Association of  Urology guidelines as a non-malignant pain perceived in structures related to the  pelvis of either women or men for at least 6 months without proven infection or  other obvious pathology. It affects the quality of life of millions of people  worldwide and has an impact similar to that reported for other chronic diseases,  such as diabetes mellitus, Crohn's disease and congestive heart failure. The  treatment of CPPS remains a challenge despite several established first line  therapies because many patients are therapy refractory. Unconventional  treatments, such as neurostimulation, neuromodulation and acupuncture may be  highly successful for treating CPPS and have a favorable adverse event profile.  Thus, these promising therapeutic alternatives should be considered more often in  daily clinical practice.
C1 Neuro-Urologie, Zentrum für Paraplegie, Uniklinik Balgrist, Universität Zürich, Forchstraße 340, CH-8008 Zürich, Schweiz.
NR 0
TC 0
SN 1433-056
EI 
J9 Urologe A
PD DEC 12
PY 2012
VL 51
IS 12
BP 1683
EP 91
DI 10.1007/s00120-012-3037-9
PG -1592
WC Chronic Pain; rehabilitation; Electroacupuncture; methods; Female; Germany; Humans; Male; Pelvic Pain; rehabilitation; Syndrome; Transcutaneous Electric Nerve Stimulation; methods; Treatment Outcome
UT PubMed:23224254
PM 23224254
DA 2012-12-12
ER

PT J
AU Gondim, DV
   Costa, JL
   Rocha, SS
   Brito, GAD
   Ribeiro, RD
   Vale, ML
AF Gondim, Delane Viana
   Costa, Jessyca Lima
   Rocha, Suellen Sousa
   de Castro Brito, Gerly Anne
   Ribeiro, Ronaldo de Albuquerque
   Vale, Mariana Lima
TI Antinociceptive and anti-inflammatory effects of electroacupuncture on experimental arthritis of the rat temporomandibular joint
SO CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
LA English
DT Article
DE acupuncture; electroacupuncture; temporomandibular joint; arthritis; zymosan; nociception; inflammation
ID neuropeptide-like immunoreactivity; randomized controlled-trial; zymosan-induced arthritis; nitric-oxide; experimental induction; complement activation; rheumatoid-arthritis; trigeminal nucleus; myofascial pain; fos expression
AB This study investigated the antinociceptive and anti-inflammatory effects of electroacupuncture (EA) on zymosan-induced acute arthritis of the rat temporomandibular joint (TMJ). Male Wistar rats were injected with saline or zymosan (control group; 2 mg) into the left TMJ. Low frequency EA (10 Hz, 30 min) was performed at acupoints (LI4, LI11, ST36, ST44) or sham points 2 h after or 1 h before zymosan administration. Mechanical hypernociception was accessed by the electronic Von Frey method after zymosan administration. Rats were sacrificed 6 h after zymosan administration and the joint was removed for histopathological analysis, myeloperoxidase activity assessment, vascular permeability observations, and immunohistochemical verification of inflammatory mediators. The results showed that EA inhibited zymosan-induced hypernociception, compared with the control group and with the sham group (p < 0.05). The results showed that EA inhibited inflammatory parameters such as neutrophil migration, vascular permeability, and tumour necrosis factor alpha (TNF-alpha), cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) expression in the TMJ compared with the sham group (p < 0.05). Histopathological analysis showed that EA significantly inhibited edema and periarticular infiltration (p < 0.05) compared with the control and sham groups. EA at acupoints produced antinociceptive and anti-inflammatory effects on zymosan-induced arthritis in the rat TMJ.
C1 [Gondim, Delane Viana; Costa, Jessyca Lima; Rocha, Suellen Sousa; Ribeiro, Ronaldo de Albuquerque; Vale, Mariana Lima] Fed Univ Ceara UFC, Fac Med, Dept Physiol & Pharmacol, BR-60430270 Fortaleza, Ceara, Brazil.
   [de Castro Brito, Gerly Anne] Fed Univ Ceara UFC, Fac Med, Dept Morphol, BR-60430170 Fortaleza, Ceara, Brazil.
C3 Universidade Federal do Ceara; Universidade Federal do Ceara
RP Gondim, DV (corresponding author), Fed Univ Ceara UFC, Fac Med, Dept Physiol & Pharmacol, Rua Colonel Nunes de Melo 1127, BR-60430270 Fortaleza, Ceara, Brazil.
EM delanegondim@yahoo.com.br
FU Fundacao Cearense de Apoio ao Desenvolvimento Cientifico e Tecnologico (FUNCAP); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
CR Al-Mobireek AF, 2000, DENTOMAXILLOFAC RAD, V29, P286, DOI 10.1038/sj.dmfr.4600546
   Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006
   BRADLEY PP, 1982, BLOOD, V60, P618
   BROTON JG, 1988, ARCH ORAL BIOL, V33, P741, DOI 10.1016/0003-9969(88)90008-8
   Buescher JJ, 2007, AM FAM PHYSICIAN, V76, P1477
   Carleson J, 1996, LIFE SCI, V59, P1193, DOI 10.1016/0024-3205(96)00309-8
   Chaves HV, 2011, J BIOMED BIOTECHNOL, V0, P0, DOI DOI 10.1155/2011/707985
   CUNHA FQ, 1992, BRIT J PHARMACOL, V107, P660, DOI 10.1111/j.1476-5381.1992.tb14503.x
   da Silva MD, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq036
   Denadai-Souza A, 2010, J DENT RES, V89, P1123, DOI 10.1177/0022034510375284
   Denadai-Souza A, 2009, EUR J PAIN, V13, P812, DOI 10.1016/j.ejpain.2008.09.012
   DICARLO FJ, 1958, SCIENCE, V127, P756, DOI 10.1126/science.127.3301.756-a
   DINARELLO CA, 1986, CANCER RES, V46, P6236
   Ernst E, 1999, ARCH OTOLARYNGOL, V125, P269, DOI 10.1001/archotol.125.3.269
   FACCIOLI LH, 1990, AGENTS ACTIONS, V30, P344, DOI 10.1007/BF01966298
   Fiorentino PM, 1999, ARCH ORAL BIOL, V44, P27, DOI 10.1016/S0003-9969(98)00095-8
   Frasnelli ME, 2005, ARTHRITIS RES THER, V7, PR370, DOI 10.1186/ar1494
   Garrido-Suárez BB, 2009, BRAIN RES BULL, V79, P339, DOI 10.1016/j.brainresbull.2009.04.014
   Gilroy DW, 2000, J MOL MED-JMM, V78, P121, DOI 10.1007/s001090000094
   Goddard G, 2002, J OROFAC PAIN, V16, P71
   Gondim DV, 2010, BRAZ J ORAL SCI, V9, P415
   HAAS DA, 1992, ARCH ORAL BIOL, V37, P417, DOI 10.1016/0003-9969(92)90026-5
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Harper RP, 2000, J DENT RES, V79, P1704, DOI 10.1177/00220345000790091101
   He Tian-Feng, 2010, ZHONG XI YI JIE HE XUE BAO, V8, P670
   Herb Kathleen, 2006, CURR PAIN HEADACHE REP, V10, P408
   Huang C, 2008, NEUROCHEM RES, V33, P2107, DOI 10.1007/s11064-008-9721-x
   ILAR (Institute of Laboratory Animal Resources), 1996, NIH PUBL, V0, P0
   Imai H, 2001, ORAL DIS, V7, P185, DOI 10.1034/j.1601-0825.2001.0070308.x
   Jung A, 2011, J DENT, V39, P341, DOI 10.1016/j.jdent.2011.02.006
   Jung JY, 2006, AM J CHINESE MED, V34, P989, DOI 10.1142/S0192415X06004466
   Kaneyama K, 2004, J ORAL MAXIL SURG, V62, P657, DOI 10.1016/j.joms.2003.08.031
   Kwan CL, 1996, J NEUROPHYSIOL, V75, P298, DOI 10.1152/jn.1996.75.1.298
   Lau WK, 2008, NEUROSCIENCE, V155, P463, DOI 10.1016/j.neuroscience.2008.06.016
   Lau WK, 2010, NEUROSCIENCE, V170, P655, DOI 10.1016/j.neuroscience.2010.07.031
   Lee JH, 2006, AM J CHINESE MED, V34, P981, DOI 10.1142/S0192415X06004454
   Lee MS, 2008, RHEUMATOLOGY, V47, P1747, DOI 10.1093/rheumatology/ken330
   Lee MJ, 2010, ANAT CELL BIOL, V43, P125, DOI 10.5115/acb.2010.43.2.125
   LEKKAS C, 1994, INT J ORAL MAX SURG, V23, P423, DOI 10.1016/S0901-5027(05)80036-0
   Li Hui, 2009, ZHEN CI YAN JIU, V34, P225
   Lundeberg T, 1996, NEUROPEPTIDES, V30, P37, DOI 10.1016/S0143-4179(96)90052-9
   Manheimer E, 2007, ANN INTERN MED, V146, P868, DOI 10.7326/0003-4819-146-12-200706190-00008
   Martin DP, 2006, MAYO CLIN PROC, V81, P749, DOI 10.4065/81.6.749
   Mi WL, 2008, BRAIN RES BULL, V77, P98, DOI 10.1016/j.brainresbull.2008.04.008
   Milam SB, 1998, J ORAL MAXIL SURG, V56, P214, DOI 10.1016/S0278-2391(98)90872-2
   MONCADA S, 1993, NEW ENGL J MED, V329, P2002
   Noiman M, 2010, J ACUPUNCT MERIDIAN, V3, P260, DOI 10.1016/S2005-2901(10)60046-5
   Oh JH, 2006, INT J NEUROSCI, V116, P1139, DOI 10.1080/00207450500513948
   PALMER RMJ, 1993, BIOCHEM BIOPH RES CO, V193, P398, DOI 10.1006/bbrc.1993.1637
   Ren K, 1999, PHYSIOL BEHAV, V67, P711, DOI 10.1016/S0031-9384(99)00136-5
   Ribeiro RA, 2000, EUR J PHARMACOL, V387, P111, DOI 10.1016/S0014-2999(99)00790-6
   Rocha FAC, 1999, INFLAMM RES, V48, P485, DOI 10.1007/s000110050491
   Rogers P A, 1992, PROBL VET MED, V4, P162
   Roveroni RC, 2001, PAIN, V94, P185, DOI 10.1016/S0304-3959(01)00357-8
   SATO T, 1986, JPN J PHARMACOL, V42, P587, DOI 10.1254/jjp.42.587
   SCHORLEMMER HU, 1977, IMMUNOLOGY, V32, P929
   Sheng LL, 2000, NEUROSCI RES, V38, P331, DOI 10.1016/S0168-0102(00)00162-0
   Smith P, 2007, J DENT, V35, P259, DOI 10.1016/j.jdent.2006.09.004
   Sun S, 2008, BRAIN RES BULL, V75, P83, DOI 10.1016/j.brainresbull.2007.07.027
   Takeshita K, 2003, J PHARMACOL EXP THER, V307, P1072, DOI 10.1124/jpet.103.057489
   Tang Michelle L Y, 2004, ANESTH PROG, V51, P2
   Tesser-Viscaíno SA, 2009, BRAIN RES, V1302, P85, DOI 10.1016/j.brainres.2009.09.056
   Tominaga K, 1999, J ORAL PATHOL MED, V28, P268
   Vale ML, 2006, EUR J PHARMACOL, V536, P309, DOI 10.1016/j.ejphar.2006.02.051
   Vivancos GG, 2004, BRAZ J MED BIOL RES, V37, P391, DOI 10.1590/S0100-879X2004000300017
   Weinberg JB, 2000, IMMUNOL RES, V22, P319, DOI 10.1385/IR:22:2-3:319
   Wong CL, 2008, J ALTERN COMPLEM MED, V14, P847, DOI 10.1089/acm.2007.0780
   YAILLEN DM, 1979, J MAXILLOFAC SURG, V7, P255, DOI 10.1016/S0301-0503(79)80050-8
   YU XM, 1995, PAIN, V60, P143, DOI 10.1016/0304-3959(94)00104-M
   ZAMMA T, 1983, INFECT IMMUN, V39, P1291, DOI 10.1128/IAI.39.3.1291-1299.1983
   Zijlstra FJ, 2003, MEDIAT INFLAMM, V12, P59, DOI 10.1080/0962935031000114943
NR 71
TC 21
Z9 23
U1 0
U2 16
PU CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS
PI OTTAWA
PA 65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA
SN 0008-4212
EI 1205-7541
J9 CAN J PHYSIOL PHARM
JI Can. J. Physiol. Pharmacol.
PD APR 15
PY 2012
VL 90
IS 4
BP 395
EP 405
DI 10.1139/Y2012-003
PG 11
WC Pharmacology & Pharmacy; Physiology
SC Pharmacology & Pharmacy; Physiology
GA 918HY
UT WOS:000302241200004
PM 22443108
DA 2026-01-16
ER

PT J
AU Lin, LL
   Wang, YH
   Lai, CY
   Chau, CL
   Su, GC
   Yang, CY
   Lou, SY
   Chen, SK
   Hsu, KH
   Lai, YL
   Wu, WM
   Huang, JL
   Liao, CH
   Juan, HF
AF Lin, Li-Ling
   Wang, Ya-Hui
   Lai, Chi-Yu
   Chau, Chan-Lao
   Su, Guan-Chin
   Yang, Chun-Yi
   Lou, Shu-Ying
   Chen, Szu-Kai
   Hsu, Kuan-Hao
   Lai, Yen-Ling
   Wu, Wei-Ming
   Huang, Jian-Long
   Liao, Chih-Hsin
   Juan, Hsueh-Fen
TI Systems biology of meridians, acupoints, and chinese herbs in disease.
SO Evidence-based complementary and alternative medicine : eCAM
LA English
DT Journal Article
AB Meridians, acupoints, and Chinese herbs are important components of traditional  Chinese medicine (TCM). They have been used for disease treatment and prevention  and as alternative and complementary therapies. Systems biology integrates omics  data, such as transcriptional, proteomic, and metabolomics data, in order to  obtain a more global and complete picture of biological activity. To further  understand the existence and functions of the three components above, we reviewed  relevant research in the systems biology literature and found many recent studies  that indicate the value of acupuncture and Chinese herbs. Acupuncture is useful  in pain moderation and relieves various symptoms arising from acute spinal cord  injury and acute ischemic stroke. Moreover, Chinese herbal extracts have been  linked to wound repair, the alleviation of postmenopausal osteoporosis severity,  and anti-tumor effects, among others. Different acupoints, variations in  treatment duration, and herbal extracts can be used to alleviate various symptoms  and conditions and to regulate biological pathways by altering gene and protein  expression. Our paper demonstrates how systems biology has helped to establish a  platform for investigating the efficacy of TCM in treating different diseases and  improving treatment strategies.
C1 Department of Life Science, National Taiwan University, No. 1, Section 4, Roosevelt Road, Taipei 106, Taiwan.
NR 0
TC 0
SN 1741-428
EI 1741-427
J9 Evid Based Complement Alternat Med
PD NOV 3
PY 2012
VL 2012
IS 
BP 372670
EP 372670
DI 10.1155/2012/372670
PG 0
UT PubMed:23118787
PM 23118787
DA 2012-11-03
ER

PT J
AU Running, A
   Seright, T
AF Running, Alice
   Seright, Teresa
TI Integrative Oncology: Managing Cancer Pain with Complementary and Alternative Therapies
SO CURRENT PAIN AND HEADACHE REPORTS
LA English
DT Review
DE Complementary therapies; Alternative therapies; Cancer; Pain; Acupuncture; Bio-Energy; Massage; Music therapy; Evidence
ID acupuncture; management
AB For the projected 1,638,910 patients with a diagnosis of cancer this year, the great majority of them (75-90 %) will experience cancer-related pain. A growing number of these patients will turn to complementary and alternative therapies to assist with the management of their pain and other cancer-related symptoms. The World Health Organization's suggested approach to pain management begins with the use of time honored opioids, but recommends the use of adjuvant therapies early in the management process. Complementary and alternative therapies are being used by more patients each year to assist with the management of their pain. Practitioners and researchers must be aware of the evidence that exists to support or refute the use of these therapies. In this manuscript we review evidence from the recent past on complementary and alternative therapies for pain with emphasis on more common modalities including acupuncture, bio-energy, massage, and music.
C1 [Running, Alice; Seright, Teresa] Montana State Univ, Coll Nursing, Bozeman, MT 59717 USA.
C3 Montana State University System; Montana State University Bozeman
RP Running, A (corresponding author), Montana State Univ, Coll Nursing, POB 17350, Bozeman, MT 59717 USA.
EM alice.running@montana.edu
CR Ali Ather, 2010, YALE JOURNAL OF BIOLOGY AND MEDICINE, V83, P123
   Anderson JG, 2012, CLIN J ONCOL NURS, V16, P43, DOI 10.1188/12.CJON.43-48
   Unknown -, 2011, IASP TAX, V0, P0
   Unknown -, 2012, CANCER FACTS AND FIGURES 2012, V0, P0
   Bao T, 2011, J PAIN SYMPTOM MANAG, V41, P995, DOI 10.1016/j.jpainsymman.2010.08.012
   Bardia A, 2006, J CLIN ONCOL, V24, P5457, DOI 10.1200/JCO.2006.08.3725
   Bennett JA, 2009, J GEN INTERN MED, V24, P1089, DOI 10.1007/s11606-009-0979-8
   Cassileth Barrie, 2007, CURR PAIN HEADACHE REP, V11, P265, DOI 10.1007/s11916-007-0202-8
   Cassileth BR, 2010, ONCOLOGIST, V15, P19, DOI 10.1634/theoncologist.2009-S504
   Cunningham JE, 2011, SUPPORT CARE CANCER, V19, P1473, DOI 10.1007/s00520-011-1231-8
   Deng Gary E, 2007, J SOC INTEGR ONCOL, V5, P65
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Ezzo JM, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002285.pub2
   Falkensteiner Maria, 2011, ISRN NURS, V2011, P929868, DOI 10.5402/2011/929868
   Fayed L, 2009, CANC CANC PAIN, V0, P0
   Gilmour J, 2011, PEDIATRICS, V128, PS187, DOI 10.1542/peds.2010-2720H
   Hopkins Hollis Anne Seton, 2010, ONCOL NURS FORUM, V37, PE344, DOI 10.1188/10.ONF.E344-E348
   Induru RR, 2011, CLEV CLIN J MED, V78, P449, DOI 10.3949/ccjm.78a.10054
   Jackson E, 2008, CLIN J ONCOL NURS, V12, P113, DOI 10.1188/08.CJON.113-120
   Johnstone PAS, 2011, J ACUPUNCT MERIDIAN, V4, P209, DOI 10.1016/j.jams.2011.09.011
   Kassab S, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004845.pub2
   Landier W, 2010, J PEDIATR NURS, V25, P566, DOI 10.1016/j.pedn.2010.01.009
   Li XM, 2011, BREAST CANCER RES TR, V128, P411, DOI 10.1007/s10549-011-1533-z
   Lyon DE, 2010, ONCOL NURS FORUM, V37, P476, DOI 10.1188/10.ONF.476-483
   NCCN Clinical Practice Guidelines in Oncology, 2010, J NATL COMPR CANC NE, V8, P0
   Nguyen TN, 2012, J PEDIATR ONCOL NURS, V27, P146, DOI 101177/1043454209355983
   ORegan D, 2010, AUTON NEUROSCI-BASIC, V157, P96, DOI 10.1016/j.autneu.2010.05.001
   Paley CA, 2011, PHYSIOTHERAPY, V97, P256, DOI 10.1016/j.physio.2010.08.008
   Paley CA, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub2
   Portenoy RK, 2011, LANCET, V377, P2236, DOI 10.1016/S0140-6736(11)60236-5
   Pujol LAM, 2007, J AM OSTEOPATH ASSOC, V107, P0
   Running A, 2011, CLIN J ONCOL NURS, V15, P374, DOI 10.1188/11.CJON.374-379
   World Health Organization, 2011, WHOS PAIN REL LADD, V0, P0
   Yamamoto K, 2011, CANCER NURS, V34, P185, DOI 10.1097/NCC.0b013e3181fe4d2d
   Yap KYL, 2010, SUPPORT CARE CANCER, V18, P883, DOI 10.1007/s00520-009-0729-9
NR 35
TC 30
Z9 36
U1 0
U2 49
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1531-3433
EI 1534-3081
J9 CURR PAIN HEADACHE R
JI Curr. Pain Headache Rep.
PD AUG 15
PY 2012
VL 16
IS 4
BP 325
EP 331
DI 10.1007/s11916-012-0275-x
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 973DP
UT WOS:000306335200007
PM 22639181
DA 2026-01-16
ER

PT J
AU Wong, RKW
   James, JL
   Sagar, S
   Wyatt, G
   Nguyen-Tân, PF
   Singh, AK
   Lukaszczyk, B
   Cardinale, F
   Yeh, AM
   Berk, L
AF Wong, Raimond K. W.
   James, Jennifer L.
   Sagar, Stephen
   Wyatt, Gwen
   Phuc Felix Nguyen-Tan
   Singh, Anurag K.
   Lukaszczyk, Barbara
   Cardinale, Francis
   Yeh, Alexander M.
   Berk, Lawrence
TI Phase 2 results from Radiation Therapy Oncology Group Study 0537 A Phase 2/3 Study Comparing Acupuncture-Like Transcutaneous Electrical Nerve Stimulation Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia
SO CANCER
LA English
DT Article
DE head and neck cancer; xerostomia; radiation; acupuncture; acupuncture-like transcutaneous electrical nerve stimulation
ID quality-of-life; cancer-patients; salivary-glands; head; irradiation; radiotherapy; release; increases
AB BACKGROUND: In this phase 2 component of a multi-institutional, phase 2/3, randomized trial, the authors assessed the feasibility and preliminary efficacy of acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) in reducing radiation-induced xerostomia. METHODS: Patients with cancer of the head and neck who were 3 to 24 months from completing radiotherapy with or without chemotherapy (RT +/- C) and who were experiencing xerostomia symptoms with basal whole saliva production =0.1 mL per minute and were without recurrence were eligible. Patients received twice weekly ALTENS sessions (24 sessions over 12 weeks) using a proprietary electrical stimulation unit. The primary study objective was to assess the feasibility of ALTENS treatment. Patients were considered compliant if 19 of 24 ALTENS sessions were delivered, and the targeted compliance rate was 85%. Secondary objectives measured treatment-related toxicities and the effect of ALTENS on overall radiation-induced xerostomia burden using the University of Michigan Xerostomia-Related Quality of Life Scale (XeQOLS). RESULTS: Of 48 accrued patients, 47 were evaluable. The median age was 60 years, 84% of patients were men, 70% completed RT +/- C for >12 months, and 21% had previously received pilocarpine. Thirty-four patients completed all 24 ALTENS sessions, 9 patients completed 20 to 23 sessions, and 1 patient completed 19 sessions, representing a 94% total compliance rate. Six-month XeQOLS scores were available for 35 patients and indicated that 30 patients (86%) achieved a positive treatment response with a mean +/- standard deviation reduction of 35.9% +/- 36.1%. Five patients developed grade 1 or 2 gastrointestinal toxicity, and 1 had a grade 1 pain event. CONCLUSIONS: The current results indicated that ALTENS treatment for radiation-induced xerostomia can be delivered uniformly in a cooperative, multicenter setting and produces possible beneficial treatment response. Given these results, the phase 3 component of this study was initiated. Cancer 2012. (c) 2011 American Cancer Society.
C1 [Wong, Raimond K. W.; Sagar, Stephen] McMaster Univ, Juravinski Canc Ctr, Dept Oncol, Hamilton, ON L8V 5C2, Canada.
   [James, Jennifer L.] Ctr Stat, Radiat Therapy Oncol Grp, Philadelphia, PA USA.
   [Wyatt, Gwen] Michigan State Univ, Coll Nursing, E Lansing, MI 48824 USA.
   [Phuc Felix Nguyen-Tan] Montreal Univ Hosp, Dept Radiat Oncol, Montreal, PQ, Canada.
   [Singh, Anurag K.] Roswell Pk Canc Inst, Dept Radiat Med, Buffalo, NY 14263 USA.
   [Lukaszczyk, Barbara] John H Stroger Jr Hosp, Cook Cty Minor Based Community Clin Oncol Prog, Dept Med Oncol, Chicago, IL USA.
   [Cardinale, Francis] Hosp St Raphael, Dept Radiat Oncol, New Haven, CT 06511 USA.
   [Yeh, Alexander M.] Indiana Univ Hlth, Dept Radiat Oncol, Indianapolis, IN USA.
   [Berk, Lawrence] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Radiat Oncol, Tampa, FL 33682 USA.
C3 McMaster University; Radiation Therapy Oncology Group (RTOG); Michigan State University; Universite de Montreal; Roswell Park Comprehensive Cancer Center; John H Stroger Junior Hospital Cook County; Hospital Saint Raphael; Indiana University Health; IU Health University Hospital; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida
RP Wong, RKW (corresponding author), McMaster Univ, Juravinski Canc Ctr, Dept Radiat Oncol, 699 Concess St, Hamilton, ON L8V 5C2, Canada.
EM raimond.wong@jcc.hhsc.ca
FU RTOG [U10 CA21661]; NCI [U10 CA37422]
CR Unknown -, 1998, PHYS THER REV, V0, P0
   BLOM M, 1993, J ORAL REHABIL, V20, P541, DOI 10.1111/j.1365-2842.1993.tb01641.x
   Blom M, 2000, ORAL DIS, V6, P15
   BUSUTTIL A, 1977, CLIN OTOLARYNGOL, V2, P199, DOI 10.1111/j.1365-2273.1977.tb01358.x
   Cheng R, 1986, CLIN J PAIN, V2, P143, DOI 10.1097/00002508-198602030-00001
   Cheng Xin-Nong, 1987, CHINESE ACUPUNCTURE AND MOXIBUSTION, V0, P0
   Cho JH, 2008, J ALTERN COMPLEM MED, V14, P523, DOI 10.1089/acm.2007.0793
   Clavel S, 2011, INT J RAD ONCOL BIOL, V0, P0
   Dawidson I, 1999, NEUROPEPTIDES, V33, P244, DOI 10.1054/npep.1999.0759
   Dawidson I, 1998, LIFE SCI, V63, P659, DOI 10.1016/S0024-3205(98)00317-8
   Dawidson I, 1998, NEUROPEPTIDES, V32, P543, DOI 10.1016/S0143-4179(98)90083-X
   Deng G, 2008, BMC COMPLEM ALTERN M, V8, P0, DOI 10.1186/1472-6882-8-37
   Ditto B, 2011, JOURNAL OF BEHAVIORAL MEDICINE, V0, P1
   Eisbruch A, 1996, INT J RADIAT ONCOL, V36, P469, DOI 10.1016/S0360-3016(96)00264-7
   Eisbruch A, 1998, INT J RADIAT ONCOL, V41, P559, DOI 10.1016/S0360-3016(98)00082-0
   Eisbruch A, 1999, INT J RADIAT ONCOL, V45, P577, DOI 10.1016/S0360-3016(99)00247-3
   FOX EJ, 1976, PAIN, V2, P141, DOI 10.1016/0304-3959(76)90109-3
   Frank R M, 1965, ACTUAL ODONTOSTOMATOL (PARIS), V19, P129
   Gadsby JG, 2000, COCHRANE DB SYST REV, V0, P0
   Garcia MK, 2009, HEAD NECK-J SCI SPEC, V31, P1360, DOI 10.1002/hed.21110
   Greenspan D, 1996, ONCOLOGY (WILLISTON PARK), V10, P7
   Henson BS, 2001, ORAL ONCOL, V37, P84, DOI 10.1016/S1368-8375(00)00063-4
   Henson BS, 1999, ORAL ONCOL, V35, P234, DOI 10.1016/S1368-8375(98)00104-3
   HOWSON DC, 1978, PHYS THER, V58, P1467, DOI 10.1093/ptj/58.12.1467
   Johnstone PAS, 2002, CANCER, V94, P1151, DOI 10.1002/cncr.10348
   Johnstone PAS, 2001, INT J RADIAT ONCOL, V50, P353, DOI 10.1016/S0360-3016(00)01530-3
   Kahn ST, 2005, ONCOLOGY-NY, V19, P1827
   Kramar A, 1996, BRIT J CANCER, V74, P1317, DOI 10.1038/bjc.1996.537
   LAITINEN J, 1976, AMERICAN JOURNAL OF CHINESE MEDICINE, V4, P169, DOI 10.1142/S0192415X76000214
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Pomeranz B, 1987, AM J ELECTROMED, V2, P22
   Proctor GB, 2007, AUTON NEUROSCI-BASIC, V133, P3, DOI 10.1016/j.autneu.2006.10.006
   Sakatani K, 2010, ADV EXP MED BIOL, V662, P455, DOI 10.1007/978-1-4419-1241-1_65
   SCHNEYER CA, 1993, AM J PHYSIOL, V264, PG935, DOI 10.1152/ajpgi.1993.264.5.G935
   Ship JA, 1997, J DENT RES, V76, P807, DOI 10.1177/00220345970760031401
   Simcock R, 2009, ACUPUNCT MED, V27, P109, DOI 10.1136/aim.2009.000935
   TALAL N, 1992, RHEUMATOL INT, V12, P43, DOI 10.1007/BF00300975
   Vergeer MR, 2009, INT J RADIAT ONCOL, V74, P1, DOI 10.1016/j.ijrobp.2008.07.059
   WANG KM, 1985, SCI SIN B-CHEM B A M, V28, P963
   WEISS WW, 1986, J ORAL MAXIL SURG, V44, P845, DOI 10.1016/0278-2391(86)90219-3
   Wong RKW, 2003, INT J RADIAT ONCOL, V57, P472, DOI 10.1016/S0360-3016(03)00572-8
NR 41
TC 39
Z9 45
U1 0
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD SEP 1
PY 2012
VL 118
IS 17
BP 4244
EP 4252
DI 10.1002/cncr.27382
PG 9
WC Oncology
SC Oncology
GA 993GN
UT WOS:000307845200022
PM 22252927
DA 2026-01-16
ER

PT J
AU Casazza, BA
AF Casazza, Brian A
TI Diagnosis and treatment of acute low back pain.
SO American family physician
LA English
DT Review
AB Acute low back pain is one of the most common reasons for adults to see a family  physician. Although most patients recover quickly with minimal treatment, proper  evaluation is imperative to identify rare cases of serious underlying pathology.  Certain red flags should prompt aggressive treatment or referral to a spine  specialist, whereas others are less concerning. Serious red flags include  significant trauma related to age (i.e., injury related to a fall from a height  or motor vehicle crash in a young patient, or from a minor fall or heavy lifting  in a patient with osteoporosis or possible osteoporosis), major or progressive  motor or sensory deficit, new-onset bowel or bladder incontinence or urinary  retention, loss of anal sphincter tone, saddle anesthesia, history of cancer  metastatic to bone, and suspected spinal infection. Without clinical signs of  serious pathology, diagnostic imaging and laboratory testing often are not  required. Although there are numerous treatments for nonspecific acute low back  pain, most have little evidence of benefit. Patient education and medications  such as nonsteroidal anti-inflammatory drugs, acetaminophen, and muscle relaxants  are beneficial. Bed rest should be avoided if possible. Exercises directed by a  physical therapist, such as the McKenzie method and spine stabilization  exercises, may decrease recurrent pain and need for health care services. Spinal  manipulation and chiropractic techniques are no more effective than established  medical treatments, and adding them to established treatments does not improve  outcomes. No substantial benefit has been shown with oral steroids, acupuncture,  massage, traction, lumbar supports, or regular exercise programs.
C1 University of North Carolina School of Medicine, Chapel Hill, NC, USA. brian_casazza@med.unc.edu
NR 0
TC 0
SN 1532-065
EI 
J9 Am Fam Physician
PD FEB 18
PY 2012
VL 85
IS 4
BP 343
EP 50
DI 
PG -293
WC Acute Disease; Analgesics, Opioid; therapeutic use; Anti-Inflammatory Agents, Non-Steroidal; therapeutic use; Exercise Therapy; Humans; Low Back Pain; diagnosis; Muscle Relaxants, Central; therapeutic use; Patient Education as Topic; Physical Examination
UT PubMed:22335313
PM 22335313
DA 2012-02-18
ER

